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ABSTRACT 
 
Angiotensin-converting enzyme (ACE) is a zinc metalloprotease that has been classically 
defined as a key regulator of blood homeostasis.  Novel insights into its function demonstrate 
its broader role in other physiological systems.  Pivotal to these roles are the specific protein-
protein interactions that allows cross-talk between different pathways.  The development of 
domain-specific ACE inhibitors calls for better understanding of the interaction of the two 
ectodomains of ACE and the role of specific interactions in processing events.  These include 
ACE-ACE interaction in homodimerisation and recognition and binding of the ACE 
secretase(s) responsible for proteolytic processing.  There is also increasing evidence for 
inter-domain interaction and movement in sACE that may be involved in shedding, 
dimerisation and domain cooperativity with respect to catalysis.   
The crystal structures of the individual domains of sACE, the N and C domains, have been 
solved whereas the full-length structure has not.  Growth of viable crystals is thought to be 
impaired by the presence of extensive glycosylation and flexibility of movement between the 
two domains.  In this study, novel disulphide bridges were engineered into the linker region of 
ACE in an attempt to limit inter-domain movement, thereby producing a candidate for 
crystallisation and to determine the effect of these bridges on inter-domain movement.  The 
use of the native unbound N domain cysteine to form a disulphide bridge with residues in the 
linker region appeared to be an effective approach. 
Protein-protein interactions were explored using site-directed mutagenesis and a panel of 
domain-specific monoclonal antibodies (mAbs) to ACE to better understand their role in ACE 
expression and processing.  Fine epitope mapping of the mAbs to ACE has elucidated regions 
involved in shedding, dimerisation and inter-domain interaction.  In this study, fine epitope 
mapping of two mAbs, known to influence shedding and dimerisation, was performed in 
order to isolate a region of the N domain of ACE that may be involved.  Three residues were 
identified in the overlapping region of the two mAb epitopes that alter sACE shedding, mAb 
binding and increase dimerisation on the cell surface highlighting the importance of this 
region in post-translational processing. 
The role of the unbound cysteine residues in each domain in dimerisation and shedding was 
investigated.  Dimerisation appears to involve both non-covalent interactions in the N domain 
and disulphide-mediated interactions in the C domain.  The latter has an effect on shedding 
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Finally, a novel ACE mutation that results in increased plasma ACE was described.  The 
increased soluble ACE is the result of significantly increased rate of shedding that follows a 
similar mechanism to wild-type ACE and implicates the N domain in ACE secretase 
interaction.  Thus, we have gained some insight into regions and residues of ACE that are 
important in the protein-protein interactions involved in processes such as shedding, 
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CHAPTER 1: Introduction 
  
Angiotensin-converting enzyme (ACE) has been classically described with respects to its 
cardiovascular roles in the renin- angiotensin-aldosterone (RAAS) and the kallikrein-kinin 
(KKS) systems that maintain blood homeostasis.  ACE mediates its effects by hydrolysing 
angiotensin I (angI) to form the potent vasoconstrictor, angiotensin II (angII), in the RAAS 
and inactivates the vasoconstrictor, bradykinin (BK), in the KKS.  In recent years other 
substrates of ACE have been identified, implicating this enzyme in other physiological 
systems.  These include cleavage of the amyloid β protein 1-42 (Aβ) associated with amyloid 
plaque formation in Alzheimer’s disease (Oba et al, 2005); its action on N-acetyl-seryl-
aspartyl-lysyl-proline (Ac-SDKP), a peptide involved in haematopoietic stem cell regulation 
(Azizi et al, 1996) and increased ACE expression in macrophages associated with resistance 
to melanoma (Shen et al, 2007).   
A better understanding of the role ACE plays in these systems is particularly relevant 
considering that ACE inhibitors are a front-line thera y for hypertension and myocardial 
infarction.  Common side effects of treatment with ACE inhibitors are a persistent dry cough 
and angioedema, sufficiently acute to induce patients to terminate treatment.  These effects 
are thought to be the result of a build-up of BK due to wholesale inhibition of ACE (reviewed 
by Dykewicz, 2004).  A new approach towards the development of ACE inhibitors is directed 
towards targeting its primary function of ang I hydrolysis, minimising the effect on other 
functions.  In order to pursue this line of investigation, a thorough understanding of the 
structure-function of ACE as well as its regulation and expression are required.  Common to 
all these functions are the specific protein-protein interactions involved.   
Cross-talk between proteins and peptides is key at almost every level of cell function; in 
enzyme-substrate interaction; intracellular signalling; for protein expression and membrane 
targeting; for proteolysis and cell-to-cell adhesion.  These interactions range from relatively 
transient ones, such as the binding of enzyme and substrate to long-term associations that are 
required for activity, such a homo- or hetero-dimer formation and enzyme complex formation.  
To understand the regulation and expression of a protein in the broader context, it is important 
to look at what interactions take place.  With ACE in particular, its extended role beyond the 
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This chapter will encompass what is known regarding the structure-function relationship of 
ACE with respect to specific protein-protein interactions involved in processes such as 
ectodomain shedding, glycosylation, dimerisation and inter-domain interaction.  
 
Figure 1.1.  Isoforms of ACE. 
 
1.1 BIOCHEMICAL PROPERTIES OF ACE 
1.1.1 Physical characteristics of ACE 
Human somatic ACE (sACE) is encoded by 26 exons from a single gene locus on 
chromosome 17 (mouse ACE chromosome 11) (Hubert et al, 1991).  The inferred amino acid 
sequence is 1306 residues, giving rise to a 170kDa protein.  It consists of a 29-residue signal 
sequence; two ectodomains: the N and C domains, each of approximately 600 residues joined 
by an 11-residue linker region; a juxtamembrane region; a 17-residue hydrophobic 
transmembrane domain and terminates in a 30-residue cytoplasmic tail (Soubrier et al, 1988; 
Wei et al, 1991a; Wei et al, 1991b) (Figure 1.1).  There is approximately 60% amino acid 
sequence identity between the two domains thought to be the result of an ancient gene 
duplication event (Hubert et al, 1991).  Each domain contains a conserved zinc-binding motif, 
HEMGH, present in the active sites of zinc metalloproteases, including thermolysin, neutral 
endopeptidase, neurolysin and collagenase (Soubrier et al, 1988).  There are 7 cysteine 
residues in each domain, 6 of which form three intramolecular disulphide bridges in an 
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The smaller isoform, testis ACE (tACE), is expressed solely in male germinal cells as a single 
110kDa ectodomain protein (Strittmatter & Snyder, 1984; Yotsumoto et al, 1984; Brentjens et 
al, 1986).  It is transcribed from an intronic promoter (Howard et al, 1990; Kumar et al, 1989; 
Lattion et al, 1989) in the 12th intron from the same gene as sACE (Bernstein et al, 1988; 
Soubrier et al, 1988; Howard et al, 1990).  Full-length human tACE cDNA was cloned by 
screening a testicular library with anti-bovine lung ACE antibodies and ACE cDNA probes 
(Ehlers et al, 1989).  This recombinant form was expressed in Chinese hamster ovary (CHO) 
cells and generated a protein that was structurally, catalytically and immunologically identical 
to its physiological counterpart (Ehlers et al, 1991).  tACE is structurally and catalytically 
identical to the C domain of sACE, except for a unique 36-residue N terminal region 
downstream of the signal sequence that is rich in serine and threonine residues (El-Dorry et 
al, 1982) *.    
A third isoform that is identical to the N domain has been isolated from human ileal fluid 
(Deddish et al, 1994) and has been found in urine of hypertensive patients (Casarini et al, 
2001).  Unlike, tACE this isoform seems to arise from limited proteolysis of sACE, rather 
than direct gene expression. 
 
1.1.2 Catalytic properties of ACE 
ACE exhibits dipeptidyl carboxypeptidase activity (Soffer & Sonnenblick, 1978) and 
endopeptidase activity (Jaspard et al, 1993).  The zinc-binding motif in each domain is critical 
for enzyme function (Wei et al, 1991a).  ACE cleaves a variety of peptides including angI, 
BK, Ac-SDKP, substance P (subsP), Aβ-peptide and luteinising hormone-releasing hormone 
(LHRH) (Bünning et al, 1983; Ehlers & Riordan, 1991a; Wei et al, 1991a).  Both domains 
can hydrolyse substrates independently, as evidenced from activity of the individual domains 
through active site knockout mutants (Wei et al, 1992) and generated by limited proteolysis of 
sACE (Sturrock et al, 1997). 
ACE falls into a small group of enzymes containing two catalytic domains, which includes 
sucrase-isomaltase (Hunziker et al, 1986), lactase-phlorizin hydrolase (Mantei et al, 1988), 
protein disulphide isomerase (Ellgaard & Ruddock, 2005) and adenylyl transferase 
(Jaggi et al, 1997).  Each domain has distinct and complementary functions in these proteins 
                                                 
*
 Residue numbers of tACE are referred to with sACE numbering throughout this document (there is a 576 
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as a result of minor differences in their active sites.  Despite the approximately 89% structural 
homology between the N and C domain active sites of sACE (Corradi et al, 2006), the two 
ectodomains display different profiles for substrate hydrolysis and chloride activation (Wei et 
al, 1991a; Wei et al, 1992).  While both domains cleave BK at relatively the same rate, angI 
hydrolysis by the C domain is approximately three times more efficient (Wei et al, 1991a; 
Georgiadis et al, 2003).  It appears that the C domain active site maintains the dipeptidyl 
carboxypeptidase function whereas the N domain active site catalyses other substrates through 
endopeptidase activity (Ehlers & Riordan, 1991a; Wei et al, 1991b; Jaspard et al, 1993).  
There has been some discussion in the literature regarding the interaction of the two domains 
in sACE with respect to their activity.  Since the turnover (kcat) of sACE was not higher than 
that of the C domain (Sturrock et al, 1997; Woodman et al, 2005; Skirgello et al, 2005), it has 
been speculated that there is some degree of negative cooperativity between the domains.  
This is supported by active site titration of inhibitors and isothermal titration calorimetry 
(Binevski et al, 2003; Anjudar-Sanchez et al, 2004; Skirgello et al, 2005).  It is thought that 
binding of substrate or inhibitors to the active site in one domain results in a conformational 
change that prevents access of compounds to the second active site.  There is evidence of 
domain interaction, both with shedding and monoclonal antibody (mAb) binding (discussed 
later in Section 1.4) and most likely extends to enzyme activity as well. 
 
1.2 THREE-DIMENSIONAL STRUCTURE OF ACE 
1.2.1 Three-dimensional structure determination of ACE  
Until recently, characterisation of ACE with respect to substrate and inhibitor specificity, 
function and post-translational processing was hampered by the lack of a three-dimensional 
(3D) structure.  This was largely due to the difficulty in obtaining reproducible crystals for 
x-ray crystallography.  The major obstacle in obtaining crystals was due to the 
microheterogeneity of glycan chains and the hydrophobicity of the transmembrane region, 
which affected the packing of the crystal lattice.  Both tACE and the N domain are heavily 
glycosylated and the presence of these oligosaccharides is required for correct folding and 
protein stability (detailed in Section 1.3.2).  The first crystal structures of human tACE and 
the N domain in complex with the inhibitor lisinopril were obtained by expressing soluble 
constructs lacking the transmembrane domain in the presence of N-butyldeoxy-nojirimycin 
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sufficient to allow for the proper folding and expression of ACE while limiting the 
heterogeneity of the oligosaccharide chain (Natesh et al, 2003, Corradi et al, 2006).  
However, the prohibitive cost of NB-DNJ and the potential loss of expression (Butters et al, 
1999) necessitated an alternate expression system.  The Drosophila melanogaster ACE 
homologue (AnCE) was successfully expressed in Hi5 insect cells, resulting in glycans 
composed of simple oligomannosidic chains (Tomiya et al, 2004; Harrison & Jarvis et al, 
2006) and was used for x-ray crystallography where the presence of sugars did not seem to 
obstruct crystal packing (Kim et al, 2003).  Similarly, another ACE homologue, ACE2, was 
expressed in a baculovirus system and the crystal structure successfully resolved (Towler et 
al, 2004).  A minimally glycosylated tACE variant, containing glycans at Asn648 and Asn685 
(tACE-g13) was developed by site-directed mutagenesis in order to develop a high through-
put and cost-effective method for crystallisation and a number of structures co-crystallised 
with different inhibitors have been solved in this way (Gordon et al, 2003; Watermeyer et al, 
2006; Watermeyer et al, 2008; Watermeyer et al, 2010).  A similar approach has recently 
been successful for the N domain (Anthony et al, 2010). 
 
1.2.2 Three-dimensional structure of single domain ACE isoforms  
1.2.2.1 N domain structures 
Two human N domain structures have been resolved.  The first, using protein purified from 
NB-DNJ-treated cells, was co-crystallised with lisinopril (Corradi et al, 2006).  The second is 
a minimally glycosylated mutant, Ndom389 (only containing glycans at Asn45, Asn416 and 
Asn480) (Anthony et al, 2010), co-crystallised with the N-domain-specific inhibitor RXP407.  
These two approaches formed different space groups but had similar overall structures 
(Figure 1.2).  Interestingly, both the NB-DNJ treated protein and Ndom389 packed as two 
molecules per asymmetrical unit.  In the first structure residues L1-D612 were modelled with 
high definition, which included the linker region (P602-D612) that connects the domains in 
sACE (Corradi et al, 2006).  The first part of the linker region (P602-Y607) is rigid due to 
hydrogen bonding between Y607 and E161, whereas the last four residues (E609-D612) are 
considered highly flexible since the side chains were not defined.   
1.2.2.2 C domain structures 
Human tACE structures, which include the NB-DNJ treated protein co-crystallised with 
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tACE-g13, co-crystallised with lisinopril and its novel derivatives as well as the C-domain-
specific inhibitor RXPA380 (Watermeyer et al, 2006; Watermeyer et al, 2008; Watermeyer et 
al, 2010; Corradi et al, 2007).  These structures resolve in the same space group as a single 
molecule per asymmetrical unit.  Residues D616-Q1194 comprising the tACE ectodomain, 
were consistently resolved in these structures whereas the N terminus and flexible 
juxtamembrane stalk were not.   
Figure 1.2.  Three-dimensional structure of ACE.  A. Overlay of the N domain (light orange) and tACE 
(blue) crystal structures (PDB accession numbers: 2C6F and 1O86, res pectively).  B. Organisation of domains, 
represented with N domain structure:  lid helices (yellow), subdomain I (blue) and subdomain II (pink ).  In A and 
B, helices and residues of interest are shown (black type), glycans resolved in structures are shown as spheres 
(N domain: green and tACE: blue) and linker region shown in orange. 
 
The ~60% sequence identity of the two domains is reflected in the high homology between 
the structures.  The most marked difference being the extension of the N domain structure at 
the N and C termini compared to tACE (Figure 1.2A).  
Both domains are dominated by α-helices, contain 6 β-sheets and a number of flexible loops 
with similar positioning in the domains.  The overall topology of the domains is ellipsoid in 
shape, with a deep central groove positioned laterally, dividing the structure into two 
subdomains, I and II (Natesh et al, 2003; Corradi et al, 2006) (Figure 1.2B).  The zinc binding 
motif, HEMGH is positioned on helix α15 at a point midway along the groove where the cleft 
is slightly pinched.  Three N-terminal helices, α1-3, form a lid subdomain over the active site 
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higher B factors, a measurement of the predicted mobility of residues, than the rest of the 
molecule suggesting some degree of flexibility.  In the N domain structure the N-terminal 
region is well defined and packs tightly against helix α3 (Natesh et al, 2003).  There are also 
differences between the active sites of the two domains, which could explain substrate 
specificity.  These differences have been exploited to develop domain selective inhibitors 
(Nchinda et al, 2006a; Nchinda et al, 2006b; Kröger et al, 2009; Watermeyer et al, 2010).  
The N-linked glycosylation sequons of both domains are situated on the surface, except for 
the last sites (N domain: N494, C domain N1196).  This N domain site is situated within the 
active site cleft and the C domain counterpart was not resolved, but is in the juxtamembrane 
stalk.  In the N domain structure, the proposed hinge region on the lid subdomain is flanked 
by the 1st and 2nd sites (N9 and N25), where the latter has been shown to be important for 
thermal stability (Anthony et al, 2010).  With tACE-g13, the glycans at N648 are within 
hydrogen bonding contact of E625 at the N-terminal end of helix α3 (2.5Å) and the 
oligosaccharide at N685 are in close proximity (3.2-4.5Å) to the side chains of T651 and 
E653 at the C terminal end of helix α1.  These glycans may play a role in stabilising the lid 
subdomain with respect to the rest of the molecule (Watermeyer et al, 2006).  This data 
supports the minimal glycosylation requirements determined by site-directed mutagenesis 
(Gordon et al, 2003) (refer to Section 1.3.2).   
 
1.2.3 Dimer interfaces of the N domain three-dimensional structures 
Both the native structure and the minimally glycosylated structure resolved as two molecules 
per asymmetric unit (Corradi et al, 2006; Anthony et al, 2010).  This is intriguing as it 
suggests that regions on the surface might be involved in dimer interactions or other protein-
protein interactions.  The N domain is more extensively glycosylated than the C domain (refer 
to Section 1.3.2) and a series of mAbs raised against sACE predominantly recognised the 
N domain indicating that it is more likely involved in interactions (Danilov et al, 1994) (refer 
to Section 1.4).  Moreover, oligosaccharides on the N domain have been implicated in ACE 
homodimerisation in a proposed carbohydrate recognition domain (CRD) (Kost et al, 2000; 
Kost et al, 2003) (refer to Section 1.3.4).  The dimer interfaces, apparent from the two 
asymmetrical units, involve different orientations of the two molecules relative to each other.  
In the first, molecule B mirrors molecule A and is almost completely inverted in a “head to 
tail” arrangement (Figure 1.3) (Corradi et al, 2006).  N416 in both molecules lies at the edge 
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Figure 1.3.  Dimer interface of wild-type N domain.  Molecule A (grey) is orientated as in figure 1.2A with 
the dimer interface centred (molecule A: red, molecule B: blue) and molecule B (blue-grey) on the left.  Helices 
are numbered (eg H1), glycans resolved in structures (green spheres) and linker region in each molecule 
(orange), zinc ion (magenta) are shown. (PDB accession number: 2C6F). 
 
In the most recent structure, the two molecules are once again arranged as mirror images and 
molecule B is rotated approximately 45° (Figure 1.4) (Anthony et al, 2010).  In this way, the 
linker region of both molecules, particularly that of molecule A lies within the interface.  
N480 in both molecules lies within this region, suggesting that it might play a role in 
interaction (Anthony et al, 2010).  The unbound cysteine (C474) on both molecules lies 
within the interface.   
The dimer interfaces partially overlap the epitope of mAb 3A5 (refer to Section 1.4), 
identified as region involved in shedding of sACE (Balyasnikova et al, 2002; Balyasnikova et 
al, 2005a).  The proposed CRD, which encompasses the epitopes of mAbs 9B9 and 3G8 are 
not concomitant with these dimer interfaces (Kost et al, 2000; Kost et al, 2003).  However the 
CRD was shown to involve oligosaccharide groups and considering the degree of flexibility 
and extension of these modifications, it is possible that groups proximal to these interfaces 
may be involved.  In particular, N480 lies on the boundary of the second interface described, 
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Figure 1.4.  Dimer interface of Ndom389 .  Molecule A (grey) is orientated as in figure 1.2A with the dimer 
interface centred (molecule A: red, molecule B: blue) and molecule B (blue-grey) on the left.  Helices are 
numbered (eg H1), glycans resolved in structures (green spheres) and linker region in each molecule (orange), 
zinc ion (magenta) are shown. (PDB accession number: 3NXQ). 
 
It is important to note that the inter-chain interactions observed in the crystal structures do not 
necessarily infer interactions in vivo, particularly as there is scant evidence to indicate which 
regions are involved in protein-protein interactions of ACE. 
 
1.2.4 Homology to other structures and evidence for hinge movement 
Based on sequence homology and kinetic properties, ACE was classed in the MA clan of 
metalloproteases, closely related to carboxypeptidase A and thermolysin (Cushman et al, 
1977; Rawlings & Barrett et al, 1993).  However the crystal structures of both the N domain 
and tACE show structural homology to the metalloproteases neurolysin (Brown et al, 2001), 
thimet oligopeptidase (TOP) (Ray et al, 2004) and Pyrococcus furiosis carboxypeptidase 
(PfCP) (Arndt et al, 2002) despite little sequence homology.  Common to all these structures 
is the ellipsoid shape, a predominance of α-helices and a deep active site channel that contains 
the zinc-binding motif (HExxH) that further divides the molecule into two subdomains.  The 
structures of two ACE homologues; ACE2, similar to the N domain (Towler et al, 2004), and 
AnCE, similar to the C domain (Kim et al, 2003), revealed the same basic topology.  













CHAPTER 1: Introduction   10 
  
limits access of larger peptides.  It has been proposed that some form of hinge mechanism 
occurs upon substrate binding, which is supported by the high B factor of residues in the lid 
helices suggesting a degree of flexibility.  Solving the crystal structures of tACE in both the 
unbound and inhibitor bound forms did not show any major differences in the position of 
these helices.  However, insights into the closely related structures allows for some inference 
of the hinge mechanism in ACE.  The structure of ACE2 in particular was solved in both 
forms and adopts an “open” and “closed” conformation (Towler et al, 2004).  Modelling of 
the tACEg13 structure based on the “open” conformation of ACE2 revealed how the lid 
helices move relative to the two subdomains to open the active site cleft (Watermeyer et al, 
2006).  This mechanism was observed in TOP, neurolysin and AnCE (Brown et al, 2001; 
Kim et al, 2003; Ray et al, 2004).  Moreover, the recent structure of the minimally 
glycosylated N domain mutant, Ndom389, bound to RXP407, while detected only in the 
“closed” conformation, hinted at hinge movement due to a slight twist in molecule A 
compared to molecule B in the asymmetrical unit.  It appears that the molecule undergoes a 
twisting motion between the N and C termini with the lid helices moving away from the 
active site cleft (Anthony et al, 2010).  Epitope mapping of the N domain-specific anti-ACE 
mAbs i2H5 and 5F1, which showed anti-catalytic activity towards ACE, also revealed 
evidence of this hinge mechanism (Skirgello et al, 2006; Danilov et al, 2007) (refer to 
Section 1.4). 
 
1.2.5 Model of sACE and proposed domain interaction 
Despite successful 3D structure determination of the individual domains of sACE, the crystal 
structure of the full-length isoform has not been resolved due to the difficulty in obtaining 
reproducible, high quality crystals.  In addition to the microheterogeneity imposed by the 
oligosaccharides, the high degree of flexibility conferred by the linker region, allowing 
movement of the two domains relative to each other, is proposed to influence crystal lattice 
formation.  The high-resolution structures of the individual domains, particularly of the linker 
region, allowed for the development of a model of sACE (Corradi et al, 2006) (Figure 1.5). 
However, the lack of data for the N-terminal helices of the C domain and the side chains of 
the linker region and flexible loop limit the accuracy of the model.  The N domain has been 
shown to negatively regulate both kinetic activity of the C domain (Andujar-Sanchez et al, 
2004) and ectodomain shedding (Woodman et al, 2005) and this may be the result of 
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to Section 1.3.3).  The last four residues of the linker region have a high degree of flexibility 
and form a prominent patch with the flexible loop (K126-S138) held in place by the 
disulphide bridge C128-C136 that may interact with the C domain, having sufficient 
flexibility to mould itself to fit against the C domain (Corradi et al, 2006).  N-glycosylation 
sequons in the flexible loop (N480) and on the lid subdomain of the C domain (N648 and 
N666) may be involved in inter-domain interaction.  Corradi et al (2006) proposed two 
models of sACE representing two extremes of interaction between the domains, based on the 
fact that only 4-7 residues showed sufficient flexibly to allow movement, namely “extended” 
and “compact” models.  In the latter, there is a greater interaction surface between the 
domains and this “compact” model is consistent with the occlusion of the C domain by the 
N domain. 
 
Figure 1.5.  Proposed model of sACE in extended (left) and compact (right) orientations .  Lid helices (pink ), 
glycans (green), the linker region (red) and the flexible loop (blue) mentioned in the text are shown.  (Figure 
from Corradi et al , 2006) 
 
Recently, the electron microscopy (EM) structure of porcine pulmonary ACE, homologous to 
human sACE, was described (Chen et al, 2010).  Despite being at comparatively low 
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other.  The structure refined was similar to the “extended” model proposed by Corradi et al 
(2006), although the domains are positioned further apart than proposed.  The linker region 
connecting the two domains was observed in this structure, separating the two domains by 
between 20-25Å.  Distinct characteristics of each domain observed in the individual EM 
structures were used to identify each domain in the full-length structure.  Interestingly, a large 
central cavity was observed for the C domain, consistent with the “open” unbound 
conformation of ACE2 (Towler et al, 2004).  The N domain was assumed to be in the 
“closed” conformation since this deep pore was not observed.  The crystal structures of the 
N domain and the “open” structure of ACE2 were modelled into the assumed analogous 
domains to determine their relative positioning.  The position of the C domain is similar to 
that described by Corradi et al (2006) where the lid subdomain is orientated towards the 
N domain and could potentially be obstructed, which supports the proposed negative 
cooperativity of the C domain by the N domain.  The linker region and flexible loop (K126-
S138) in the N domain, modelled as a tight fit in the sACE model, are orientated away from 
the C domain at the C-terminal end of the active site cleft.  Interestingly, this is consistent 
with one of the dimer interfaces of the N domain crystal structures (Figure 1.3) (refer to 
Section 1.2.3).  
 
1.3 CELLULAR PROCESSING OF ACE AND PROTEIN-PROTEIN 
INTERACTIONS INVOLVED  
Extensive study of the expression of ACE in mammalian cell culture systems; including 
transformed cell lines such as CHO, human endothelial kidney (HEK) and primary cultures 
including human umbilical vein endothelial cells (HUVEC); have identified the following 
cellular events: ACE is glycosylated during processing (Section 1.3.2), undergoes ectodomain 
shedding (Section 1.3.3), has been shown to form homodimers on the cell surface 
(Section 1.3.4), and acts as an initiator of an intracellular signalling pathway (Section 1.3.5).  
Each of these functions requires specific, regulated protein-protein interactions in order to 
take place.  What is currently understood about these processes and the interactions involved 
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1.3.1 Protein-Protein Interactions 
Biological processes require the co-ordinated interactions of different proteins and peptides.  
These range from transient to permanent associations and can involve both homo- or hetero-
oligomeric interactions (reviewed in Nooren & Thornton, 2003).  The obligate formation of 
enzyme complexes required for function or the non-obligate protein-ligand, enzyme-inhibitor 
or antibody-antigen associations are some examples.  There is a continuous equilibrium 
between these types of interactions depending on physiological conditions, the cellular 
environment and the likelihood of different components encountering each other.  Protein-
protein interactions involve specific interaction surfaces that require the coordination of a 
number of residues.   The characterisation of these interaction surfaces as a means to define 
types of protein-protein interactions, considering the diversity of these associations, has led to 
the development of a number of databases and online services  (Janin et al, 2008).   
These interaction surfaces consist of hydrophobic interactions or polar interactions between 
groups in the amino acid side chain, and the protein backbone to some extent.  Transient 
interactions in particular comprise either weak non-covalent interactions or strong interactions 
that require a molecular trigger to disrupt.  The interaction surfaces of tighter associations, 
such as dimers, seem to contain a greater percentage of hydrophobic residues (Nooren & 
Thornton, 2003; Janin et al, 2008; Ma et al, 2003).  Interestingly, interaction surfaces contain 
binding hotspots, which encompass highl  conserved residues (Ma et al, 2003). 
 
1.3.2 Glycosylation of ACE and its involvement in protein-protein interactions 
1.3.2.1 Structure and function of glycosylation  
Membrane proteins undergo either N-linked or O-linked glycosylation in the rough 
endoplasmic reticulum (ER) and Golgi apparatus, where oligosaccharide synthesis and chain 
elongation occur, respectively (reviewed by Lis & Sharon, 1993; Gahmberg & Tolvanen, 
1996; Wyss & Wagner, 1996; Sears & Wong, 1998).  N-linked polysaccharide chains are 
synthesised from the pentasaccharide core consisting of two N-acetylglucosamine and three 
mannose residues (GlcNac2Man3).  This is attached to an asparagine residue in the sequon 
Asn-X-Ser/Thr -Y (Ronin et al, 1981) with a preference for sequons containing a threonine 
(Kasturi et al, 1997), where X or Y are not proline residues (Bause, 1983; Roitsch & Lehle, 
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threonine residues, by an N-acetylgalactosamine dissacharide (GalNac2), where these residues 
appear in clusters (Wilson et al, 1991). 
Oligosaccharide chains play important roles in two key aspects, namely they ensure correct 
folding and processing of proteins in the ER and, through the sequence variety introduced in 
the Golgi during chain elongation, confer greater heterogeneity to proteins, introducing a 
greater potential for interactions.  Oligosaccharides can extend some distance from the peptide 
backbone and thus act as individual domains.  The oligosaccharide sequence of N-linked 
chains is determined by the expression of particular enzymes in the Golgi and is thus specific 
to cell type and cellular conditions (reviewed by Kobata, 1992; Sears & Wong et al,1998;  
Helenius & Aebi, 2001).  
 
Figure 1.6.  Glycosylation of ACE.   
 
1.3.2.2 Glycosylation patterns of ACE isoforms 
In human somatic ACE, there are 10 potential N-linked glycosylation sequons in the 
N domain and 7 in the C domain, three of which are conserved between the domains (sites 
N45/N648, N82/N685 and N131/N731) (Figure 1.6).  Five of the sites in tACE are 
complementary to the sites in rabbit tACE (Yu et al, 1997; Kasturi et al, 1994).  Across four 
species (human, rat, rabbit and guinea pig) 7-8 sites are known to be glycosylated (Ripka et 
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performed.  The extent of glycosylation of tACE and a soluble N domain counterpart has been 
well defined.  Enzymatic deglycosylation, limited proteolysis and mass spectrometry showed 
that 6 of the potential sites of human tACE are glycosylated, with three sites (N731, N913 and 
N1162) present in both unglycosylated and glycosylated forms (Yu et al, 1997).  Using a 
similar approach, eight of the ten potential N-linked glycosylation sites in the N domain were 
shown to be glycosylated (N9, N25, N45, N82, N117, N131, N416 and N480) (Anthony et al, 
2010).  The C-terminal site (N domain: N494, C domain: N1196) is unglycosylated in both 
the N and C domains.  In tACE, this was proposed to be due to the presence of a tryptophan at 
position X (NWT) that prevents formation of the Asx-turn (Gordon et al, 2003), which is 
necessary for chain elongation (Imperiali & O’Connor, 1999).  The juxtamembrane mutant, 
tACE-Δ6, generated a novel sequon at N620 (NRSE) that was glycosylated, which appears to 
corroborate this suggestion (Schwager et al, 1999).  However, both unglycosylated sites in the 
N and C domains contain a proline at position Y (N domain: NVTP, C domain: NWTP) that 
would prevent formation of the Asx-turn and subsequent glycosylation (Bause et al, 1983; 
Roitsch et al, 1989).  This was confirmed by the recent finding that the tACE P1199L mutant, 
in which the proline is removed, is glycosylated at N1196 (Sturrock et al, unpublished results) 
and further explains why this same site in tACE-Δ6 is glycosylated since this site also lacks a 
proline at position Y. 
1.3.2.3 Role of glycosylation in ACE folding and expression 
The unique 36-residue N-terminal region of tACE, rich in serine and threonine residues, is 
heavily O-glycosylated (Ehlers et al, 1992).   O-glycosylation of tACE was not required for 
the expression of active enzyme since a human tACE construct lacking the unique N-terminal 
region was expressed and enzymatically active (Ehlers et al, 1992) as was rabbit tACE 
expressed in ldlD cells, which are unable to produce O-linked and complex N-linked sugars 
(Kasturi et al, 1994).  Since tACE has been shown to play a role in fertility, binding 
spermatozoa to the zona pellucida (Hagaman et al, 1998), it is possible that the O-linked 
sugars are involved, however the specific role of these modifications has not been established.   
Rabbit tACE expressed in E.coli (Sadhukhan & Sen, 1996) or in HeLa cells in the presence of 
tunicamycin (Kasturi et al, 1994) was degraded intracellularly implicating N-linked 
glycosylation in correct folding and expression of tACE.  Furthermore, a null mutant lacking 
all five N-linked glycan sequons showed the same results (Sadhukhan & Sen, 1996).  A 
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expressed in the presence of the α-glucosidase-I inhibitor NB-DNJ (Yu et al, 1997) and was 
used for 3D structure determination of ACE (Natesh et al, 2003) (refer to Section 1.2). 
Determination of the minimal glycosylation requirements for the expression of correctly 
folded, enzymatically active ACE using site-directed mutagenesis has been conducted for 
both the N domain and tACE (Sadhukhan & Sen, 1996; Gordon et al, 2003; Anthony et al, 
2010).  In both human and rabbit tACE, there is a preference for intact glycosylation sequons 
at the N-terminus for expression of active protein (Sadhukhan & Sen, 1996; Gordon et al, 
2003) and the presence of glycans is not site specific.  Intact glycosylation sequons at either 
the first and second sites was sufficient for rabbit tACE expressed in HeLa cells whereas the 
third site was not (Sadhukhan & Sen, 1996).  Similarly, the first and third sites (N648 and 
N685) in human tACE expressed in CHO cells were sufficient but the second (N666) was not 
(Gordon et al, 2003).  The site preferences between the two studies suggest that glycosylation 
requirements differ between species and between cell types.  The requirements of 
glycosylation for the expression of active N domain were surprisingly different to tACE 
(Anthony et al, 2010).  First, three C-terminal sites were preferred (the 7th: N289, 8th: N416 
and 9th: N480 sites) and mutants lacking all but the N terminal sites were inactive.  Second, 
the expression of an active protein, demonstrated by the mutant Ndom389 having intact sites 
at positions N45, N416 and N480, required the presence of at least three sites.  Two of these 
were required to be the 7th, 8th or 9th sites, but there was some redundancy (Anthony et al, 
2010). 
1.3.2.4 Role of glycosylation in thermal stability of ACE 
The N domain has a higher melting temperature than the C domain (Tm = 70C versus 55C 
respectively), thus it is more thermostable (Voronov et al, 2002; O’Neill et al, 2008; Anthony 
et al, 2010).  This has been attributed to the higher proportion of α-helices, increased proline 
content and extent of glycosylation of the N domain (Voronov et al, 2002).  Recent studies 
with minimally glycosylated N domain and tACE mutants demonstrate that thermostability 
does indeed depend on the presence of glycosylation with a preference for sugars at particular 
positions (O’Neill et al, 2008; Anthony et al, 2010).  In tACE, the presence of glycosylation 
at the 5th (N913) and 6th (N1162) sites confers greater thermostability (O’Neill et al, 2008) 
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1.3.2.5 Role of ACE glycosylation in protein-protein interactions 
Oligosaccharides within each domain of ACE are proximal to key interfaces.  Sites N9, N25, 
N45 and N82 in the N domain and N648, N666 and N685 in the C domain lie within or are 
proximal to the hinge region thought to be involved in substrate access.  Moreover, certain 
sites resolved in tACE are sufficiently close to residues to form an interaction (Watermeyer et 
al, 2006) (refer to Section 1.2.2).  The dimer interfaces observed with the N domain crystal 
structures also have glycans within sufficient contact (Corradi et al, 2006; Anthony et al, 
2010) (refer to Section 1.2.3) and glycans are implicated in inter-domain interaction in the 
model of sACE (Corradi et al, 2006).  Furthermore, fine epitope mapping of domain-specific 
mAbs to ACE implicated glycans in these interactions (Danilov et al, 2007; Gordon et al, 
2010; Balyasnikova et al, 2005a; Balyasnikova et al, 2007; Balyasnikova et al, 2008) (refer to 
Section 1.4.2) and ACE homodimerisation involved sialic acid or galactose residues (Kost et 
al, 2003) (refer to Section 1.3.4).  Since glycosylation is cell and tissue specific, the pattern of 
glycosylation of sACE may be an important regulator in cell associated and plasma ACE, as 
has been implicated in a recent investigation using anti-ACE mAbs to investigate sarcoidosis 
(Danilov et al, 2010a).  Moreover, a very recent study has shown that removal of galactose 
residues from ACE can modulate its activity (Batista et al, 2011). 
 
1.3.3 Interaction of ACE and its cognate sheddase in ectodomain shedding 
Although ACE is expressed as an integral membrane protein, soluble forms are found in 
plasma and other fluids (Hoop r, 1991).  This is the result of regulated cleavage secretion of 
ACE (Ehlers et al, 1991; Wei et al, 1991b; Oppong & Hooper et al, 1993; Parvathy et al, 
1997) at the plasma membrane (Beldent et al, 1995) through the action of an unidentified 
sheddase (Ehlers & Riordan, 1991b).  Thus, ACE falls into a class of membrane proteins that 
are proteolytically processed from the cell surface, which include integral membrane proteins 
such as the amyloid precursor protein (APP) (Palmert et al, 1989; Weidemann et al, 1989); 
ectoenzymes such as neprilysin (NEP) (Erdös et al, 1985); adhesion molecules such as 
L-selection and neural cell adhesion molecule (NCAM) (Nybroe et al, 1989) and receptors 
such as tumour necrosis factor-α (TNF-α) (Porteu et al, 1991) (reviewed in Ehlers & Riordan, 
1991b; Garton et al, 2006; Edwards et al, 2008; Hayashida et al, 2010).  The cleavage 
secretion of ACE in endogenously expressed cells is mirrored in cells overexpressing 
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(Ramchandran et al, 1994), indicating a common machinery amongst mammalian cells and 
thus these cell lines are a model system to study the mechanism of shedding.  
The search for the ACE secretase is on going.  Sheddases include metalloproteases, serine 
proteases and aspartate proteases, which tend to be distinguished by their inhibitor profile 
(Hooper et al, 1997).  ACE shedding is stimulated in the presence of phorbol esters such as 
phorbol 12,13-dibutyrate (PDBu) or phorbol-12-myristate-13-acetate (PMA) 
(Ramchandran et al, 1994; Ehlers et al, 1995).  This mechanism of membrane protein 
proteolysis is the result of protein kinase C (PKC) activation of the secretase most likely by 
direct phosphorylation (Bosenberg et al, 1992; Caporaso et al, 1992; Pandiella et al, 1992).  
Both basal and phorbol ester stimulated shedding are inhibited by hydroxamate-based matrix 
metalloprotease (MMP) inhibitors, including TNF-α protease inhibitors (TAPIs), compound 3 
(TAPI-II) (Ramchandran & Sen, 1995) and batimastat, which suggests that the ACE secretase 
involved is a zinc metalloprotease (Parvathy et al, 1997; Schwager et al, 1998).  Interestingly, 
shedding is stimulated in the presence of the serine protease inhibitor 3,4-dichloroisocoumarin 
(DCI) (Ehlers et al, 1995; Schwager et al, 1999), a phenomenon uniquely described for the 
proteolysis of APP by α-secretase and ACE by its unknown sheddase (Parkin et al, 2002).  
DCI-activated shedding is also inhibited by TAPI-1, suggesting that it is an activator for the 
sheddase involved in ACE shedding (Schwager et al, 1999). 
It is known that the sheddase is a metalloprotease and a requirement for shedding is that ACE 
is inserted into the membrane (Ramchandran & Sen, 1995; Beldent et al, 1995).  Cleavage 
secretion of membrane proteins such as the amyloid precursor protein (APP) has been shown 
to occur in lipid rafts or caveolae on the membrane.  However, this does not seem to be a 
requirement for ACE shedding since introduction of a glycosylphosphatidylinisotol (GPI) 
anchor that targets proteins to caveolae had no effect on shedding (Parkin et al, 2003).  
ADAM 17, or TNF-α converting enzyme (TACE or ADAM17), a common protease involved 
in shedding of many proteins, has been ruled out as the cognate ACE sheddase since TACE 
does not cleave ACE efficiently (Parvathy et al, 1998a) and ACE is still released from the 
membrane in TACE negative cell lines (Sadhukhan et al, 1999).  Knockdown of two 
metalloproteases, TACE and ADAM10, in human SH-SY5Y cells expressing either ACE or 
APP demonstrated that neither of these sheddases are involved in ACE shedding, but does 
reduce α-secretase release of APP (Allinson et al, 2004).  The ACE sheddase has a highly 
similar profile to the α-secretase that cleaves APP (Parvathy et al, 1997; Parvathy et al, 
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distinguished by the action of 4-aminophenylmercuric acetate (APMA), which stimulates 
shedding of ACE but not APP (Allinson et al, 2004). 
Pinpointing the major ACE sheddase has involved identifying regions or residues of ACE 
required for sheddase interaction.  This has been performed through two approaches, firstly, 
identification of the cleavage site and sequence/structural requirements in the stalk region for 
sheddase recognition and secondly, the identification of recognition motifs in the 
juxtamembrane region or ectodomain.   
Cleavage occurs within the juxtamembrane stalk between R1203 and S1204, in both the 
sACE (Woodman et al, 2000) and tACE (numbering of scissile bond residues in tACE - 
R627-S628) (Ehlers et al, 1996) isoforms.  The corresponding site in rabbit tACE is between 
R663 and S664 (Ramchandran et al, 1994).  Deletion mutants of the stalk region have 
demonstrated a weak specificity of the secretase for ACE, where despite removal of a number 
of residues and extended regions of the juxtamembrane stalk, ACE is still shed (Ehlers et al, 
1996; Schwager et al, 1998; Schwager et al, 1999).  From these investigations, it appears that 
the sequence around the cleavage site is not pivotal for cleavage to occur, but requires an 
unfolded stalk of 10-15 residues.  Furthermore, the secretase positions itself according to the 
ectodomain and requires a minimum distance from the membrane.  Two investigations 
showed that mutations in the stalk region can induce ACE shedding by alternate sheddases.  
In the first, an Asn to Gln mutation at position 1196 in tACE altered the cleavage site 
resulting in shedding of ACE resistant to DCI stimulation (Alfalah et al, 2001).  The same 
was observed when a serine/threonine rich sequence was introduced into the stalk region with 
the mutant ACE-JGL (Schwager et al, 1999).  Recently, substitutions in rabbit tACE of 5 
amino acids on the boundary of the ectodomain and flexible juxtamembrane showed that 
these residues were important for secretase recognition and corroborate the specific 
interaction of a sheddase (Chattopadhyay et al, 2008).   
1.3.3.1 Recognition of ACE by the sheddase 
The relaxed specificity of the cleavage site as demonstrated by numerous stalk mutations of 
ACE indicates that this is not the most significant region for sheddase recognition, which 
leaves the cytoplasmic tail and ectodomain.  Removal of the cytoplasmic tail results in 
increased basal shedding (Sadhukhan et al, 1998; Chubb et al, 2004) and therefore does not 
appear to contain a recognition motif.  Chimeras of ACE and CD4, a protein that is not shed, 
showed that the presence of the ACE ectodomain is sufficient to induce shedding and 
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However, these results are controversial in light of a similar study conducted with the 
ectodomain of another unshed protein, porcine membrane dipeptidase (MDP) where the 
presence of the juxtamembrane stalk, the transmembrane domain and cytoplasmic tail of ACE 
was sufficient to induce shedding (Pang et al, 2001).  It was proposed that the lack of 
shedding of the ACE/CD4 chimera was as a result of insufficient folding of the ACE portion, 
which included some of the ectodomain.  However, an ACE mutant lacking the C domain and 
thus with the N domain adjacent to the stalk region, ACEΔC, was not shed, corroborating the 
presence of a specific recognition motif in the C domain (Pang et al, 2001).  A conclusion of 
this study was that shedding might be the result of the action of two classes of sheddases, 
where the first has a strong affinity for residues in the juxtamembrane stalk and the second 
interacts with ACE via a specific recognition motif in the ectodomain.  
Although shedding occurs at the same cleavage site in the two ACE isoforms, sACE is shed 
less efficiently than tACE (Beldent et al, 1995; Woodman et al, 2000), suggesting different 
regulation and ACE-secretase interaction.  It was initially proposed that sACE was cleaved at 
a different site to tACE and this was the result of alteration of shedding by the N domain, 
which directs the secretase to an alternative site (Beldent et al, 1995).  However, it was shown 
that sACE is cleaved at the same site as tACE, which supports the hypothesis that cleavage is 
regulated by the N domain, possibly via occlusion of a C-domain recognition motif 
(Woodman et al, 2000).  Moreover, a region of the N domain has been implicated in the 
regulation of sACE shedding through the investigation of domain-specific mAbs to ACE.  
Three N-domain-specific mAbs, 9B9, 3A5 and 3G, were shown to alter shedding efficiency 
(Balyasnikova et al, 2002) (refer to Section 1.4).  This was proposed to be the result of 
conformational changes induced by mAb binding that would alter the access of the sheddase 
to the stalk region.  The secretase involved in mAb-induced shedding appeared to be distinct 
from that responsible for basal shedding and phorbol ester induced shedding.  ACE domain 
chimeras, where the two domain positions were swopped or the N domain as replaced with a 
second C domain, indicated that a recognition motif exists in the C domain and that the 
N domain negatively regulates shedding by occluding the C domain recognition motif 
(Woodman et al, 2005).  The crystal structure of tACE (Natesh et al, 2003) and homology 
modelling of the N domain allowed for identification of surface regions that could be 
implicated and, harnessing the high degree of sequence homology between the domains, 
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to delineate the recognition motif (Woodman et al, 2006).  This either disrupted ACE 
expression or altered its enzyme activity but did not alter shedding.   
Unlike other secreted proteins, such as aberrant release of APP in Alzheimer’s disease (Haass 
& Selkoe, 2007) and release of TNF-α in the inflammatory response (Kriegler et al, 1988; 
Gearing et al, 1994), the biological significance of secreted or plasma ACE is unknown.  It is 
possible that release of ACE from certain tissues allows for its action at distal sites.  
Alternatively, tethering the enzyme to the membrane could concentrate its effects, which 
could be regulated by ectodomain shedding.  It has been shown that membrane-bound sACE 
is critical for AngII production in the vascular endothelium since soluble ACE is not 
sufficient to restore blood pressure in null ACE mice (Kessler et al, 2007), suggesting a 
requirement for localised action. 
1.3.3.2 Regulation of ACE shedding 
In order to understand the physiological role of soluble ACE, the regulatory processes 
involved have been investigated by probing protein-protein interactions.  
Immunoprecipitation of ACE from ACE89 cells, a mouse epithelial cell line stably transfected 
with ACE, revealed an interaction with immunoglobulin binding protein (BiP) and PKC 
(Santhamma et al, 2000).  BiP is a chaperone expressed in the ER that facilitates protein 
folding (Munro & Pelham, 1987; Gething, 1999).  Interaction of BiP with ACE prolonged cell 
surface expression, but had no effec  on shedding.  The same study found that distinct 
isoforms of PKC interact directly with ACE and that these interactions are disrupted in the 
presence of phorbol esters.  However, there is scant evidence to link this interaction and 
shedding and it is more likely that the phorbol induced shedding response is mediated by PKC 
activation of the sheddase rather than ACE directly.  Moreover, PKC may be involved in 
regulation of ACE phosphorylation by CK2 (Fleming, 2006) (detailed in Section 1.3.5). 
Interestingly, tyrosine phosphorylation of the ACE ectodomain appears to regulate shedding 
where treatment of cells with pervanadate, a tyrosine phosphatase inhibitor, increased 
shedding of tACE (Santhamma et al, 2004).  Both ACE and BiP were phosphorylated 
indicating a regulation of shedding at the expression level.  This appeared to be independent 
of the PKC dependent pathway and involved p38 mitogen-activated protein (MAP) kinase. 
Investigations into ACE signalling have shown that phosphorylation by CK2 modulates ACE 
shedding (refer to Section 1.3.5) through serine phosphorylation.  Increased basal shedding in 
the absence of the cytoplasmic tail (Sadhukhan et al, 1998; Chubb et al, 2004) is indicative of 
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shown that interaction of calmodulin (CaM) with the cytoplasmic tail of rabbit tACE reduces 
shedding and that ACE is phosphorylated by CaM at S1270 (Chattopadhyay et al, 2005).  In 
this case, phosphorylation does not appear to have an effect on shedding, but may be the 
result of cell and species differentiation.  It may be that regulated shedding requires activation 
by PKC and is therefore independent of phosphorylation of the cytoplasmic tail whereas basal 
shedding is regulated by CK2 phosphorylation.   
Thus, it is apparent from the extensive investigation into cleavage secretion of ACE that it is a 
regulated process that involves specific protein-protein interactions and several potential 
regulatory pathways.  A deeper understanding of the key components of these pathways could 
help to elucidate the role of ACE shedding.  Furthermore, identifying regions or residues of 
ACE that are important for regulation of shedding and for interaction with secretases, 
co-factors or other key components would greatly enhance our understanding of these 
pathways. 
 
1.3.4 Dimerisation of ACE 
1.3.4.1 Importance of dimerisation 
Dimerisation on the cell surface is an important regulatory mechanism for many receptors; 
including those involved in cardiovascular regulation; such as the angII receptors, type 1 and 
type 2 (reviewed in Mogi et al, 2009) and BK 2 receptor (B2K-R) (AbdAlla et al, 1999).  
Dimerisation is initiated upon ligand binding and activates intracellular signalling cascades.  
Homo- and hetero-dimerisation of enzymes is also a common phenomenon, with more than 
two-thirds of described enzymes existing in dimeric or multimeric forms (reviewed in 
Marianayagam et al, 2004).  This increases enzyme stability, enables enzyme activation and 
creates binding sites for co-factors to improve enzyme function.  The endothelin converting 
enzyme 1 (ECE-1), which is structurally homologous to ACE, forms homodimers that 
increase catalytic efficiency (Shimada et al, 1996) whereas the closely related protein, NEP, 
does not.   
1.3.4.2 Homodimerisation of ACE 
Higher molecular weight (MW) forms of ACE have been observed during gel electrophoresis 
of purified samples (Naim et al, 1992; Kohlstedt et al, 2006) and have been attributed to 
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system (Kost et al, 1998; Kost et al, 2000 Kost et al, 2003) and in primary cell culture, 
HUVEC and porcine aortic endothelial cells  (Kohlstedt et al, 2006).  
It was demonstrated that sACE has the ability to form a homodimer using a split-ubiquitin 
assay in Saccharomyces cerevisiae (Kohlstedt et al, 2006).  In the reverse micelle system 
purified full-length sACE was detected as both a monomer and higher MW variants consistent 
with dimeric and oligomeric forms (Kost et al, 2003).  An N-domain isoform, generated by 
limited proteolysis of human sACE by trypsin, formed both monomer and dimer in the same 
system and the bovine N domain counterpart formed multiple higher MW forms (Kost et al, 
2000; Kost et al, 2003).  Purified tACE was detected solely as a monomer.  Dimers observed 
with sACE and the N domain were inhibited in the presence of galactose (Kost et al, 2000; 
Kost et al, 2003), indicating that carbohydrate residues were likely involved in dimer 
formation and a carbohydrate recognition domain in the N domain was proposed (Kost et al, 
2000; Kost et al, 2003).  A putative region of the N domain involved in dimerisation was 
identified using two mAbs to ACE (described in more detail in Chapter 4).  These two mAbs, 
9B9 and 3G8, shown to affect shedding of ACE from CHO cells, inhibited dimerisation in 
reverse micelles. 
Formation of ACE dimers on the surface of porcine aortic endothelial cells was induced by 
ACE inhibitors and initiated the intracellular signalling cascade (detailed in Section 1.3.5) 
(Kohlstedt et al, 2006).  The presence of either sugars such as galactose and glucose and the 
mAbs mentioned previously had no effect on this process (Kohlstedt et al, 2006).  Active site 
knockout mutants demonstrated that an active C domain was required for this inhibitor-
associated dimerisation to occur.  These two studies are the first indication of self-association 
of ACE and implicate this process in other important cellular events such as shedding and 
intracellular signalling. 
The mechanism of ACE homodimerisation is unclear.  In work by Kost et al, carbohydrate 
residues and a carbohydrate recognition domain in the N domain are implicated suggesting a 
non-covalent interaction (Kost et al, 1998; Kost et al, 2000; Kost et al, 2003) and more 
detailed mapping of the epitopes of the mAbs that inhibit dimerisation would be useful in 
understanding this further.  The C domain dependent dimerisation described by Kohlstedt et 
al (2006) was detected by chemical cross-linking of cell lysate and thus it is unclear what 
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1.3.4.3 Heterodimeric interactions of ACE 
The substrate promiscuity of ACE and its increasing role in physiological pathways, 
implicates a number of protein-protein interactions in communication and regulation of these 
processes.  What is known regarding protein-protein interactions of ACE and components of 
other systems is detailed here. 
There is a degree of cross-talk between components of the RAAS and KKS.  The B2K-R is 
resensitised, namely it is able to re-couple with G-protein for signal transduction, in the 
presence of ACE inhibitors (Minshall et al, 1997; Marcic et al, 1999; Marcic et al, 2000) and 
this was found to be dependent on direct interaction of ACE, through the formation of 
heterodimers on the cell surface (Chen et al, 2006).  Binding of ACE inhibitors is thought to 
stabilise the heterodimer and prevent homodimer formation of B2K-R, which would 
otherwise lead to internalisation (Marcic et al, 2000). 
Recently, heterodimerisation of ACE and the GPI-anchored protein carboxypeptidase M 
(CPM) has been described (Sun et al, 2008).  This corroborated the finding that ACE has 
GPI-ase activity, cleaving proteins such as CPM from the membrane, which was linked to 
male fertility (Kondoh et al, 2005).  However, this novel function of ACE was not 
substantiated in a follow-up study using various GPI-anchored proteins (Leisle et al, 2005) 
and remains controversial. 
 
1.3.5 Intracellular Signalling of ACE 
Kohlstedt et al  (2002, 2004, 2005, 2006) have shown in both primary HUVEC endogenously 
expressing ACE and ACE overexpressed in porcine aortic endothelial cells that ACE can act 
as a signalling molecule initiating an intracellular cascade to regulate gene expression.  The 
same signalling pathway has been demonstrated in CHO cells overexpressing murine sACE 
(Sun et al, 2010).  There is also preliminary evidence to suggest that the same occurs in a 
mouse model (Fleming, 2006).  Recently, this was also described in preadipocytes and 
adipocytes (Böttcher et al, 2006; Kohlstedt et al, 2009; Kohlstedt et al, 2010), demonstrating 
a link in the ACE inhibitor effects on the development of type-2 diabetes.   
There are 5 serine residues in the short cytoplasmic tail of human ACE and 1 tyrosine and 
3 serines in murine ACE, potential sites for phosphorylation and the initiation of a signalling 
cascade.  Three serines of human ACE lie within consensus binding sites for PKC (S1253), 
protein kinase A (PKA) (S1263) and casein kinase (CK2) (S1270) (Kohlstedt et al, 2002).  A 
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D-ribofuranosylbenzimidazole (DRB), a CK2 inhibitor, did.  Further investigation showed 
that ACE is phosphorylated by CK2 (Kohlstedt et al, 2002) at S1270 resulting in association 
of MAP kinase kinase 7 (MKK7) and the activation of c-Jun N-terminal kinase (JNK) leading 
to phosphorylation of c-Jun (Kohlstedt et al, 2004).  c-Jun then translocates to the nucleus and 
activates gene expression of ACE and cyclooxygenase-2 (COX-2), which is involved in pain 
and inflammation (Kohlstedt et al, 2004; Kohlstedt et al, 2005) (Figure 1.7).   
This signalling cascade is initiated by binding of ACE inhibitors and, to some extent, BK 
(Kohlstedt et al, 2004).  However, angI, the major substrate for ACE, does not initiate this 
cascade in porcine aortic endothelial cells overexpressing human ACE.  Interestingly, angI 
and BK, as well as angII, were shown to increase JNK activity in CHO cells overexpressing 
murine ACE (Sun et al, 2010), suggesting species specificity in this pathway. 
 
Figure 1.7.  ACE signalling pathway.  Binding of ACE inhibitors  (ACEi) induces dimer formation, which 
activates CK2, phosphorylating ACE at S1270 leading to association of MKK7. JNK is then activated and 
phosphorylates c-Jun, which translocates to the nucleus and activates gene expression. 
  
The mechanism involved in ACE inhibitor initiation of signalling is unclear, although it is 
most likely induced by conformational changes upon binding.  ACE homodimerisation has 
been shown to mediate signalling upon inhibitor binding (Kohlstedt et al, 2006).  This 
requires an active C domain, demonstrated by active site knockouts.  Once again there 
appears to be some degree of species selectivity since murine ACE active site knockouts 
showed some preference for signalling via the C domain, although the N domain alone 
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some degree of negative cooperativity between domains with regards to JNK activation upon 
substrate binding. 
CK2 phosphorylation of ACE appears to regulate basal shedding of ACE (Kohlstedt et al, 
2002).  Soluble ACE is not phosphorylated and the S1270A mutant, which lacks the ability to 
be phosphorylated, was shed more efficiently.  Once phosphorylated by CK2, ACE is retained 
in the plasma membrane.  Phorbol ester stimulated shedding was independent of this process, 
indicating that this results in activation of a metalloprotease by PKC whereas basal shedding 
is regulated by CK2 phosphorylation.  
 
1.4 PROBING PROTEIN-PROTEIN INTERACTIONS WITH ANTI-ACE 
MONOCLONAL ANTIBODIES 
1.4.1 Use of monoclonal antibodies for protein structure-function analysis 
MAbs being targeted to specific regions of a protein are valuable tools in structure-function 
studies.  Fine-epitope mapping of mAbs to a particular protein, in combination with site-
directed mutagenesis, can facilitate the identification of regions or hotspots on the surface 
involved in protein-protein interactions, particular functions or facilitate structure 
determination.   
 
1.4.2 Epitopes of domain-specific anti-ACE monoclonal antibodies 
The 3D structures of both domains has facilitated fine-epitope mapping of domain-specific 
anti-ACE mAbs.  The epitopes of these mAbs have been defined using a combination of site-
directed mutagenesis, cross-species reactivity and reactivity towards different ACE isoforms 
and deletion constructs or chimeras.  Residues that affect mAb-ACE interaction were used to 
delineate regions of 700-800Å2, encompassing the mAb epitopes.  The epitopes of eight 
N domain-specific mAbs (9B9, 3G8, 3A5, i1A8, 6A12, 1G12, 5F1 and i2H5) and eight 
C domain-specific mAbs (1B3, 1B8, 3F10, 1E10, 4E3, 2H9, 3F11 and 2B11) have been 
mapped to regions of each domain (Danilov et al, 1994; Balyasnikova et al, 2005b; 
Skirgello et al, 2006; Danilov et al, 2007; Balyasnikova et al, 2007; Balyasnikova et al, 2008; 
Naperova et al, 2008a; Gordon et al, 2010).  The binding of these mAbs to different ACE 
chimeras has allowed for the identification of regions that may be involved in protein-protein 
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different ACE isoforms has given an indication of the interaction surface between the two 
domains.   
1.4.2.1 N domain-specific monoclonal antibodies 
The epitopes of the eight N domain-specific mAbs were classed into three antigenic regions, 
based on competitive binding assays (Danilov et al, 1994) (Figure 1.8).  The first consists of 
mAb 5F1, the second of mAbs i2H5, 1G12 and 6A12 and the third of mAbs 3A5, i1A8, 9B9 
and 3G8.  Interestingly, mAb 3A5 competitively inhibited binding of all other mAbs despite 
having different epitopes, which could be explained by a gross conformational change in the 
N domain upon binding of mAb 3A5 that alters the epitopes of the other mAbs.   
The first antigenic region contains the epitope of mAb 5F1 and is localised on the distal side 
of the molecule compared to the other N domain-specific mAbs (Danilov et al, 1994; 
Danilov et al, 2007).  It is proximal to the linker region and spans the active site cleft 
(Danilov et al, 2007).  N-linked glycosylation sites N45 and N117 lie within the epitope of 
mAb 5F1 and sites N133 and N480 are proximal to this epitope.  The second antigenic region 
(mAbs i2H5, 1G12 and 6A12) is localised on the C terminal portion of the N domain on 
subdomain II.  N-linked glycosylation site N416 lies within this region and site N289 lies 
within the epitope of mAb 6A12.  The epitopes of mAbs i2H5, 6A12 and 1G12 overlap to an 
extent, encompassing the flexible loops between helices α18 and α19 and between helices α23 
and α24 (Skirgello et al, 2006; Balyasnikova et al, 2007).  The epitope of mAb i2H5 lies 
below this overlap at the C terminal edge of the active site cleft, with mAb 6A12 above it and 
mAb 1G12 to the anterior portion, distal to the active site cleft.  The third antigenic region 
encompasses four epitopes (mAbs 3A5, i1A8, 9B9 and 3G8) with varying degrees of overlap 
in the N terminal protein of subdomain II, distal to the active site cleft.  The epitope of i1A8 is 
positioned proximal to the epitope of mAb 1G12 albeit slightly closer to the N terminal 
portion.  The epitope of mAb i1A8 overlaps with those of mAb 3G8 and 9B9, which 
themselves overlap and are positioned within the lid subdomain (Danilov et al, 1994; 
Gordon et al, 2010).  N-linked glycosylation sites N9, N25, N82 lie within this overlapping 
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Figure 1.8.  Epitopes of N domain-specific mAbs .  Surface structure of wild-type N domain depicting the 
epitopes of 8 mAbs, divided into three regions (A, B and C) (PDB accession no 2C6F). 
 
A. SF1 B. 1 G12, SA 12, i2HS, (3AS) 
c. 9B9, 3GS, i1 AS, 3AS 
-9B9 3G8 
9B9, 3G8 overlap 
i1A8 -3A5 1G12 -6A12 _ 1G12, 6A12, i2H5 overlap 
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1.4.2.2 C domain-specific monoclonal antibodies 
The C domain-specific mAbs have not been as extensively investigated as their N domain 
counterparts.  However, some preliminary epitope mapping has allowed for the localisation of 
their epitopes and implicated particular regions in ACE function and inter-domain interaction 
(Naperova et al, 2008a; Naperova et al, 2008b; Balyasnikova et al, 2008).  Competitive 
binding assays placed the eight C domain-specific epitopes into three antigenic regions 
(Naperova et al, 2008b) (Figure 1.9).  The first comprises mAbs 1B8 and 3F10, the second 
mAb 1B3 and the third mAbs 2H9, 1E10, 4E3, 2B11 and 3F11 (Naperova et al, 2008a).   
The first region lies towards the C-terminus of the C domain on the edge of the active site 
cleft.  It encompasses the flexible loop (T726-E738), which forms a large protrusion from the 
surface.  This loop is homologous to the flexible loop in the N domain (K126-S138) proposed 
to create a large reaction surface for domain interaction (Corradi et al, 2006).  Epitope 
mapping showed that the epitope of mAb 1B3 overlaps the epitopes of mAbs 1B8 and 3F10. 
Figure 1.9.  Epitopes of C domain-specific mAbs .  Surface structure of wild-type C domain depicting the 
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The mAb 1B3 epitope lies on the C-terminal end of the C domain, recognising the 
juxtamembrane stalk in particular (Balyasnikova et al, 2005b).  Epitopes within the third 
antigenic region (mAbs2H9, 1E10, 4E3, 2B11 and 3F11) lie on the N-terminal portion of the 
C domain (Naperova et al, 2008a).  mAbs 1E10 and 4E3 bind to overlapping epitopes, 
encompassing the lid helices α2 and α3.  The epitopes of mAbs 2H9, 3F11 and 2B11 lie in an 
overlapping region distal to the active site cleft.  Interestingly, the unique 36-residue region of 
tACE did not alter binding of the C domain-specific mAbs and does not appear to confer 
immunogenicity. 
1.4.3 Anti-catalytic activity of domain-specific anti-ACE monoclonal antibodies 
The N domain-specific mAbs 3A5 and i2H5, which each lie in different antigenic regions, 
show anti-catalytic properties towards ACE (Danilov et al, 1994; Danilov et al, 2007; 
Skigello et al, 2006,).  Similarly, mAb 5F1 was shown to have an inhibitory effect on ACE 
activity, observed at only high concentrations due to the weak binding of the mAb to ACE 
(Danilov et al, 2007).  MAbs 3A5 and i2H5 bind the enzyme-substrate complex more readily 
in kinetic analysis using the synthetic substrates benzyloxycarbonyl-Phe-L-His-Leu (ZFHL) 
and hippuryl-L-His-L-Leu (HHL) and bind ACE more efficiently in the presence of the ACE 
inhibitor lisinopril (Skirgello et al, 2006).  This not only demonstrates that ACE undergoes a 
conformational change upon substrate binding, corroborating the proposed hinge mechanism, 
but also explains the anti-catalytic effect.  Since the mAb i2H5 epitope is proximal to the 
active site cleft, it can be argued that binding locks ACE into the “closed” position hampering 
access of substrates.  Comparably, the epitope of mAb 5F1 spans the active site cleft and its 
inhibitory effect can be explained in the same way (Danilov et al, 2007).  Binding of mAb 
3A5, which is positioned distal to the active site, appears to confer a gross conformational 
change on the N domain that subsequently alters substrate access.  A similar anti-catalytic 
effect was observed towards the C domain with mAbs 4E3 and 1E10 (Naperova et al, 2008a).  
In this case the ratio of conversion of ZFHL to HHL (Danilov et al, 2008) was used to assess 
the activity of each domain in the presence of mAbs.  Since the epitopes of these mAbs lie in 
the lid subdomain, it is possible that their interaction with ACE prevents the proposed hinge 
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1.4.4 Effect of domain-specific anti-ACE monoclonal antibodies on shedding 
The N domain-specific mAbs 9B9 and 3A5 have been demonstrated to stimulate shedding of 
ACE (by 3- and 4-fold respectively) whereas mAb 3G8 inhibited shedding by 30% 
(Balyasnikova et al, 2002; Balyasnikova et al, 2005).  The inhibitor profile of mAb-induced 
shedding was altered compared to basal and phorbol ester induced shedding.  The DCI 
induction of shedding was much stronger in the presence of mAbs and the presence of the 
PKC inhibitor, staurosporine, unexpectedly stimulated mAb shedding further.  This implicates 
an alternate shedding mechanism.  It has been proposed that binding of these antibodies 
results in conformational change that allows better access of the secretase, most likely due to 
rearrangement of the two domains.  This could either result in exposure of the C domain 
recognition motif or the juxtamembrane stalk containing the cleavage site.  
Binding of the C domain-specific mAbs 1B3, 1B8 and 3F10 depend on the presence of the 
juxtamembrane region (Naperova et al, 2008a) and are thus valuable in probing the 
conformation of the stalk region and the effect of changes in this region on ACE cleavage 
secretion (Balyasnikova et al, 2005b; Naperova et al, 2008a).  In particular, mAb 1B3 was 
used to define the effect of the P1199L mutation on shedding and has been developed in 
conjunction with mAb 9B9 in an immunoassay to detect P1199L and other ACE mutants in 
plasma (Danilov et al, 2005).   
1.4.5 Effect of N domain-specific an i-ACE monoclonal antibodies on dimerisation 
As has been mentioned in Section 1.3.4, sACE forms dimers in reverse micelles that appear to 
be mediated by a carbohydrat  recognition motif in the N domain (Kost et al, 2000; Kost et 
al, 2003). A potential dimer interface was identified using the panel of N domain-specific 
mAbs.  Both mAbs 9B9 and 3G8 in overlapping epitopes of the same antigenic region 
inhibited dimer formation in the reverse micelle system (Kost et al, 2003).  Interestingly, 
these two mAbs have opposite effects on shedding (Section 1.4.4), suggesting a link between 
these two processes.  Fine epitope mapping identified residues that play an important role in 
mAb binding and the role of this region in dimerisation and shedding is detailed in Chapter 4 
(Gordon et al, 2010).  
1.4.6 Use of monoclonal antibody binding to determine domain interactions 
The N domain-specific mAbs 1G12 and 6A12, and mAb i2H5 to some extent, were more 
reactive towards the N domain than full-length sACE, indicating that the epitopes of these 
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binding of mAbs 1G12 and 6A12 to plasma ACE, but not the N domain alone, was increased 
in the presence of ACE inhibitors and EDTA.  The latter chelates the active site zinc, 
rendering ACE inactive.  This suggests that upon inhibitor binding there is rearrangement of 
the domains, reducing the degree to which the N domain is occluded by the C domain, 
thereby exposing the epitopes of these two mAbs.  The use of domain-specific inhibitors and 
active site knockouts could not distinguish a particular domain, which implies that both 
domains are involved in this rearrangement.  Similarly, the epitopes of the C domain-specific 
mAbs 1E10 and 4E3 appear to be occluded by the N domain, since they bound tACE more 
efficiently that sACE (Naperova et al, 2008a).   
 
Figure 1.10.  sACE domain interaction.  The “compact” and “extended” models of membrane-bound sACE are 
depicted with the position of the mAb epitopes shown as circles.  The potential masking of the epitope s by each 
domain in the “compact” model can be seen. 
 
The position of the antigenic region in the N domain containing the epitopes of mAbs 1G12, 
6A12 and i2H5 is consistent with the model proposed by Corradi et al (2006).  The authors 
indicated there is a range within the proposed model wherein the two domains could interact.  
With a slight rotation of the C domain around the N domain in the “compact” model, the 
C domain comes into close proximity to the antigenic region containing the epitopes for 
mAbs 1G12, 6A12 and i2H5.  The C domain lid subdomain, wherein the epitopes of mAbs 
1E10 and 4E3 are located, is in contact with the N domain in both the “extended” and 
“compact” models and was modelled in a similar orientation in the EM structure (Chen et al, 
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1.5 AIMS OF RESEARCH 
As has been laid out in this chapter, cellular ACE expression and function is regulated by 
specific protein-protein interactions; from correct folding in the ER, to cell surface 
expression, ectodomain shedding, enzyme function including substrate binding and domain 
interaction and intracellular signalling.  However, there are many aspects of these events that 
are not clearly understood.  Identifying surface regions or residues of ACE that may be 
involved in these processes may give insight into regulatory pathways of ACE expression.  In 
this way, the structure-function of ACE with respect to shedding and dimerisation and the 
interaction of the two domains may be explored.   
 
The objectives of this study were: 
1. To investigate the effect of introducing a novel disulphide bridge on stabilising inter-
domain movement of sACE. 
2. To identify region/residues involved in dimerisation and shedding using fine-epitope 
mapping. 
3. To determine the role of the free cysteines in each domain in dimerisation and shedding. 
4. To determine the biochemical mechanism of increased plasma ACE observed with a 
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CHAPTER 2:  Materials And Methods 
 
2.1 MUTAGENESIS AND SUBCLONING 
2.1.1 ACE constructs 
Recombinant full length human somatic ACE cloned into the sequencing vector pBluescript 
KS II (pBS-sACE) was used as a template for site-directed mutagenesis.  This sequence 
encodes the entire ACE coding region including the signal sequence, N-terminal and 
C-terminal catalytic domains, the transmembrane region and the cytoplasmic tail (Figure 2.1).  
A soluble N-domain form of ACE in the plasmid pBluescript SK II (pBS-Ndom) was also 
used as a template.  This construct was generated by Pierre Redelinghuys as part of his 
doctoral work from the pECE-ACED629 plasmid, a generous gift from Prof. S Danilov 
(University of Illinois at Chicago, USA) (Balyasnikova et al, 2003).  This sequence is a 
truncated form of sACE that contains the catalytic N domain, 11 residues of the linker region 
and 17 residues of the C domain, terminated at D628 by a stop codon introduced via an 
engineered XbaI site.   
The generation of each mutant by site-directed mutagenesis is described in the relevant 
chapter.  Briefly, pBS-Ndom was used to generate Ndom-H600C, Ndom-EY/CC (Chapter 3), 
and mutants for epitope mapping (Chapter 4).  pBS-sACE was used to generate sACE-H600C 
(Chapter 3), sACE-Q22A (Chapter 4), sACE-C474S, sACE-C1072S and sACE-CC/SS 
(Chapter 5). 
For expression of protein in CHO cells, genes were cloned into the mammalian expression 
vector pcDNA3.1 (Invitrogen, USA), which contains a neomycin resistance gene for selection 
of stable cell lines.  Full-length sACE was generated by excising the entire coding region 
from pBS-sACE with XbaI and HindIII and cloning it into pcDNA3.1(+).  Wild-type soluble 
N domain was generated by cloning the coding region via EcoRI/XbaI into pcDNA3.1(-). 
Constructs pcDNA-Ndom-H600C and pcDNA-Ndom-EY/CC (Chapter 3) were generated by 
Gannie Tzoneva using the approach described above.  Briefly, site-directed mutagenesis was 
performed using pBS-Ndom as a template to introduce cysteine residues at either position 
H600 or positions E161 and Y607.  These constructs, NdomH600C and NdomEY/CC, were 
then cloned into pcDNA3.1(+) for expression in CHO cells. 
Soluble sACE constructs were generated by introducing a fragment containing the mutation 
into pcDNA-sACE-NJ.  This construct is a truncated form of sACE that lacks the 
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N-terminal portion of sACE into pcDNA-tACE-Δ36NJ via XbaI/SfiI.  The tACE-Δ36NJ 
construct is a fully N-glycosylated soluble form of tACE, which lacks the unique N-terminal 
O-glycosylated region and was created by introducing two stop codons and an EcoRI site at 
S1201 (Yu et al, 1997).   
Another soluble sACE isoform (pcDNA-solsACE), transfected into CHO cells, available in 
our laboratory was used as a source of wild-type sACE for protein purification.  This protein 
also lacks the transmembrane domain and cytoplasmic tail and is truncated at S1211, 
downstream of the endogenous cleavage site.  
tACE-Δ36-NJ and CCdom-AC were used in western blotting experiments (refer to Chapter 5, 
Section 5.2.2).  CCdom-ACE is a two-domain construct where the N domain has been 
replaced by a second C domain (Woodman et al, 2005).   
 
Figure 2.1  Schematic representation of ACE constructs .    
 
2.1.2 Site-directed mutagenesis  
Mutagenesis was performed using a PCR-based method adapted from the Quickchange® 
Site-Directed Mutagenesis protocol (Stratagene La Jolla, CA, USA).  Complementary primers 
containing the desired mutation were designed with WATCUT 
(http://watcut.uwaterloo.ca/watcut, designed by Michael Palmer, University of Waterloo, 
Canada.), using the restriction analysis and silent mutation analysis software, and purchased 
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Restriction enzyme sites were introduced through silent mutations to facilitate screening.  
Mutagenesis was performed with either Pfu Turbo polymerase (Promega, USA) or High 
Fidelity Taq polymerase (Kapa Biosystems, South Africa) on a Hybaid Express thermocycler 
(Hybaid Ltd, UK) (refer to Appendix A.1.8).  Aliquots of the PCR products were visualised 
by agarose gel electrophoresis, while the remainder was DpnI digested overnight, transformed 
into E.coli JM109 competent cells and plated on Luria agar plates with 100g/ml ampicillin 
(refer to Appendix A.1.3).  DNA was isolated from overnight cultures of picked colonies and 
screened by restriction enzyme digestion (refer to Appendix A.1.4 & A.1.5).  Mutations were 
confirmed by DNA sequencing analysis using primers flanking the multiple cloning site (T7 
and T3) and internal primers complementary to ACE cDNA (refer to Appendix A.1.2).    
Sequencing reactions were performed by Di James (Molecular and Cell Biology DNA 
Sequencing Service, UCT, South Africa) using Big Dye® Terminator v3.1 Cycle Sequencing 
kit (Applied Biosystems, USA) and Half-dye Mix (Bioline, UK).  Electrophoresis was 
performed by Macrogen Inc. (Korea) using a 3730XL DNA sequencer (Applied Biosystems, 
USA). 
sACE-Y465D was a gift from Prof S. Danilov and comprises sACE cDNA containing the 
Y465D mutation in the pcDNA-Hyg vector. 
2.1.3 Introduction into a mammalian expression vector 
pBS-sACE or pBS-Ndom constructs containing the desired mutation were introduced into the 
mammalian expression vector pcDNA3.1 (- or + depending on the desired orientation of the 
multiple cloning site).  Details of the subcloning of each mutant into pcDNA are described in 
the relevant chapters, following the same general protocol described below.   
DNA was digested with the relevant restriction enzymes to excise the vector (pcDNA) and 
insert DNA (pBS-sACE or pBS-Ndom  mutants) and separated by agarose gel electrophoresis 
refer to Appendix A.1.5).  The bands of interest were excised and gel purified using the 
Wizard SV Gel and PCR Clean-up System (Promega, USA) as per the manufacturer’s 
instructions.  DNA ligation was performed using T4 DNA Ligase (Fermentas, USA) at 4C 
for 48 hours and transformed into competent E.coli JM109 cells and plated on Luria agar 
plates with 100g/ml ampicillin (refer to Appendix A.1.6).  DNA was isolated from overnight 
cultures of colonies, digested with restriction enzymes and separated by agarose gel 
electrophoresis to confirm the presence of the mutation.  Sufficient DNA for transfection was 
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determined spectrophotometrically using a Nanodrop 2000 (Thermo Scientific, USA).  The 
correct orientation and size of the ACE construct and the desired mutation were confirmed by 
restriction enzyme digestion and agarose gel electrophoresis. 
2.1.4 RNA isolation and RT-PCR 
CHO cells grown to confluency in enriched medium were lysed in Trizol® reagent 
(Invitrogen, USA) and separated into an organic and aqueous phase by the addition of 
chloroform.  RNA was precipitated from the aqueous phase with isopropanol and washed 
with 70% ethanol.  RNA was resuspended in 50l nuclease-free double distilled deionised 
water (dH2O), quantitated by nanodrop and visualised by agarose gel electrophoresis.  RNA 
from cell lines expressing the mutants, untransfected CHO cells, and total human placental 
RNA (included as a positive control) was used to synthesise cDNA with the Advantage® RT-
for-PCR kit (Clonetech Laboratories, USA) (refer to Appendix A.1.7).  ACE DNA was 
amplified by PCR from total cDNA using internal primers to ACE DNA (1R and 3F) (refer to 
Appendix A1.1).  Human glyceraldehyde-3-phosphate dehydrogenase (G3PDH) cDNA was 
amplified as a positive control using the supplied primers.  PCR was performed with Hi-Fi 
Taq polymerase (Kapa Biotech, South Africa) on a Hybaid Express thermocycler (Hybaid 
Ltd, UK) (refer to Appendix A.1.8.3).  PCR products were visualised by agarose gel 
electrophoresis. 
 
2.2 PROTEIN EXPRESSION AND CHARACTERISATION 
2.2.1 Expression of recombinant ACE in mammalian cells 
2.2.1.1 Transfection into mammalian cells 
DNA was introduced into CHO cells using the calcium phosphate method according to the 
manufacturer’s instructions (Profection Mammalian Transfection System, Promega, USA).  
After transfection, cells were grown to confluency in enriched medium [50% Dulbecco’s 
Modified Eagle Medium (DMEM) (Sigma, USA), 50% HAMS-F12 (Sigma, USA) 
supplemented with 10% foetal calf serum (FCS)(Sigma, USA) and 20M HEPES buffer] 
containing 0.8mg/ml geneticin G418 (Sigma, USA) for pcDNA3.1 constructs or 400g/ml 
hygromycin (Sigma, USA) for pcDNAHyg-Y465D to select for positive clones.  Cells were 
grown in the presence of selective medium until all cells in the negative control plates (no 
vector DNA added) had died off and colonies were observed in the transfected plates.  In the 
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C474S, sACE-C1072S, sACE-CC/SS, sACE-H600C and sACE-Y465D), cells were then 
lifted and seeded for fluorescence-activated cell sorting (FACS).  For the soluble isoforms 
(sACE-NJ and sACE-H600C), individual clones were picked and grown to confluency.  Cells 
were then serum starved overnight in minimal medium [50% DMEM, 50% HAMS-F12 
supplemented with 2% FCS, 20M HEPES buffer, 100U/ml penicillin and 100g/ml 
streptomycin], and the medium assayed for ACE activity.  Colonies that produced the highest 
ACE activity were used in our experiments.  Soluble N domain mutants were used without 
clonal selection. 
2.2.1.2 Selection of high expressing cells lines 
For selection of high expressing cell lines by FACS, approximately 5x106 cells were lifted 
from confluent flasks and washed twice in phosphate-buffered saline (PBS).  They were then 
labelled for an hour with 10g/ml mAb 5C5 (an N domain-specific anti-ACE monoclonal 
antibody), followed by extensive washing in PBS.  Cells were then incubated for an hour with 
a goat anti-mouse IgG FITC-conjugated F(ab’)2 fragment (Dako, Denmark), followed again 
by extensive washing in PBS.  FACS was performed on labelled cells by Ronnie Dreyer at the 
Flow Cytometry Core Facility  (Department of Immunology, UCT, South Africa) on a FACS 
VantageTM SE cytometer (BD Biosciences, USA).  Cells were gated according to highest 
fluorescence into enriched medium with 100U/ml penicillin and 100g/ml streptomycin.  
Cells were grown to confluency and then assayed for ACE activity. 
For experiments described below, medium was harvested and cells lysed in 1% triton lysis 
buffer (0.05M HEPES, 0.5M NaCl, 1% triton X-100, 1mM PMSF) containing Protease 
Inhibitor Cocktail (Set III, Calbiochem, USA - 0.2mM AEBSF, 0.16M Aprotinin, 0.01mM 
Bestatin, 3M E-64, 4M Leupeptin and 2M Pepstatin A).  Samples were centrifuged at 
10000xg for 5 minutes and the supernatant extracted. For plate precipitation assays and 
western blotting, medium was concentrated using Amicon or Micron centrifuge columns 
(Millipore, USA) to between 80 and 100mU/ml ACE. 
2.2.2 Determination of ACE activity 
Cell lysate, medium or purified protein was assayed for ACE activity using the synthetic 
peptide ZFHL (for preparation refer to Appendix A.2.5.1) as a substrate and the fluorescent 
adduct o-phthaldialdehyde for detection using a fluorescent assay (Friedland et al, 1976) 
adapted for a microtitre plate as described previously (Schwager et al, 2006).  Assays were 
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incubated with 30μl 1mM ZFHL in 1X potassium phosphate buffer (100mM 
KHPO4/KH2PO4, pH 8.3) at 37°C for 15 minutes, 1 hour or 4 hours, depending on expression 
levels of ACE in cells.  Enzyme activity was stopped by addition of 120μl 0.4M NaOH.  The 
HL moiety was derivitised with o-phthaldialdehyde (24mg/ml in methanol) at room 
temperature for 10 minutes.  This reaction was stopped with 30μl 3M HCl.  Fluorescence 
intensity was measured using a fluorescence spectrophotometer (Varian Inc., USA) at λexcitation 
= 360nm and λemission = 485nm.   1 milliunit (mU) of ACE activity was calculated as nmol His-
Leu (HL) formed/minute from a standard curve of fluorescent units (FU) versus HL 
concentration (refer to Appendix A.2.2).  
2.2.3 Protein purification 
Soluble N domain and sACE cell lines were seeded into four 150cm2 flasks and grown to 
confluency in enriched medium.  Cells were then incubated in minimal medium, with medium 
being harvested and frozen after 48-72 hours for four harvests.  Medium was thawed at 4C 
overnight and protein was purified by lisinopril sepharose affinity chromatography (Bull et al, 
1985).  For N domain constructs, 0.8M NaCl was added to the medium to facilitate 
purification.  Medium was applied to a sepharose-28-lisinopril column and washed 
thoroughly (0.5M NaCl, 20mM HEPES, pH 7.5) to remove unbound protein.  ACE was 
eluted from the column with 50mM Borate (pH 9.5) followed by overnight dialysis against 
50mM HEPES.  Protein concentration determined by Bradford protein assay (BIO-RAD 
Bradford reagent, USA) (Appendix A.2.1) or by A280 absorbance on a nanodrop.  Protein was 
then concentrated on Amicon centrifuge columns to approximately 1mg/ml.  Sodium dodecyl 
sulphate (SDS)-polyacrylamide gel electrophoresis (PAGE) (Section 2.2.7) and Coomassie 
staining was performed to visualise the purity and integrity of the purified protein. 
2.2.4 Determination of ACE shedding 
Cells were grown until confluency in enriched medium.  Confluent cells were then grown in 
the presence of minimal medium or serum-free medium (Gibco Opti-MEM, Invitrogen, USA) 
for 4 hours (high ACE expressing cell lines) or for 16 or 24 hours (low ACE expressing cell 
lines).  Medium was harvested and cells were lysed in 1% triton lysis buffer and assayed for 
ACE activity as described above.  The percentage ACE shed was calculated as the ratio of 
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2.2.4.1 Effect of phorbol ester and DCI stimulation or TAPI inhibition on ACE shedding 
To determine the effects of stimulation or inhibition of the ACE secretase cells were grown to 
confluency overnight in enriched medium.  They were then incubated for 4 hours in minimal 
medium containing 1M PDBu (Sigma, USA), 10M TAPI-1 (Sigma, USA) or 
200M 3,4-DCI (Sigma, USA).  Medium and cell samples were collected and shedding was 
determined as described (Section 2.2.4). 
2.2.4.2 Antibody-induced shedding 
Similarly, 10g/ml purified (or 1:50 dilution of culture fluid) anti-ACE monoclonal 
antibodies in minimal medium was added to confluent cells for 4 hours (high ACE expressing 
cell lines) or 24 hours (low ACE expressing cell lines).  Samples were collected and shedding 
was determined as described (Section 2.2.4). 
2.2.4.3 Effect of substance P on ACE shedding 
Cells were grown in the presence of 10M substance P in minimal medium for 4 hours and 
shedding determined as described (Section 2.2.4). 
2.2.5 Plate precipitation assay 
Total cell lysate and concentrated cell culture medium were sent to our collaborator 
Prof. S. Danilov, who performed the plate precipitation assays.  Microtiter plates bound with 
goat-anti-mouse IgG were coated with different anti-ACE mAbs and were incubated with 
serum-free culture medium or cell lysates.  In some experiments, mAbs were adsorbed to the 
wells of microtiter plates directly, without the goat-anti-mouse bridge.  In all experiments 
anti-mouse IgG wells were included to control for non-specific antibody binding.  
The amount of ACE precipitated by a given mAb reflects the binding affinity and was 
quantified by two methods: 
i) Precipitated ACE activity in the wells was estimated using substrates Hip-His-Leu or 
Z-Phe-His-Leu, as described previously (Danilov et al, 1994).   
ii) The amount of precipitated ACE protein was quantified by incubation with sheep anti-
ACE polyclonal antibodies conjugated with horseradish peroxidase (HRP) from an ACE 
ELISA kit (Chemicon Int, USA), followed by a spectrophotometric assay with 
tetramethylbenzidine (TMB) as a substrate (Danilov et al, 1996). 
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2.2.6 Cell ELISA 
sACE cell lines were grown to confluency overnight in microtitre plates in enriched medium.  
Once confluent, cells were incubated on ice with blocking buffer (PBS with 2% skim milk) to 
minimise non-specific binding and then in the presence of 10g/ml anti-ACE mAbs in the 
same buffer before fixing to minimise the loss of epitopes on membrane bound ACE.  Cells 
were fixed with 4% para-formaldehyde and incubated in blocking buffer containing a goat 
anti-mouse IgG HRP-conjugated antibody, which was used to detect the amount of mAb 
bound to ACE spectrophotometrically using a TMB substrate.  In all experiments, control 
wells containing untransfected cells and wells with anti-mouse IgG added to CHO-sACE cells 
were used to determine the non-specific binding of anti-ACE mAbs and antibodies in general, 
respectively.  The percentage binding of anti-ACE mAbs was calculated as the percentage of 
binding to the IgG control. 
2.2.7 Polyacrylamide gel electrophoresis 
Purified protein, medium or cell lysates were mixed with sample buffer (20% glycerol, 
6% SDS, 125mM Tris, Bromophenol blue, pH 6.8) either with or without reducing agent 
[5% -mercaptoethanol (-ME) or 50mM dithiothreitol (DTT)] and boiled for 5 minutes.  
Samples were separated by SDS-PAGE using the Mini PROTEANTM III system (BIO-RAD, 
USA) with 7% resolving (0.1% SDS, 375mM Tris buffer, pH 8.8) and 3% stacking 
(0.1% SDS, 125mM Tris buffer, pH 6.8) gels in a Tris-glycine tank buffer (pH 8.3) at 
25mA/gel.  Gels were either stained with Coomassie dye or used for western blotting as 
described below. 
2.2.7.1 Two-dimensional gel electrophoresis 
Purified sACE was separated by SDS-PAGE under non-reducing conditions.  This lane was 
then excised and placed perpendicularly along a 7% resolving gel and a 3% stacking gel was 
set above the gel slice.  The gel was run under reducing conditions by adding sample buffer 
containing 5% -ME.  The gel was then stained with Coomassie dye to visualise protein. 
2.2.7.2 Native PAGE 
Samples were mixed with sample buffer (without SDS).  Non-denaturing PAGE was 
performed in the same way as SDS-PAGE, except SDS was excluded from the resolving gel, 
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2.2.8 Western blotting to detect ACE and cross-linking of proteins 
After SDS-PAGE, protein was transferred to Hybond ECL nitrocellulose membrane 
(GE Healthcare LifeSciences, UK) in transfer buffer (20mM Tris-base, 150mM glycine, 
20% methanol) at 100V for 1 hour using the Mini PROTEANTM III system.  For detection of 
protein, membranes were incubated in blocking buffer (Tris-buffered saline, 0.1% tween-20, 
5% skim-milk) containing culture fluid of the anti-ACE mAbs 4G6 and 1D8, specific to the 
N domain and C domain respectively.  Binding of mAb was detected using either goat anti-rat 
(to detect 4G6) or goat anti-mouse (to detect 1D8) HRP-conjugated antibody using the ECL+ 
detection system (GE Healthcare LifeSciences, UK) or the Immun-star WesternCTM detection 
system (BIO-RAD, USA).  Chemiluminescence was detected by autoradiography or with a 
chemiluminescence detector (G:BOX Chemi, Syngene, USA).  Densitometry of detected 
protein was performed using GeneTools software (Syngene, USA). 
For dimerisation studies, confluent cells were serum starved overnight in minimal medium or 
Opti-MEM and then cross-linked for 1 hour on ice with 1mM bis[sulfosuccinimidyl] suberate 
(BS3) in PBS.  Excess crosslinker was quenched with 20mM Tris (pH 7.5) for 15 minutes at 
ambient temperature.  Cells were then lysed in 1% triton lysis buffer with protease inhibitor 
cocktail and resolved by SDS-PAGE and ACE detected by western blotting. 
2.2.9 CnBr digestion and MALDI MS/MS 
Approximately 500g of purified Ndom-H600C, wild-type sACE and sACE-H600C in 
70% formic acid were cleaved overnight with cyanogen bromide (CnBr) and then freeze-
dried.  Protein was resuspended in dH2O to a final concentration of 5mg/ml.  50g of cleaved 
protein was separated by SDS-PAGE in the presence or absence of 5% -ME and peptides 
detected by Coomassie stain. 
Bands of interest were excised, cut into 1mm2 pieces and destained with 
200mM NH4CO3:acetonitrile (ACN) (50:50) until clear.  Samples were dehydrated with 
100% ACN and dried on a Savant SpeedyVac (ThermoScientific, USA).  Samples were sent 
to the Centre for Proteomic and Genomic Research (CPGR, Cape Town, South Africa) for 
further analysis.  Briefly, samples were reduced with 5mM Tris (2-carboxyethyl) phosphine 
(TCEP) (Fluka, USA) in 100mM NH4CO3 in the dark for 30 minutes at room temperature. 
Excess TCEP was removed and the gel slices dehydrated.  Cysteine protection was performed 
by carbamidomethylation with 100mM iodoacetamide (Sigma, USA) in 100mM NH4CO3 for 
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with 50mM NH4CO3 and dehydrated.  An in-gel tryptic digest was performed by rehydrating 
the gel slices in trypsin solution (Promega, USA) to a 20ng/l final concentration and 
incubating at 37C overnight.  Peptides were extracted from the gel slices with 50l 0.1% 
trifluoroacetic acid (TFA) (Sigma, USA).  Samples were dried down, resuspended in 50l 
dH2O and further dried down to 20l to remove residual NH4CO3. 
Peptides were spotted onto a 10mg/ml -cyano-4-hydroxycinmanic acid matrix (Fluka, USA) 
in 80% ACN, 0.2% TFA for a final concentration of 5mg/ml matrix in 40% ACN, 0.1% TFA, 
10mM NH4H2PO4.  Mass spectrometry was performed with a 4800 MALDI TOF/TOF 
(Applied Biosytems) with all spectra recorded in positive reflector mode.  Spectra were 
generated with 400 laser shots/spectrum at a laser intensity of 3800 (arbitrary units) with a 
grid voltage of 16kV.  Peptides spots were internally calibrated with trypsin autolytic 
fragments. 
2.2.10 Cleavage site determination 
Purified sACE-Y465D was resolved by SDS-PAGE and protein detected by Coomassie stain.  
The sACE band was excised and an in-gel tryptic digest and MALDI-MS/MS was performed 
as described above. 
2.2.11 Thermal stability determination 
10nM purified wt sACE or sACE-H600C in 50mM HEPES buffer was incubated in 0.2mm 
tubes at 55C for 2.5, 5, 10, 15, 30, 60, or 90 minutes on a thermocycler plate and then placed 
on ice.  A zero time control was placed on ice throughout the incubation.  ACE activity was 
determined for each time point using ZFHL as a substrate (Section 2.2.2).  The percentage 
residual activity was determined according to the zero time sample. 
2.2.12 Substrate hydrolysis 
2.2.12.1 HPLC 
HPLC was performed using a sephadex C18 Jupiter column.  37nM wild-type sACE or 
sACE-Y465D and 50M substrate [angI or subsP (for preparation refer to Appendix A.2.6.1)] 
in 50mM HEPES buffer (containing 300mM NaCl, 10M ZnSO4) were incubated for 1 hour 
at 37C.  Sample was separated by HPLC over a 14-70% ACN in 0.1% TFA gradient.  
Sample runs were compared to those with buffer only and substrate only.  Absorbance was 
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2.2.12.2 Fluorogenic assay 
Hydrolysis of angI was performed using acetyl-angI (Bachem, Switzerland) to decrease 
background fluorescence caused by interaction of the primary amine with the derivitising 
agent.  5nM ACE was incubated with increasing concentrations of angI in the M range, from 
0-1000M, for 15 minutes at 37C in the same 50mM HEPES used for HPLC.  The same 
procedure for the ZFHL plate assay was followed, using o-phthaldialdehyde to detect product 
(refer to Section 2.2.2).  A Michealis-Menton curve was determined by plotting the nmol 
HL/minute formed versus the change in substrate concentration in Graphpad Prism (GraphPad 
Software Inc, USA).   
The rate of hydrolysis of subsP was determined using fluorescamine to derivitise the product.  
0-500M subsP were incubated with 5nM sACE at 37C for 15 minutes.  The reaction was 
stopped with 1M HCl and then neutralised with 1M NaOH.  The pH was increased by the 
addition of 5X potassium phosphate buffer (500mM KHPO4/KH2PO4, pH 8.3).  Hydrolysis 
products were then derivitised by the addition of 2mg/ml fluorescamine (in acetone).  The 
fluorescence intensity was measured at excitation = of 390nm and emission = 475nm.  Baseline 
fluorescence was determined at a range of concentrations using subsP alone (refer to 
Appendix A.2.3).  These values were used to normalise the experimental values.  The rate of 
hydrolysis was plotted as the nmol/min product determined from complete overnight 
hydrolysis of subsP by ACE vs the substrate concentration (refer to Appendix A.2.4).   
 
2.3 STATISTICAL ANALYSIS 
Data was entered into GraphPad PRISM 4.0 software (GraphPad software Inc, USA) and 
analysed using in-built statistical software.  One-way and two-way ANOVAs with 
Bonferri/Tukey post tests were performed.  Results were viewed as statistically significant 
when p < 0.05.  Statistically significant data in figures of Chapters 3, 4, 5, and 6 are indicated 
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CHAPTER 3:  Towards limiting inter-domain movement in somatic ACE: 
the introduction of additional cysteine residues in the linker region 
 
3.1 INTRODUCTION 
The elucidation of the crystal structures of the N and C domains (Corradi et al, 2006, 
Natesh et al, 2003) has allowed for deeper insight into the structure-function relationship of 
ACE by furthering the understanding of substrate binding (Watermeyer et al, 2010), domain 
selectivity and inhibitor design (Watermeyer et al, 2008), post-translational processes such as 
shedding and dimerisation (Chattopadhyay et al, 2008; Kost et al, 2003) and has facilitated 
epitope mapping of ACE mAbs (Danilov et al, 2007; Naperova et al, 2008a).   
However, little is known regarding the interaction between the two domains of sACE and the 
nature of their interactions with respect to substrate binding and domain cooperativity, as well 
as protein-protein interactions relating to shedding and dimerisation.  This is largely due to the 
lack of detailed structural knowledge of full-length sACE.  The crystal structure of sACE has 
not as yet been determined.  A model of sACE has been extrapolated from the N and C 
domain crystal structures, but is limited due to parts of the structures that could not be 
resolved (Corradi et al, 2006) (refer to Chapter 1, Section 1.2.5).  These include three 
N-terminal residues of the tACE structure and several side chains on the linker of the 
N domain (Corradi et al, 2006).  The recently described EM structure of full-length sACE was 
consistent with the “extended” model proposed by Corradi et al (2006) (Chen et al, 2010), 
indicating that the linker region is capable of a large degree of movement.  However, this 
structure did little to elucidate the interaction of the two domains proposed in the “compact” 
model. 
To date, attempts at obtaining crystals of sACE have been unsuccessful.  This is thought to be 
the result of two limitations.  The first is the presence of post-translational glycosylation, 
which hampers the formation of a uniform crystal lattice due to the sequence heterogeneity 
and flexibility within the glycan chains (McPherson et al, 1982; Butters et al, 1999).  The 
second is thought to be due to the flexibility afforded by the inter-domain linker region.  By 
removing either one or both of these limitations, it may be possible to generate candidates for 
crystallisation.   
The minimal glycosylation requirements for the expression of active N domain and tACE 
have been investigated and have facilitated reproducible crystallisation and determination of a 
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Anthony et al, 2010).  The application of this approach to full-length sACE may be a viable 
means to generate a candidate for crystallisation. 
The proposed model of sACE (Corradi et al, 2006) indicates that there is a range of 
conformations wherein the two domains can interact.  This range of movement is governed by 
the flexibility of the linker region, which would allow rotation and movement of the domains 
relative to one other.  Engineering a disulphide bridge into the linker region may limit the 
range of movement and restrict the overall conformational flexibility.   
The introduction of covalent linkages through an engineered disulphide bridge has been a 
successful approach in improving protein stability and to enable structure determination.  De 
novo disulphide bridges were used to determine the role of subunit interactions in the 
formation of f-actin filaments by cryo-EM (Kim et al, 2000; Orlova et al, 2001).  In addition, 
these novel disulphides bridges can be useful tools for limiting movement to further 
understand the role of certain regions in conformational changes, an analysis that was 
performed with the coil-coiled region of E.coli RNA polymerase (Anthony et al, 2002).  The 
introduction of disulphide bonds successfully facilitated X-ray crystallography of thioredoxin 
multimers (Das et al, 2007), an active conformation of methionine synthase (Datta et al, 
2008) and the HIV-1 hexameric capsomer (Pornillos et al, 2010).  The stability of Drosophila 
melanogaster acetlycholinesterase was improved by the introduction of novel disulphide 
bonds without affecting enzyme activity (Siadat et al, 2006).  It is evident from the literature 
that engineered disulphide bonds are a useful tool in furthering our understanding of the 
structure-function relationship of enzymes.  An important consideration in this approach is 
that the de novo bonds should not alter the native protein conformation or enzyme activity.   
The introduction of a disulphide bond in the linker region of sACE, relative to the N domain 
may limit inter-domain movement.  The 11-residue linker region (P602-D612) between the 
N and C domains was well defined in the recently solved crystal structure of the N domain 
(Corradi et al, 2006).  The first part of the linker was rigid, despite predictions that this region 
is highly flexible.  This is due to the constraint imposed by a hydrogen bond between residues 
E161 and Y607.  A flexible loop proximal to this region is held in place by the C128-C136 
disulphide bond and is proposed as a possible surface for domain interaction (Figure 3.1).  
Thus, by limiting movement in this region, the overall structure of sACE could potentially be 
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Figure 3.1.  C-terminal region of the N domain.  The flexible linker region (orange) from residues P602-D612 
(from left to right) is indicated.  The side chains of the C474 free thiol and native C128-C136 bridge (magenta), 
residues E161 and Y607 (cyan) are indicated as stick models and glycans as spheres (green).  The straight-line 
measurement between the C atoms of E161 and Y607 was 9.3Å (yellow dashed line).  
 
The aim of this study was to limit the inter-domain movement of human sACE towards 
generating a sACE candidate for crystallisation and investigating domain cooperativity. 
This included the following objectives: 
1. To engineer a disulphide bridge in the linker region of N domain ACE as proof of 
concept. 
2. To introduce a successful N domain mutant into full- length sACE and soluble sACE. 
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3.2 RESULTS 
3.2.1 In silico design of de novo disulphide bridges in ACE 
The recently solved structure of the N domain included the well-defined linker region 
between the N and C domains (PDB accession number 2C6F) (Corradi et al, 2006).  This 
facilitated the design of novel disulphide bridges to limit inter-domain movement using the 
N domain structure in PYMOL v0.99 (DeLano Scientific LLC).  
The free thiol C474 is positioned in the short -sheet 6 before a flexible loop, proximal to the 
linker region, and could potentially form a disulphide bridge with cysteine residues introduced 
into this region (Figure 3.2).  Three sites within range of C474, with C  atoms between 5-7Å 
apart, were identified by straight-line measurements: W599, H600 and P601.  These comply 
with the criterion that theoretical cysteine residues should be within 6Å of each other to form 
a disulphide bridge (Orlova et al, 2001; Kim et al, 2000).  In addition, the degree of flexibility 
afforded by the position of these residues in the linker region could theoretically allow for 
movement of an introduced cysteine 2Å towards C474 to favour the formation of a novel 
disulphide bridge.   
 
Figure 3.2.  C474 and H600.  The flexible linker region (orange) from residues P602-D612 (from left to right).  
The side chains of the C474 free thiol (magenta) and H600 (cyan) are shown as stick models.  The straight-line 
measurement between the C atoms of C474 and H600 was 5.6Å (yellow dashed line).  
 
The position of the free thiol limited the range of potential sites for the introduction of 
cysteine residues to the upper portion of the linker region.  Thus, the position of a novel 
disulphide formed may not greatly limit the movement of this region or interaction of the two 
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region closer to the C domain was examined for potential sites.  The hydrogen bond between 
Y607 in the linker region and E161 in helix 8 was identified as a potential target for 
conversion to a disulphide bond (Figure 3.1).  The distance between the C  atoms was less 
than 10Å, well within range for formation of a disulphide considering the flexibility of the 
linker region. 
As a proof of principle, mutagenesis was initially performed on the soluble N domain 
construct pcDNA-Ndom, which contains 11 residues of the linker region and the first 17 
residues of the C domain.  A single cysteine residue was introduced at site H600 to generate a 
disulphide bridge with the free cysteine (C474).  The double mutant E161C/Y607C was 
designed to form a novel disulphide bridge at a more preferable site.  The presence of the de 
novo disulphide bridge was determined by proteolysis, SDS-PAGE and MALDI-MS/MS.  
Successful mutants were cloned into full-length sACE to determine their effect on protein 
expression, processing, thermal stability and inter-domain interaction. 
 
3.2.2 Site-directed mutagenesis and cloning into a mammalian expression vector 
3.2.2.1 N domain constructs: Ndom-H600C and Ndom-EY/CC 
Two constructs, NdomH600C and NdomEY/CC, in pcDNA3.1(+) were previously generated 
in our laboratory (refer to Methods in Chapter 2, Section 2.1.1).   
 
Figure 3.3.  Subcloning of H600C into pcDNA-sACE.  A 617bp fragment was excised from pBS-sACE-
H600C via AgeI/XhoI and inserted into pcDNA-sACE and pcDNA-sACE-NJ to generate full length and soluble 
constructs respectively.  The positions of common restriction enzymes are indicated (positions tha t differ in 
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3.2.2.2 Full-length sACE construct: sACE-H600C 
A full-length sACE construct of H600C was generated.  Since there were no compatible 
cloning sites to allow for the subcloning of a fragment containing H600C from the N domain 
into sACE, site-directed mutagenesis was repeated using pBS-sACE as a template (for 
Methods refer to Chapter 2, Section 2.1.2).  A region flanking the mutation was sequenced 
using two internal primers complementary to ACE, 3R and 5R (refer to Appendix A.1.2 for 
details), which confirmed the presence of the mutation and that the remaining sequence was 
unchanged.  A 617bp fragment of this region, containing the mutation, was subcloned into 
full-length sACE in pcDNA3.1(-) (pcDNA-sACE) via AgeI/XhoI sites (Figure 3.3) (Methods 
in Chapter 2, Section 2.1.3).  Restriction enzyme digestion verified the correct size and 
orientation of the ACE cDNA and the presence of the mutation (Figure 3.4). 
 
 
Figure 3.4.  Full-length and soluble sACE-H600C constructs in pcDNA.  A. Restriction map of pDNA-
sACE-H600C depicting sites used to verify the correct size of the sACE insert (BamHI/HindIII) and to confirm 
the presence of the mutation (BsaXI).  The novel BsaXI site introduced during site-directed mutagenesis 
(position 2837) is indicated with an asterisk.  The positions of restriction enzyme sites of pcDNA -sACE-NJ are 
indicated in italics.  B.  Gel electrophoresis of restriction enzyme digests.  Lanes 1, 4 are undigested full-length 
and soluble pcDNA-sACE respectively.  BamHI/HindIII digestion: sACE and sACE-H600C, full-length (lanes 2 
and 3 respectively) and soluble (NJ, lanes 5 and 6 respectively).  BsaXI digestion: sACE and sACE-H600C, full-
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3.2.2.3 Soluble sACE constructs for ACE protein purification: wt and sACEH600C-NJ 
Soluble wt sACE used for purification and protein analysis was derived from a construct that 
was available in our laboratory.  It contains the sACE sequence truncated at S1211 (pcDNA-
sACE-sol), 8 residues downstream of the endogenous cleavage site (R1203) (Woodman et al, 
2000), stably expressed in CHO cells (Methods in Chapter 2, Section 2.1.1).  Soluble sACE-
H600C was generated by subcloning the 617bp AgeI/XhoI fragment bearing the mutation 
from pBS-sACE-H600C into pcDNA-sACE-NJ (Figures 3.3 and 3.4).  This construct 
contains the sACE coding region truncated at S1201.  Sufficient protein yields for purification 
was obtained from a high expressing cell line generated by clonal selection. 
 
3.2.3 Determination of the formation of novel disulphide bridges in N domain mutants  
3.2.3.1 Expression and purification of a single cysteine N domain mutant in CHO cells  
High expressing cell lines were generated by clonal selection of stably transfected CHO cells 
(refer to Chapter 2, Section 2.2.1 for Methods).  Sufficient quantities of soluble ACE were 
detected in culture fluid by an ACE activity assay to allow for the preparation of bulk cultures 
for protein purification (for Methods refer to Chapter 2, Section 2.2.2).  Protein was purified 
by lisinopril-sepharose affinity chromatography with sufficient yields for further experiments 
(NdomH600C: 4mg/L) (Methods in Chapter 2, Section 2.2.3).  Purified protein was separated 
by SDS-PAGE to assess purity (Figure 3.5) (refer to Chapter 2, Section 2.2.7 for Methods).  A 
clear band resolved at approximately 95kDa, the expected size for fully glycosylated 
N domain ACE (Corradi et al, 2006). 
Figure 3.5.  SDS-PAGE of purified Ndom-H600C.  10g of purified protein was separated by 10% SDS-
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3.2.3.2 Investigation of disulphide bridge formation between C474 and H600C  
3.2.3.2.1 Cyanogen bromide cleavage and SDS-PAGE 
Approximately 500g of purified Ndom-H600C was cleaved with cyanogen bromide (CnBr) 
and peptide fragments separated by SDS-PAGE under non-reducing and reducing conditions 
to detect the formation of a disulphide bridge between residues C474 and H600C (Figure 3.6) 
(for Methods refer to Chapter 2, Section 2.2.9).  A band of approximately 18kDa (S2) 
corresponding to the free thiol fragment (FT) was detected under reducing conditions.  A band 
(S3) was detected in the range corresponding to the 8kDa novel thiol fragment (NT) under 
reducing conditions.  Moreover, a band of approximately 25kDa (S1) was detected under non-
reducing conditions.  The discrepancy in size between the expected and observed with S1 and 
S3 is due to glycosylation at position N480 (Anthony et al, 2010). 
Figure 3.6.  CnBr cleavage of Ndom-H600C. A. Schematic representation of Ndom-H600C.  Ndom comprises 
the N domain (grey box), linker region (solid line) and N-terminal region of the C domain (white box).  The 
cysteine residues with the three inter-chain disulphide bridges are shown.  The free thiol C474 and the mutation 
H600C are indicated (bold). The C-terminal CnBr fragments of interest are shown as the free thiol containing 
fragment (FT) and the novel thiol containing fragment (NT) with their predicted sizes (glyc: N-linked 
glycosylation).  The predicted novel disulphide bridge C474-H600C is indicated as a dashed line with the 
expected size of the disulphide-linked FT and NT fragments shown. B. CnBr digestion of purified Ndom-H600C 
and 16% SDS-PAGE in the absence or presence of -ME.   
 
The striking size difference observed between the non-reduced and reduced samples was 
consistent with the formation of a cysteine bridge between the free cysteine (C474) and the 
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introduced cysteine (H600C).  The three native intra-chain disulphide bonds each lie on the 
same CnBr peptide, thus reduction of these bonds would not account for the size shift 
observed.  The three bands (S1, S2, and S3) from Ndom-H600C were excised; and in-gel 
tryptic digests performed before the peptides were subjected to MALDI MS/MS. 
3.2.3.2.2 MALDI-MS/MS of Ndom-H600C 
MALDI-TOF/TOF analysis was performed on tryptic digests of the non-reduced S1 and 
reduced S2 and S3 fragments (Figure 3.7 and Table 3.1) (Methods in Chapter 2, 
Section 2.2.9).  Masses could be assigned to FT in S2 and to both FT and NT in S1.  The latter 
was confirmed by MS/MS fragmentation of four tryptic peptides.  The tryptic peptide 
containing H600C could not be identified in S1 or S2.  C474 was identified in peptides from 
S1 and S2 (m/z 1190.59 and m/z 1190.60 respectively).   The mass profile of S3 did not 
correspond to NT, but matched a number of masses within the N domain, including the 15kDa 
fragment.  This suggests that S3 is not NT and most likely contains a mixture of CnBr 
digested fragments since a number of fragments were predicted to be of similar size.  
Identification of both FT and NT peptides in the non-reduced S1 and the lack of any NT 
peptides in the reduced S2 strongly suggests the formation of the additional disulphide bridge.   
Since the formation of the novel C474-C600 disulphide appeared to be successful, the H600C 
mutation was introduced into full- length sACE (Section 3.2.4). 
 
Table 3.1.  Observed masses of Ndom-H600C fragments after CnBr and tryptic digest.  MALDI TOF/TOF 
was performed on CnBR fragments S1, S2 and S3 after digestion with  trypsin. MS/MS was performed on four 
peptides of S1.  Tryptic peptides containing C474 (in FT) and H600C (in NT) are indicated in bold. 
CnBr fragment analysed: S1  S2 S3 
 Residue  
no 
Calculated 













 188-199 1416.61   1416.61 1416.64 
 241-245 678.38   678.38 678.39 
 433-446 1724.92 1724.92 IAFLPFGYLVDQWR 1724.93  
 447-453 808.41 808.41  808.41 808.41 
 459-467 1362.62 1362.62 YNFDWWYLR 1362.63  
FT 470-479 1190.66 1190.59  1190.60  
 490-500 1342.71 1342.73 FHVPNVTPYIR 1342.73  
 518-532 1807.81 1807.81  1807.83  
 546-577 1357.72 1357.72  1357.73  
NT 
560-572 1352.77 1352.77 VGLDALDAQPLLK   
573-622 5922.75     
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Figure 3.7.  MALDI TOF/TOF spectra of Ndom-H600C CnBr fragments after tryptic digest.  Three bands 
were excised from an SDS-PAGE and subjected to in-gel tryptic digest and MALDI-TOF/TOF, namely the non-
reduced S1 (A), reduced S2 (B) and the reduced S3 (C) fragments.  The tryptic peptide containing H600C is 
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3.2.3.3 Expression of a double cysteine N domain mutant in CHO cells  
pcDNA-Ndom-EY/CC was stably transfected into CHO cells for expression and protein 
purification (for Methods refer to Chapter 2, Section 2.2.1).  No significant ACE activity was 
detected in medium compared to wt and untransfected controls in repeat transfections 
(Table 3.2) (Methods in Chapter 2, Section 2.2.2).  This seemed to indicate that the mutant 
was not being expressed, either due to low mRNA expression levels from an inefficient 
transfection or through targeted degradation during processing.  To investigate the expression 
of Ndom-EY/CC, the presence of ACE mRNA was determined by RT-PCR and protein levels 
detected by Western blot analysis.  
 
Table 3.2.  ACE activity in cell lysate and medium from CHO cells.  ACE activity was determined using 
ZFHL as a substrate.  Data is the mean of one experiment performed in triplicate.  Protein concentration in total 
cell lysates was determined using Bradford reagent. 
 
3.2.3.4 Determination of expression of Ndom-EY/CC 
3.2.3.4.1 Detection of mRNA levels in transfected CHO cells 
Total RNA was extracted from CHO cells stably transfected with pcDNA-Ndom-EY/CC.  As 
controls, total RNA was extracted from untransfected CHO cells and cells transfected with 
pcDNA-Ndom (wt soluble N domain) (Figure 3.8A) (refer to Chapter 2, Section 2.1.4 for 
Methods).  
Equivalent amounts of total RNA were used to synthesise cDNA from these three cells lines 
as well as from the control, namely total human placental RNA.  An 860bp portion of the 
N domain was amplified by RT-PCR as well as a 983bp portion of G3PDH, included as a 
positive control (Figure 3.8B).  The 983bp G3PDH amplicon was visible in all three cells 
lines and the positive control upon gel electrophoresis, as expected.  From visual inspection, 
the levels of G3PDH mRNA appear to be lower in the wt N domain and Ndom-EY/CC (wt > 
EY/CC) transfected cells compared to untransfected cells.  Since G3PDH mRNA levels are 
expected to be consistent, the differences observed are likely due to three factors.  First, 
inconsistent cDNA synthesis across the total RNA samples used and second, inconsistent 
amplification of cDNA across samples or finally, incorrect quantification of RNA.   
 CELLS  MEDIUM 






CHO 0.04 ± 0.00 1.62 ± 0.03   0.51 ± 0.13 
wt Ndom 3.14 ± 0.08 1.98 ± 0.13 13.78 ± 0.21 
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Figure 3.8.  Expression of Ndom-EY/CC mRNA.   A. Control RNA (human total placental RNA, lane 1) and 
RNA extracted from untransfected CHO cells (lane 2) and CHO cells expressing either wt Ndom (lane 3) or 
Ndom-EYCC (lane 4) were separated by agarose gel eletrophoresis.  B. R -PCR was performed on extracted 
RNA and control RNA using a control primer (G3PDH, lanes 1-4) and ACE specific primers 1R and 3F (lanes 5-
7).  Lane 1 control RNA, lanes 2 & 5 untransfected CHO cells, lanes 3 & 6 wt Ndom and lanes 4 & 7 Ndom-
EYCC. 
 
The 860bp ACE amplicon was detected in both the wt N domain and Ndom-EY/CC cell lines, 
but not the untransfected CHO cells.  Similar to G3PDH, there are decreased levels of the 
Ndom-EY/CC amplicon compared to wt.  This serves to confirm that the lower ACE and 
G3PDH levels observed for Ndom-EY/CC transfected cells are due to decreased amounts of 
cDNA available, compared to the other samples.  Hence, if the levels of mRNA are adjusted 
according to the G3PDH, there is expression of Ndom-EY/CC, albeit to a lower degree than 
wt.  This indicates that Ndom-EY/CC DNA was introduced into CHO cells at sufficient levels 
for mRNA expression.  Thus, the lack of ACE activity in Ndom-EY/CC transfected cells was 
mostly likely due to aberrant processing of protein. 
3.2.3.4.2 Determination of protein expression of Ndom-EY/CC  
Total cell lysate and cell culture medium from untransfected CHO cells and CHO cells 
expressing either wt N domain and Ndom-EY/CC were collected in parallel with total RNA 
extraction (Table 3.2).  Equivalent amounts of cell lysate and medium were separated by 
SDS-PAGE and N domain ACE visualised by Western blot analysis (Figure 3.9) (Methods in 
Chapter 2, Section 2.2.8).  As expected, a band resolving at 90kDa was observed in the lysate 
of cells expressing wt N domain, corresponding to immature protein and a roughly 95kDa 
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observed is the result of the addition of glycans during processing.  The mature form is not 
observed in the cell lysate as this a soluble construct that is released into the extracellular 
milieu upon processing.   
A band of similar size as wt N domain was observed in the lysate of cells expressing Ndom-
EY/CC.  A similarly sized band in the medium could be faintly detected by visual inspection.  
The levels of Ndom-EY/CC in cells appear to be higher than that of wt.  It appears that there 
is improper processing of this mutant, where protein is retained in cells and is not processed to 
the mature form.  This is most likely the due to improper folding, resulting in targeted 
degradation of the protein 
 
Figure 3.9.  Western blot analysis of transfected CHO cells .  Total cell lysate (C) and medium (M) from 
untransfected CHO cells (CHO) and CHO cells transfected with wt Ndom (WT) and Ndom-EYCC (EYCC) were 
separated by 10% SDS-PAGE.  Western blot analysis was performed and ACE detected using the N domain- 
specific mAb 4G6. 
 
3.2.4 Characterisation of a novel disulphide bridge in sACE-H600C 
3.2.4.1 Expression of a single cysteine somatic ACE mutant in CHO cells 
Full-length and soluble sACE-H600C constructs were transfected into CHO cells (Methods in 
Chapter 2, Section 2.2.1).  High expression levels of the full-length protein were obtained by 
FACS, yielding sufficient levels of ACE for further experiments, determined by an ACE 
activity assay of the total cell lysate and cell culture medium (450-500mU/ml in cell lysate 
and 10-15mU/ml in medium) (for Methods refer to Chapter 2, Section 2.2.2).  The full-length 
protein was used to characterise the effect of H600C on ACE expression, shedding and 
conformation (Section 3.2.4.4).  
A cell line expressing soluble sACE-H600C (pcDNA-sACE-H600C-NJ) with sufficient ACE 
activity (30mU/ml) in cell culture medium for protein purification was isolated by clonal 
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the formation of the engineered disulphide and the effect of the mutation on enzyme stability 
(Section 3.2.4.3). 
3.2.4.2 Purification of soluble wt sACE and sACE-H600C 
Lisinopril-sepharose affinity chromatography (Methods in Chapter 2, Section 2.2.3) of 
harvested cell culture medium yielded 1.2 mg/L medium sACE and 8.3 mg/L sACE-H600C.  
Both samples resolved as a single band of approximately 190 kDa by SDS-PAGE equivalent 
to fully glycosylated sACE (Figure 3.10).  Both wt sACE and sACE-H600C migrated as 
diffuse bands characteristic for glycoproteins. 
 
Figure 3.10.  SDS-PAGE of purified wt sACE and sACE-H600C.  5g-10g of purified wt sACE (wt) and 
sACE-H600C (H600C) protein were separated by 6% SDS-PAGE and visualised by Coomassie Blue staining.   
 
3.2.4.3 Determination of C474-H600C disulphide bridge formation 
3.2.4.3.1 Cyanogen bromide digestion and SDS-PAGE 
As with Ndom-H600C, purified wt sACE and sACE-H600C were cleaved with CnBr and the 
resultant fragments separated by SDS-PAGE under non-reducing and reducing conditions 
(Figure 3.11) (for Methods refer to Chapter 2, Section 2.2.9).  A prominent band of 
approximately 18kDa (S2) corresponding to FT was observed in both wt and sACE-H600C 
under reducing conditions.  The disappearance of this band and the appearance of a prominent 
band of approximately 37kDa (S1) in sACE-H600C under non-reducing conditions are 
consistent with the formation of a disulphide bridge between FT and NT fragments.  Once 
again, the discrepancy between the expected and observed sizes of S1 and S2 can be 
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The non-reduced sACEH600C S1 fragment was excised and used for MALDI MS/MS 
analysis to confirm the presence of the disulphide bridge. 
 
Figure 3.11.  CnBr cleavage of sACEH600C.  A. Schematic representation of sACE.  The N domain (grey 
box), linker region (solid line) and N-terminal region of the C domain (white dashed box) are indicated.  The 
cysteine residues, disulphide bridges and CnBr fragments are depicted as in Figure 3.6.  B. 16% SDS-PAGE of 
CNBr peptides of wt sACE and sACE-H600C in the absence or presence of -ME.  
 
3.2.4.3.2 MALDI MS/MS of sACE-H600C 
An in-gel tryptic digest was performed on S1 and the peptides analysed by MALDI-TOF/TOF 
(Figure 3.12 & Table 3.3) (Methods in Chapter 2, Section 2.2.9).  Masses were assigned to 
both the FT and NT peptides and three masses were confirmed by MS/MS fragmentation.  A 
fragment corresponding to the C474 peptide was identified (m/z 1190.60), however the tryptic 
peptide containing H600C was not.  These results strongly suggest that a disulphide bridge 
was formed between C474 and H600C in sACE. 
 
C474 H600C 
C128-C134 C330-C348 C516-C528 
N  C  
FT 
429 560 662 
NT 
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Figure 3.12.  MALDI TOF/TOF spectrum of sACE-H600C CnBr fragments after tryptic digest.  The 
tryptic peptide containing H600C is indicated with the expected mass in brackets.  NT peptides are indicated in 
bold. 
 
Table 3.3.  Observed masses of sACE-H600C S1 CnBr fragment after tryptic digest.  The peptides 
containing C474 (FT) and H600C (NT) are indicated in bold. 
CnBr fragment analysed: S1  






Peptide sequence  
(determined by MS/MS) 
 433-446 1724.92 1724.93  
 447-453 808.41 808.43 WGVFSGR 
 459-467 1362.62 1362.64 YNFDWWYLR 
FT 470-479 1190.66 1190.60  
 490-500 1342.71 1342.73  
 518-532 1807.81 1807.81  
 551-557 899.50 899.51  
NT 
560-572 1352.77 1352.76  
573-622 5905.71   
623-629 957.43 957.46 FVEEYDR 
 
3.2.4.4 Characterisation of sACE-H600C 
3.2.4.4.1 Constitutive shedding of sACE-H600C 
The amount of ACE shed from the cell surface of CHO cells expressing wt sACE and sACE-
H600C was determined from an activity assay of total cell lysate and cell culture medium 
after incubation in minimal medium for four hours (Figure 3.13) (for Methods refer to 
Chapter 2, Section 2.2.4).  sACE is shed inefficiently from the cell surface (3-6% of total after 
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increase in shedding of sACE-H600C compared to wt.  This may be the result of subtle 
conformational changes induced by the presence of the disulphide bridge. 
Figure 3.13.  Shedding of sACE-H600C.  Shedding was calculated as the percentage ACE activity in medium 
of total activity in medium and cell lysate from CHO cells expressing s ACE and sACE-H600C.  Data is the 
mean±SD of three experiments (sACE) or two experiments (sACE-H600C) performed in triplicate.  A. 
Percentage shed of total activity, B. Percentage shed of wt sACE.   
 
3.2.4.4.2 Effect of the H600C mutation on ACE conformation 
A panel of domain-specific monoclonal antibodies (mAbs) to ACE were used to determine 
the effect of the H600C mutation on the conformation of ACE and to detect any change in 
domain interaction (Figure 3.14).  The conformation of membrane-bound ACE was 
determined with a cell-based ELISA assay (for Methods refer to Chapter 2, Section 2.2.6).  
N domain-specific mAbs showed a similar trend in binding of sACE-H600C compared to wt 
with the exception of mAbs 3A5, 1G12 and i2H5.  Noticeably higher levels of bound mAb 
were detected for sACE-H600C for each of these three mAbs (149.45% ± 4.91%, p < 0.001; 
123.74% ± 8.17%, p < 0.05 and 156.37% ± 16.63%, p < 0.01 binding of wt, respectively).  No 
remarkable difference in binding of C domain-specific mAbs to sACE-H600C compared to 
wt was observed, besides a significant increase in affinity for mAb 4E3 (130.96% ± 5.87%, 
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Figure 3.14.  Cell ELISA of sACE-H600C.  A cell based ELISA assay was performed on CHO cells expressing 
sACE and sACE-H600C using the panel of domain-specific mAbs.  Data is shown as the % binding of wt, 
normalised as the ratio of binding to control (IgG) and is the mean±SD of two experimenrts performed in 
triplicate.   
 
3.2.4.4.3 Thermal stability of sACE-H600C 
The effect of the de novo disulphide bridge formed betw en C474 and H600C on sACE 
thermal stability was determined (Figure 3.15) (Methods in Chapter 2, Section 2.2.11).  The 
loss of activity over time after incubation at 55C showed similar trends for wt, as previously 
reported (O’Neill et al, 2008) where rapid loss and apparent destabilisation of sACE occurs 
after 5 minutes (23% residual activity).  A similar trend was observed for sACE-H600C, 
which appears to indicate that the novel disulphide has not improved sACE thermal stability. 
Figure 3.15.  Thermal stability of wt (black) and sACE-H600C (grey) was determined by incubation at 55C 
over 90 minutes.  Data is represented as the percent residual activity remaining compared to control (sample left 
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3.3 DISCUSSION 
The crystal structures of both the N (Corradi et al, 2006) and C domains (Natesh et al, 2003) 
of ACE have been solved individually, but the solution of the full-length 3D structure of ACE 
remains elusive.  The presence of heterogeneous glycosylation on both domains and the 
degree of inter-domain flexibility afforded by the linker region have been suggested as 
possible reasons for the difficulty in obtaining sACE crystals.  As discussed in Chapter 1, 
minimally glycosylated variants of the N and C domains have facilitated reproducible crystal 
formation (Gordon et al, 2003; Watermeyer et al, 2006; Anthony et al, 2010) and may be a 
viable approach for solving the 3D structure of sACE.   
A second and possibly parallel approach would be to limit the flexibility of the linker region 
and thereby constrain the two domains through the introduction of an intra-molecular 
disulphide bridge.  The use of de novo disulphide bridges has been a successful approach in 
stabilising proteins for molecular studies.  These include the subtilisins (Bryan et al, 2000), 
RNaseA (Pecher et al, 2009) and F-actin filaments (Kim et al, 2000). 
In this study, novel disulphide bridges were designed in silico between residues in the 
N domain and the linker region (Figures 3.1 & 3.2).  To ascertain the position at which a 
novel disulphide bridge would limit inter-domain movement, two strategies were employed: 
1) to utilise the free thiol (C474) to interact with a novel cysteine at position 600 in the linker 
region, and 2) to modify the stabilising hydrogen bond between residues E161 and Y607 in 
the lower portion of the linker region by creating a de novo disulphide bridge.  Cysteine 
residues were introduced by site-directed mutagenesis and mutant protein stably expressed in 
CHO cells.  The presence of the novel disulphide bridge was verified by limited proteolysis of 
purified protein and SDS-PAGE and MALDI MS/MS of the resulting peptides.  These 
mutations were initially introduced into a soluble N domain construct as proof of concept.  
Utilisation of the free thiol in the N domain appeared to be a successful strategy to introduce a 
de novo disulphide bridge.  The introduction of H600C into the N domain resulted in the 
formation of C474-C600 disulphide linkage confirmed by CnBr cleavage, SDS-PAGE and 
MALDI MS/MS (Table 3.1, Figures 3.6 & 3.7). 
The double cysteine mutant Ndom-EY/CC, designed to impose greater restriction of 
movement of the linker region, was not properly processed - as determined by RT-PCR and 
western blotting analysis (Table 3.2, Figures 3.8 & 3.9).  Despite detectable levels of mRNA 
and protein in the cell lysate, negligible amounts of mature, active soluble protein were 
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protein expression is the result of misfolding or insufficient glycosylation (Helenius & Aebi, 
2001).  Two glycosylation sequons lie in close proximity to E161C and Y607C at sites N131 
and N480.  However, the conversion of E161 and Y607 to cysteine residues is unlikely to 
affect the attachment of glycans at these sites.  A native intra-molecular disulphide bridge, 
C128-C136, lies within 12Å of E161 and 16Å of Y607 on a flexible loop that is exposed on 
the surface (Figure 3.1).  Furthermore, the free thiol of C474 lies within 14Å of E161 and 17Å 
of Y607.  Considering the flexibility of the linker region and the loop wherein the C128-C136 
bridge lies, it is possible that the presence of additional cysteine residues in close proximity to 
this region may have a detrimental effect on protein folding by interfering with the formation 
of the C128-C136 bridge and allowing formation of non-native disulphide bonds.  A similar 
observation was made when introduction of novel cysteine residues resulted in loss of 
expression of acetylcholinesterase (Siadat et al, 2006).  
Thus, data from the two mutants Ndom-H600C and Ndom-EY/CC indicate that the strategy 
of utilising the free thiol is a less disruptive means of introducing a novel disulphide bridge.   
The effect of this novel disulphide linkage on ACE expression, processing and inter-domain 
interaction was assessed in the sACE isoform. The introduction of H600C into full-length 
sACE resulted in the successful formation of the novel C474-C600 linkage, detected by 
limited proteolysis and MALDI MS/MS (Table 3.3, Figures 3.11 & 3.12).  The de novo 
disulphide linkage had no adverse effect on protein expression since membrane-bound sACE-
H600C was expressed as a catalytically active protein that was proteolytically processed from 
the membrane and the soluble version was also expressed as an active protein (Figures 3.10 & 
3.13).  
In order to assess the potential of any mutants containing engineered disulphides as 
crystallisation candidates, it was important to determine the effect of the novel disulphide 
bridge on sACE stability and inter-domain interaction.  This was investigated using thermal 
stability assays and cell ELISA with the panel of domain-specific ACE mAbs.   
The mutation had no effect on thermal stability, contrary to our expectations (Figure 3.15).  
This was based on previous observations that interactions between the N and C domains may 
have a stabilising effect on sACE (O’Neill et al, 2008).  This could be due to the following 
factors: first, the de novo disulphide linkage, while present, is insufficient to constrain the 
linker region in such a way as to improve stability and second, the formation of the C474-
C600 linkage is not energetically favourable, resulting in a mixed population of both 
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observed by SDS-PAGE was of a greater intensity than the wt or non-linked peptide 
indicating that the majority of the protein exists in the disulphide-bridged form. 
To evaluate the effect of H600C on inter-domain interaction, changes in the conformation of 
the two domains were determined using the domain-specfic monoclonal antibodies to ACE 
(Figure 3.14).  The epitopes of eight N domain-specfic mAbs (9B9, 3G8, i1A8, 6A12, 1G12, 
5F1 and i2H5) and eight C domain-specfic mAbs (1B3, 1B8, 3F10, 1E10, 4E3, 2H9, 3F11 
and 2B11) have been mapped to 700-800Å2 regions of each domain (Danilov et al, 1994; 
Balyasnikova et al, 2005a; Balyasnikova et al, 2007; Balyasnikova  et al, 2008; Danilov et al, 
2007; Naperova et al, 2008a; Gordon et al, 2010) (Chapter 1, Section 1.4).  The binding of 
these mAbs to different ACE chimeras has allowed for the identification of regions where the 
two domains may be in close proximity.  Most noticeably the epitopes of the N domain-
specfic mAbs 1G12 and 6A12 appear to be occluded by the C domain (Balyasnikova et al, 
2007).  Similarly, the epitopes of the C domain-specfic mAbs 1E10 and 4E3 appear to be 
partly occluded by the N domain and it has been proposed that a point of contact between the 
two domains may lie within these epitopes (Naperova et al, 2008a).  This point of contact on 
the N domain is proximal to the overlapping epitopes of mAbs 3A5, 1G12 and i2H5, which is 
distal to the linker region and C474-C600 disulphide bridge.  All three of these mAbs showed 
increased affinity for sACE-H600C.  Moreover, the same effect was observed for the 
C domain-specfic mAb 4E3.  This suggests that the novel disulphide has had some effect on 
inter-domain interaction..  
Determining the effects of the novel C474-C600 disulphide bridge on inter-domain interaction 
and protein stability by thermal denaturation and cell ELISA were inconclusive.  There 
appeared to be some localised effect on the interaction of the two domains, evidenced by the 
increased affinity for certain mAbs, but there was no effect on thermal stability.  The 
engineering of disulphide bonds successfully improved the stability of acetylcholinesterase 
(Siadat et al, 2006) and Rhizomucor miehei lipase (Han et al, 2009), where changes in thermal 
stability were measured in a similar manner.  This suggests that the failure to detect an effect 
of the C474-H600C disulphide bridge on thermal stability was more likely the result of the 
bridge not being favourably positioned than the methods used.  
This study was limited by the lack of information regarding the interaction of the two 
domains.  Inter-domain movement has been hypothesised based on the negative cooperativity 
of the two domains with regards to substrate hydrolysis (Binevski et al, 2003; Andujar-
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two domains (Corradi et al, 2006) and from mAb binding (Balyasnikova et al, 2007; 
Naperova et al, 2008a).  However, a means to directly determine inter-domain interaction and 
movement has not been established.  It was hoped that the determination of the effect of the 
de novo bridge on thermal stability and protein conformation would be sufficient to detect 
changes in this respect.  At this stage, the reasons for no significant effect on conformation 
and enzyme stability have not been established and there remains the possibility that the 
position of the C474-C600 linkage is not ideal to produce an effect.  
In summary, the introduction of de novo disulphide bonds in the linker region between the 
two domains may still be an effective approach towards limiting inter-domain movement and 
developing a candidate for crystallisation.  However, the positioning of the bridge is critical in 
eliciting the desired effect.  While the use of the free thiol to form the de novo C474-C600 
bridge was successful, results suggest that this is not in an optimal position to elicit a strong 
stabilising effect.  The crystal structure of the N domain indicates that the flexible linker 
region is held in position by a hydrogen bond between the side chains of residues E161 and 
Y607 (Corradi et al, 2006).  To effectively limit inter-domain movement, this position seemed 
optimal, however introduction of cysteines at these positions led to protein misfolding.  It may 
be useful to determine the role of the C128-C136 bridge in protein expression and stability 
and whether these sites could be removed or altered. 
Finally, the question remains as to whether the introduction of de novo disulphides into sACE 
is a viable approach for obtaining crystal for 3D structure determination.  Particularly since 
the difficulty in obtaining crystals has also been attributed to the presence of a high degree of 
heterogeneous glycosylation.  An additional approach would be to introduce any de novo 
disulphide bridges into a minimally glycosylated version of sACE, thereby reducing both 
problems thought to hamper crystallisation of sACE.  With this in mind, sACE-H600C was 
expression in CHO cells in the presence of the α-glucosidase inhibitor N-butyl-
deoxynojirimycin (NB-DNJ) to limit the heterogeneity of glycan residues (Butters et al, 
1999).  Sufficient protein was obtained for purification and has been sent for crystallisation 
trials (performed in the laboratory of Prof. K. Ravi Acharya, University of Bath, UK), the 
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CHAPTER 4:  Dimerisation and shedding: Fine epitope mapping of 





Monoclonal antibodies are valuable tools in biology, due to their high degree of specificity 
(reviewed in Ladner et al, 2007).  Epitope mapping of target regions has enhanced a number 
of molecular techniques including ELISA (He et al, 2010) and flow cytometry (Danilov et al, 
2003; Nikolaeva et al, 2006); as well as in therapeutics including targeted immunotherapy, for 
diagnostic tools, identification of cell and serum markers and vaccine development (Baloria et 
al, 2011).  Moreover, the understanding of the structure-function relationship of a number of 
proteins has been enhanced through epitope mapping.  Some examples include the 
characterisation of human mAbs to the hepatitis C virus envelope 2 protein (Iacob et al, 
2008); epitope mapping of three mAbs to adenovirus type 2 E3/19K protein used to 
investigate the immune response to infection (Menz et al, 2008) as well as the investigation of 
the multiple drug resistant P-glycoprotein and its role in chemotherapy (Cianfriglia et al, 
2002) 
Defining the epitope of a mAb identifies distinct regions of a protein.  In combination with 
site-directed mutagenesis, epitope mapping can be used to define particular residues involved 
in protein-protein interactions. 
 
4.1.1 Monoclonal antibodies to ACE and their effect on processing and function 
Extensive mapping of the epitopes of a panel of eight N domain-specific (Balyasnikova et al, 
2005a; Balyasnikova et al, 2007; Skirgello et al, 2006; Danilov et al, 2007; Gordon et al, 
2010) and eight C domain-specific (Balyasnikova et al, 2008, Naperova et al, 2008a) 
monoclonal antibodies to ACE has been performed (refer to Chapter 1, Section 1.4).  Binding 
of these antibodies affects ACE activity (Skirgello et al, 2006), proteolytic cleavage 
(Balyasnikova et al, 2002, Balyasnikova et al, 2005a) and dimerisation (Kost et al, 2003, 
Gordon et al, 2010).  Recently epitope mapping of the N domain-specfic antibody 5F1 has 
been used to shed light on hinge movement upon substrate binding (Danilov et al, 2007). 
                                                 
†
 The work described in this chapter was part of a larger study conducted in collaboration with Prof S. Danilov 
(University of Illinois at Chicago, USA) and was recently published (Gordon et al, 2010).  This chapter focuses 
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Two of these mAbs, 9B9 and 3G8, which bind overlapping regions of the N domain 
(Danilov et al, 1994), were shown to have a significant effect on ACE shedding 
(Balyasnikova et al, 2002) and homodimerisation (Kost et al, 2003).  The presence of mAb 
9B9 increased ACE shedding from the surface of CHO cells and inhibited dimerisation in 
reverse micelles (Balyasnikova et al, 2002; Kost et al, 2003).  Conversely, mAb 3G8 had an 
inhibitory effect on both shedding and dimerisation in the same experiments.  In order to 
identify regions or residues that may be involved in these processes, fine epitope mapping of 
mAbs 9B9, 3G8 and i1A8 was performed.  mAb i1A8 was included since the proposed 
epitope of this antibody overlaps those of mAbs 9B9 and 3G8 to a large extent (Danilov et al, 
1994) but its binding has no effect on dimerisation (Kost et al, 2003) or shedding 
(Balyasnikova et al, 2002).  Thus, it was used to eliminate residues within the overlapping 
regions of these epitopes. 
 
4.1.2 The N domain epitopes of anti-ACE mAbs 9B9, 3G8 and i1A8   
The proposed epitope of mAb 9B9 was localised to the N-terminal portion of the N domain, 
based on precipitation of different ACE isoforms, cross-species reactivity and sequence 
homology (Balyasnikova et al, 2005a; Gordon et al, 2010).  This epitope is localised around a 
four-amino acid motif, 9NFSA12, which is conserved amongst the mammalian ACE species 
that mAb 9B9 recognises (Gordon et al, 2010).  The degree of binding of mAb 9B9 is thought 
to be affected by glycan residues since ACE from human umbilical vein endothelial cells 
(HUVEC) and macrophages is precipitated by mAb 9B9 to a much smaller extent than that 
from CHO cells.  
The proposed epitope of mAb 3G8 overlaps that of mAb 9B9 (Danilov et al, 1994) and lies 
within a region that is partially occluded by the C domain since mAb 3G8 bound sACE 
significantly less than the N domain, similar to what was observed for mAbs 1G12 and 6A12 
(Balyasnikova et al, 2007).  This epitope contains residues within the first 141 amino acids 
because mAb 3G8 bound the ACE chimera N-del-ACE/BglII, which has the first 141 residues 
of the C domain replaced by the N domain (Balyasnikova et al 2005a; Gordon et al, 2010).  
As with mAb 9B9, binding of mAb 3G8 is affected by the type and extent of glycosylation, 
evident by the increased binding of mAb 3G8 observed with CHO cells compared to COS and 
human embryonic kidney (HEK) cells.  Furthermore, NB-DNJ treatment of CHO cells led to 
increased precipitation of sACE by mAb 3G8 as well as that of purified ACE from seminal 
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The putative epitope for mAb i1A8 overlaps both the mAb 9B9 and 3G8 epitopes (Danilov et 
al, 1994).  It does not seem to be occluded by the C domain since sACE and the N domain are 
precipitated equally by this antibody (Gordon et al, 2010).  The binding of mAb i1A8 appears 
to be influenced by glycans, as with mAbs 9B9 and 3G8.  Changes in binding were observed 
for ACE from different sources and sACE was precipitated more efficiently from the culture 
fluid of NB-DNJ treated cells.  Neuraminidase treatment of purified plasma and seminal fluid 
ACE had the same effect. 
Based on previous cross-species comparisons, Q22, Q87, R90 and R96 were identified as 
possible residues within the epitopes of mAbs 9B9 and 3G8 (Balyasnikova et al, 2005a, 
Gordon et al, 2010).  These formed a basis for fine epitope mapping using site directed 
mutagenesis to target specific residues. 
 
Thus, the aim of this study was to perform fine epitope mapping of mAb 9B9, 3G8 and i1A8. 
This involved the following objectives: 
1. To perform fine epitope mapping of mAbs 9B9, 3G8 and i1A8 by site-directed 
mutagenesis. 
2. To identify residues in the overlapping region of the epitopes of mAbs 9B9 and 3G8 that 
may be involved in ACE dimerisation and shedding. 
3. To characterise the effect of these residues on ACE shedding, dimerisation and mAb 
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4.2 RESULTS 
4.2.1 Site-directed mutagenesis and construction of mutants in a mammalian 
expression vector 
4.2.1.1 N domain mutants for fine epitope mapping 
To further define the epitopes of the three monoclonal antibodies 9B9, 3G8 and i1A8, key 
residues were identified within these epitopes through site-directed mutagenesis. 
Using the crystal structure of the ACE N domain (PDB accession number 2C6F) (Corradi et 
al, 2006), the surface residues within the proposed epitopes were examined to identify those 
that were exposed or caused protuberances from the structure, and thus would more likely to 
be involved in ACE-mAb interactions. 
Mutations of 10 amino acids (indicated in bold below) were generated, which formed part of a 
larger panel of mutations produced in collaboration with Prof. S. Danilov (University of 
Illinois at Chicago, USA).  
In order to disrupt interactions between ACE and mAbs 9B9, 3G8 and i1A8, surface residues 
were altered to the corresponding amino acid of a different species (Q18H, Q30V, I79V, 
R90K, R96G, N203E, EG315-316AE, L562S) or of the C domain (R541A, K542T, K557Q, 
D558L).  Alternatively, residues were converted to amino acids with small sides chains to 
drastically alter the local extended surface conformation (P3A, Q6A, D13A, Q22A, Q87G, 
R340A, D374A, R550A) or to alter the properties of the side chain without having a large 
effect on the surface structure (G4E, L19E).  Furthermore, three glycosylation sequons were 
disrupted to determine the role of glycan chains in antibody binding (N9Q, N25Q, N82Q).   
 
Figure 4.1.  Cloning of N domain mutants into pcDNA3.1(+).  The ACE N domain containing mutations 
generated by site-directed mutagenesis was excised from pBS-Ndom via EcoRI/XbaI.  This 2kb fragment was 
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Figure 4.2.  Restriction enzyme digestion of pcDNA-Ndom mutants.  Each box contains a schematic map of 
pcDNA-Ndom mutant construct (left) and agarose gel electrophoresis of wild-type pcDNA-Ndom (W) and 
mutant (M) (right).  The restriction enzyme used for detection of the mutation is indicated (bold).  The molecular 
weight marker included in each gel was HindIII/EcoRI digested lambda DNA. 
BamHI 
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Site-directed mutagenesis was performed to generate the 10 mutants (highlighted in bold 
above) using pBS-Ndom as a template (refer to Methods in Chapter 2, Section 2.1.2).  
Sequencing of the entire N domain insert confirmed the presence of the desired mutations and 
the lack of any spurious mutations that may have been introduced during mutagenesis.  
Complete N domain genes containing each of these ten mutants were excised as a 2kb 
fragment via the restriction sites EcoRI and XbaI and introduced into pcDNA3.1(+) 
(Figure 4.1) (Methods in Chapter 2, Section 2.1.3).  The correct size and orientation of the 
insert and the presence of the mutated ACE cDNA was confirmed by restriction enzyme 
digestion (Figure 4.2). 
 
Figure 4.3.  Cloning of Q18H and L19E into pcDNA-sACE.  A 292bp fragment containing either Q18H or 
L19E was generated by BamHI/EheI digestion of pcDNA-Ndom-Q18H and pcDNA-Ndom-L19E respectively 
and introduced into pcDNA-sACE.   
 
4.2.1.2 Introduction of mutants into full length sACE 
Three mutations within the overlapping region of the mAbs 9B9 and 3G8 epitopes - Q18H, 
L19E and Q22A - were introduced into somatic ACE for further characterisation (refer to 
Methods in Chapter 2, Section 2.1.3).  pcDNA-sACE-Q18H and pcDNA-sACE-L19E were 
generated using the constructs pcDNA-Ndom-Q18H and pcDNA-Ndom-L19E respectively 
(Figure 4.3).  BamHI/EheI fragments containing the N-terminal region of Ndom-Q18H and 
Ndom-L19E were cloned into pcDNA-sACE.  sACE-Q22A was generated by site directed 
mutagenesis of pBS-sACE and the entire sACE cDNA was sequenced using internal primers 
to the ACE gene, confirming both the presence of the mutation and the lack of any undesired 
mutations (Methods in Chapter 2, Section 2.1.2).  sACE-Q22A was introduced into 
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Figure 4.4.  Cloning of sACE-Q22A into pcDNA3.1(-).  sACE containing Q22A was excised from pBS-sACE-
Q22A via XbaI/HindIII, and the 4.06kb fragment and introduced into pcDNA3.1(-). 
 
Restriction enzyme analysis was performed on the pcDNA-sACE constructs (Figure 4.5).  
Additional bands observed with SacI, ApaI and PsiI digestion of pcDNA-sACE-Q18H, 
pcDNA-sACE-L19E and pcDNA-sACE-Q22A respectively, confirmed the presence of the 
mutations and the correct size and orientation of the sACE insert. 
 
Figure 4.5.  Restriction enzyme digestion of pcDNA-sACE mutant constructs.  Schematic representation of 
pcDNA-sACE constructs (left) with restriction enzyme used in digestion indicated (bold), and agarose gel 
electrophoresis of wt (W) and mutant (M) pcDNA-sACE contructs (right). A. pcDNA-sACE-Q18H, B. pcDNA-
sACE-L19E and C. pcDNA-sACE-Q22A. 
 
4.2.2 Expression of N domain mutations in CHO cells 
Soluble wt Ndom and the 10 Ndom mutations were stably transfected in CHO cells (refer to 
Methods in Chapter 2, Section 2.2.1) and ACE detected by activity assay of culture fluid 
(Methods in Chapter 2, Section 2.2.2).  All mutants were active and had comparable activity 
to wt, indicating that there was no detrimental effect on enzyme expression or function.  
Sufficient activity was obtained to conduct experiments and these cell lines were expanded 
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Figure 4.6.  ACE activity of Ndom mutants stably expressed in CHO cells.  An ACE activity was assay 
performed on culture fluid harvested from CHO cells after 24 hour incubation.  Data is the mean±SD of one 
experiment performed in triplicate. 
 
4.2.3 Effect of mutations on monoclonal antibody binding to the N domain 
Soluble N domain mutants were precipitated from culture fluid by mAbs 9B9, 3G8 and i1A8 
to quantitate the effect of these mutations on mAb binding (Figure 4.7) (refer to Methods in 
Chapter 2, Section 2.2.5).   
Figure 4.7.  The effect of mutations on the precipitation of Ndom ACE by mAbs .  Results are expressed as a 
percentage of precipitated ACE activity from each mutant to that of wt Ndom and shown as mean±SD of 4 to 6 
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Of these mutations, only two had an effect on binding of mAb 9B9; D13A increased binding 
1.5-fold and R340A decreased binding by 25%.  Both of these residues are conserved across 
all the mammalian ACE proteins that are recognised by mAb 9B9.  Three residues, Q18H, 
L19E and Q22A had the most marked effect on mAb 3G8 binding (30%, 37% and 7% of wt, 
respectively).  While the removal of glycans at position N25 and N82 either increased or 
decreased binding respectively, the same mutation at position N9 had no effect.  Cross-species 
reactivity and sequence homology indicated that sites Q22, Q87, R90 and R96 were important 
residues for mAb 9B9 and 3G8 binding (Gordon et al, 2010).  Interestingly mutations at all 
four residues affected binding of mAb 3G8, but had no effect on mAb 9B9 binding.  
Mutations within the C-terminal region of the N domain altered binding of mAb i1A8, most 
notably R90K, R96G and L562S (185%, 260% and 60% of wt, respectively).  In addition, 
increased binding of ACE to mAb i1A8 was observed after removal of glycans at sites N9 and 
N82 (2.5- and 3.5-fold, respectively). 
 
4.2.4 Fine epitope mapping of mAbs 9B9, 3G8 and i1A8 epitopes 
Results obtained from cross-species reactivity and sequence homology, immunoblotting of 
ACE chimeras (Gordon et al, 2010) as well as anti-ACE antibody precipitation of N domain 
mutations generated by site-directed mutagenesis (Figure 4.7) were used for fine epitope 
mapping of the epitopes of mAbs 9B9, 3G8 and i1A8.  The surface structure of the N domain 
was used to define a 700-800Å2 area for each epitope, delineated by residues whose mutations 
altered mAb binding (Figure 4.8).  
9B9 Epitope.  The epitope for mAb 9B9 was delineated by the 9NFSA12 motif (Gordon et 
al, 2010).  The removal of a bulky side chain at residue 13, allowing for better access of the 
antibody to this motif, would explain the increased precipitation observed with D13A 
compared to wt.  Therefore, this epitope was drawn to include the 9NFSA12 motif and 
residue R340 (since mutation of this residue decreased binding), but not residues I79, Q87, 
R90 and D374 because mutation of these sites had no effect on mAb binding. 
3G8 Epitope.  The mutations that had the greatest effect on mAb 3G8 binding - namely 
Q18H, L19E, Q22A, I79V, Q87G, R90K, R96G and D374A – defined the area of this epitope 
where the proposed epitope was drawn to include these residues and exclude D13 and R340, 
which had no effect.  This epitope also includes the glycosylation sequons at sites N25 and 
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epitope also contains residues within the first 141 amino acids in agreement previous findings 
(Balyasnikova et al, 2005a; Gordon et al, 2010).   
 
Figure 4.8.  Fine epitope mapping of mAbs 9B9, 3G8, and i1A8 . Surface representations of Ndom ACE from 
the crystal structure (PDB accession code 2C6F).  A. Amino acid residues whose subst itution altered mAb 9B9, 
3G8, and i1A8 binding are indicated as follows: mAb 9B9 (orange), mAb 3G8 (yellow), mAb i1A8 (blue), both 
mAbs 9B9 and i1A8 (pink ) and both mAbs 3G8 and i1A8 (cyan).  Residues Q18, L19, and Q22 are highlighted 
(red).  The proposed epitopes for mAbs 9B9 (orange circle), 3G8 (yellow circle), and i1A8 (blue circle) are 
defined.  B. Epitope depicted on surface with residues that lie within the epitopes of mAb 9B9 (orange), 3G8 
(yellow), i1A8 (pink ) and within the overlapping region of mAbs 9B9 and 3G8 (light orange).  The epitope of 
mAb 3A5 is indicated for reference (purple).  Glycosylation sites (green) are indicated in both structures. 
 
i1A8 Epitope.  The epitope for mAb i1A8 lies closer to the C terminus than the epitopes for 
mAb 9B9 and 3G8 since mutagenesis of residues in this region affected binding.  The limits 
of this epitope were defined by the residues that had the greatest effect, from N203 to R541 
and R340 to L562. 
The epitopes of mAbs 9B9, 3G8 and ilA8 overlap to some extent.  mAb i1A8 overlaps largely 
with the epitope of mAb 3A5 (Skirgello et al, 2006) (refer to Chapter 1, Section 1.4).  
Residues Q18, L19, Q22 and N25 lie within the region where epitopes of mAb 9B9 and 3G8, 
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Thus, through fine epitope mapping of mAbs 9B9, 3G8 and i1A8 a region containing residues 
Q18, L19, Q22 and N25 was identified.  Three mutants, Q18H, L19E and Q22A were 
introduced into full-length sACE to determine their effect on mAb binding, ACE shedding, 
and dimerisation.  
 
4.2.5 Expression of full-length sACE mutations in CHO cells 
Wt full-length sACE, sACE-Q18H, sACE-L19E and sACE-Q22A were stably transfected in 
CHO cells and clones picked from the transfection dish to elicit high-expressing clones (refer 
to Methods in Chapter 2, Section 2.2.1).  ACE protein was detected by activity assay of 
culture fluid and cell lysate (Methods in Chapter 2, Section 2.2.2).  Sufficient activity was 
obtained to conduct experiments, albeit low levels of activity were detected in medium.  
There was a slight increase in ACE activity in the cell lysates of sACE-L19E and sACE-
Q22A compared to wt (Table 4.1).  This could be due to differences in transfection efficiency 
or increased ACE expression as the result of the mutation. 
 
Table 4.1.  ACE activity of sACE mutants transfected into CHO cells .  ACE activity was determined after 





wt sACE 25.06 ± 1.58 0.14 ± 0.02 
sACE-Q18H 26.52 ± 3.08 0.23 ± 0.04 
sACE-L19E 50.22 ± 8.69 0.51 ± 0.02 
sACE-Q22A 51.63 ± 6.29 0.56 ± 0.04 
 
4.2.6 Effect of Q18H, L19E and Q22A on shedding of sACE 
Basal shedding of the mutant cell lines was determined by calculating the ratio of ACE 
activity in the medium versus the total in medium and cell lysate, after a prolonged incubation 
in minimal medium (Figure 4.9) (refer to Methods in Chapter 2, Section 2.2.4).  Shedding of 
wt sACE was low, with 3-6% activity detected in medium, as reported previously 
(Woodman et al, 2000).   
Basal shedding of sACE-Q18H, sACE-L19E and sACE-Q22A was significantly higher than 
that of wt (181% ± 25%, 203% ± 41% and 197% ± 28%, respectively).  This indicates that the 
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Figure 4.9.  Basal shedding of wild-type sACE, sACE-Q18H, sACE-L19E, and sACE-Q22A. Shedding was 
calculated as the percentage ACE activity in harvested medium of total activity in cell lysate and medium.  
Results are mean±SD of three experiments performed in triplicate, presented as percentage total ACE shed of 
wild-type.  
 
4.2.7 Effect of Q18H, L19E and Q22A on mAb binding to membrane bound sACE 
Changes in mAb 9B9 and 3G8 binding to full-length sACE constructs was determined with 
an ELISA assay on live cells (refer to Methods in Chapter 2, Section 2.2.6).  mAb 3A5 was 
included as a positive control for ACE-mAb interaction as it binds strongly to the N domain 
of sACE (Figure 4.10) (Balyasnikova et al, 2002).  Increased mAb 9B9, 3G8 and 3A5 binding 
was observed for sACE-Q18H, sACE-L19E and sACE-Q22A compared to wt (Figure 4.10A), 
which agrees with the higher ACE activity detected in cell lysate and further confirms the 
increased levels of ACE expression in these cell lines.  However, no significant difference in 
mAb binding to sACE-Q18H, sACE-L19E and sACE-Q22A was observed for ACE mAb, 
when normalised for increases in cell surface expression (Figure 4.10B).  This suggests that 
none of these residues is responsible for mAb binding alone.  However, significant differences 
were observed when single N domain mutants were precipitated from culture fluid by the 
same ACE mAbs (Figure 4.7).  Since the single N domain was used for precipitation and full-
length sACE was used in the ELISA experiment, different criteria for mAb binding would be 
involved which could include changes in surface structure, glycosylation patterns and in the 
case of sACE inter-domain interaction(s).  Furthermore the differences in experimental setup 
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Figure 4.10.  Cell ELISA of sACE constructs.  A. Results are shown as percentage binding of control 
antibody, IgG, and B. % percentage binding of mAb 3A5, mean±SD of three separate experiments performed in 
triplicate 
 
4.2.8 Effect of mutations on ACE shedding in the presence of mAbs 
The presence of certain ACE mAbs in culture fluid has been shown to have an effect on ACE 
shedding from the surface of CHO cells (Balyasnikova et al, 2002; Kost et al, 2003; 
Skirgello et al, 2006).  Both mAb 9B9 and 3A5 significantly increase the amount of somatic 
ACE shed from the cell surface (2.7 and 4.1-fold, respectively) (Balyasnikova et al, 2002), 
whereas mAb 3G8 has been shown to have an inhibitory effect (36% decrease in shedding) 
(Balyasnikova et al, 2002).  The effect of the Q18H, L19E and Q22A mutations on mAb-
induced shedding of sACE from CHO cells was determined (Figure 4.11) (refer to Methods in 
Chapter 2, Section 2.2.4.2).  Wt sACE, sACE-Q18H, sACE-L19E and sACE-Q22A were 
incubated in the presence of mAbs 9B9 and 3G8 and with mAb 3A5, a positive control for 
shedding, and with IgG and mAb i2H5, negative controls for antibody binding and shedding 
respectively.  As expected, shedding of wt, sACE-Q18H, sACE-L19E and sACE-Q22A was 
increased in the presence of mAbs 3A5 (2.4 to 3-fold), but not with IgG and i2H5.  Shedding 
of wt sACE was increased in the presence of mAb 9B9 (1.2-fold) as previously shown 
(Balyasnikova et al, 2002) and no significant change in shedding occurred in the presence of 
mAb 3G8.  There was no significant change in shedding of mutant sACE compared to wt.  
Thus, it seems that these single mutations have no effect on mAb 9B9-induced shedding of 
ACE and that Q18, L19 and Q22 alone are not involved in this mechanism.  It was surprising 
that Q18H, L19E and Q22A had no effect on mAb 3G8-induced shedding since the noticeable 
effect these mutations had on binding of the N domain (Figure 4.7) suggested that they may 
be involved.  As with mAb 9B9, this may be due to synergistic effects by more than one 
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compared to other antibodies such as mAbs 9B9 and 3A5, which could explain why the 
inhibitory effect of this antibody was not observed in any of the cell lines. 
 
Figure 4.11.  mAb-induced shedding performed on sACE cell lines . Results are a mean±SD of three 
experiments performed in triplicate and expressed as the percentage shedding of IgG control.   
 
The low expression levels of these cell lines resulted in minimal ACE activity in culture fluid 
(Table 4.1).  Thus, the shedding assay and ACE activity assay were optimised to allow for 
reproducibility in these experiments.  The incubation time of the cell lines was increased from 
4 hours to 24 hours to allow for sufficient accumulation of ACE in culture fluid to be detected 
by the activity assay.  Incubation times in the activity assay were also extended to obtain 
sufficient values above background.  Since these conditions were not optimal, this may 
explain the large degree of error observed in the experiments. 
 
4.2.9 Effect of mutations on ACE dimerisation 
Since it was shown in reverse micelles that mAbs 9B9 and 3G8 inhibit homodimerisation of 
both sACE and the N domain (Kost et al, 2003), the effect of Q18H, L19E and Q22A on 
dimerisation of sACE in CHO cells was investigated (Figure 4.12).  CHO cells expressing wt 
sACE, sACE-Q18H, sACE-L19E and sACE-Q22A were incubated either in the presence or 
absence of the membrane-impermeable crosslinker bis[sulfosuccinimidyl] suberate (BS3) and 
immunoblotting performed on cell lysate under both non-reducing and reducing conditions 
(refer to Methods in Chapter 2, Section 2.2.8).  Under non-reducing conditions in the absence 
of crosslinker, sACE resolved as three distinct bands of approximately 190, 350 and >400kDa 
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was no significant difference between the wt and mutants with respect to D1 
(Figure 4.12A, -BS3 lanes).  With the addition of the reducing agent, DTT, the oligomer 
disappears and the dimer is visibly reduced (Figure 4.12B, -BS3 lanes).  The dimer population 
that is still present could be formed through non-covalent interactions, although these would 
most likely be disrupted during sample preparation.  An alternative is that these are 
covalently-mediated and that there was incomplete reduction of the dimeric species.  These 
observations seem to indicate the involvement of intermolecular disulphide bridges in ACE 
dimerisation/oligomerisation.   
 
Figure 4.12.  Crosslinking and western blot analysis of sACE constructs . A and B. Representative blots of 
three separate experiments is shown (top), ACE was detected with the C domain-specific mAb 1D8. 
Densitometry was performed to determine the relative intensity of each band to the monomer (bottom).  In each 
panel, values are mean ± SD.  O:  oligomer; D1: dimer; D2:  crosslinked dimer; M: monomer; XL: crosslinker. 
 
In the presence of BS3, an additional, slightly larger dimeric form of ACE (D2) appears that 
has greater intensity than the dimeric form observed in the absence of crosslinker (D1) 
(Figure 4.12, +BS3 lanes).  In the absence of reducing agent, this form is significantly 
increased with sACE-Q22A compared to wt, but not sACE-Q18H and sACE-L19E 
(Figure 4.12A, + BS3 lanes).  Under reducing conditions, the higher molecular weight forms 
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This could be the result of a mixed population of susceptible disulphide-mediated and 
insufficiently crosslinked dimers.  The appearance of an additional dimer in the presence of 
crosslinker can be explained as follows:  first, dimers formed by the action of BS3 may have 
decreased mobility and would thus resolve as larger forms compared to the non-cross linked 
dimers.  Second, crosslinking may have resulted in an ACE heteromer, as has been shown 
with carboxypeptidase M (CPM) (Sun et al, 2008).  It must be noted that the latter study was 
conducted using Madin-Darby canine kidney (MDCK) cells transfected with ACE, which 
have high endogenous expression of CPM.  Third, the crosslinked dimer (D2) may be a fully 
glycosylated form whereas the non-crosslinked form is a disulphide-mediated form of 
immature ACE glycoforms.  The two glycoforms are routinely observed by immunoblotting 
of cell lysates from ACE expressing cells under reducing conditions (Ehlers et al, 1992, 
Kasturi et al, 1994).   
Crosslinking of ACE on the cell surface facilitated the visualisation of ACE dimers that are 
most likely mediated by non-covalent interactions.  The overlapping region of the mAbs 9B9 
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4.3 DISCUSSION 
MAbs to ACE are valuable tools in western blotting (Balyasnikova et al, 2008), ELISA 
(Danilov et al, 1996), immunohistochemistry (Danilov et al, 1987) and flow cytometry 
(Danilov et al, 2003).  Furthermore, our understanding of the structural and functional aspects 
of ACE shedding (Balyasnikova et al, 2002; Balyasnikova et al, 2005a), dimerisation (Kost et 
al, 2003; Gordon et al, 2010), binding and the detection of inhibitors (Balyasnikova et al, 
2005b) and mutations (Kramers et al, 2001; Nesterovitch et al, 2009; Danilov et al, 2010b) 
has been improved by the use of mAbs to ACE.  Fine epitope mapping of mAbs defines 
regions that may be involved in these functions and in this study the epitopes of the mAbs 
9B9, 3G8 and i1A8 were scrutinised in order to define a region that may be involved in 
shedding and dimerisation. 
Both mAbs 9B9 and 3G8 have been shown to inhibit N domain dimerisation in reverse 
micelles (Kost et al, 2003).  Furthermore, shedding of sACE from CHO cells is induced by 
mAb 9B9 whereas mAb 3G8 was shown to have an inhibitory effect (Balyasnikova et al, 
2002).  The third mAb, i1A8, has no effect on dimerisation or shedding despite the proximity 
of its epitope to those of mAbs 9B9 and 3G8 (Danilov et al, 1994) and was therefore useful in 
ruling out candidate regions.  
Site-directed mutagenesis was performed on the N domain to identify residues involved in 
mAb binding.  Together with findings from cross-species reactivity and comparison of the 
N domain secondary structure (Gordon et al, 2010), fine epitope mapping of these three mAbs 
was performed (Figure 4.8).  mAbs 9B9 and 3G8 were mapped to the N-terminal region and 
mAb i1A8 to the region overlapping the epitope of mAb 3A5 (Danilov et al, 1994).  
Interestingly, mAb 3A5 has anti-catalytic effects and induces shedding whereas binding of 
mAb i1A8 does not (Balyasnikova et al, 2002, Skirgello et al, 2006).  An overlapping region 
of the epitopes of mAb 9B9 and 3G8, but not i1A8, contained residues important for binding 
of mAb 3G8, namely Q18, L19, Q22 and N25. 
Full-length sACE variants of Q18H, L19E and Q22A were stably expressed in CHO cells to 
determine the effects of these mutations on mAb binding, shedding and dimerisation. 
There was noticeable increase in surface expression, detected by both activity assays of cell 
lysate and by cell ELISA (Table 4.1 & Figure 4.10A).  In addition, the mutations led to a 
significant increase in shedding (Figure 4.9).  This implicates these residues and the 
overlapping region of the epitopes of mAbs 9B9 and 3G8 in ACE processing, particularly its 
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The recognition motif for the cognate ACE secretase has yet to be identified and it is possible 
that regions in the N domain may be involved in interaction with the secretase, particularly 
since some sheddases have been shown to require interaction with regions distal to the 
cleavage site for proteolysis (Takeda et al, 2006).  Tyrosine phosphorylation in the 
ectodomain was shown to increase ACE shedding, further implicating the distal domains in 
ACE cleavage secretion (Santhamma et al, 2004). 
This region may be involved in dimerisation and have an effect on shedding.  The orientation 
of the N domain with respect to the C domain is likely to have an effect on cleavage secretion 
(Woodman et al, 2000; Woodman et al, 2005) and it may be this alone that is responsible.  
This is reinforced by the proposal that binding of mAbs 9B9 and 3G8 position sACE in such a 
way as to respectively allow or obstruct access of the secretase (Balyasnikova et al, 2005a; 
Kost et al, 2003).  Residues within the overlapping region of mAbs 9B9 and 3G8 may be 
involved in domain interaction, evidenced by the fact that the mAb 3G8 epitope may be partly 
occluded by the C domain (Gordon et al, 2010).  Mutations of Q18, L19 and Q22 that 
enhance shedding may alter the orientation of the two domains, improving the interaction of 
the C domain with the secretase.  However, these mutations had no effect on shedding in the 
presence of mAbs suggesting a synergistic effect involving a number of residues.  
The role of the overlapping region of the tw  epitopes of mAbs 9B9 and 3G8 in dimerisation 
was investigated by western blotting (Figure 4.12).  Both mAbs inhibit dimerisation of the 
N domain and sACE in reverse micelles (Kost et al, 2003), implicating this domain in dimer 
formation.  Furthermore, competitive inhibition of dimerisation in the same system by 
carbohydrates such as Neu5Ac- and Gal-terminated saccharides suggests that this may 
involve a carbohydrate recognition domain.  This is reinforced by the appearance of dimers 
after crosslinking, most likely mediated by non-covalent interactions.  The increased 
formation of crosslinker dimer upon mutation of Q22 points towards the involvement of this 
overlapping region.  Glycan sequons N9 and N82 are proximal and N25 lies within this 
region, all three sites are glycosylated in the N domain (Anthony et al, 2010) and could 
potentially be involved in dimer formation.  Kohlstedt et al (2006) found that sACE 
overexpressed in porcine aortic endothelial cells and endogenous ACE in primary HUVEC is 
present in both monomeric and dimeric forms.  These dimers are significantly increased in the 
presence of ACE inhibitors and require an active C domain.  The addition of mAbs 9B9 and 
3G8 as well as saccharides had no effect on ACE inhibitor induced dimerisation in porcine 
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reverse micelles are one and the same.  It is possible that ACE dimerisation is mediated by 
both non-covalent, via glycans, and covalent interactions, via disulphide-bridges, as has been 
seen with the human bradykinin B2 receptor (Michineau et al, 2006).  Furthermore, the 
presence of dimers in the absence of crosslinking and their susceptibility to reducing agents 
suggests that covalent interactions may be involved.  The role of disulphide-bridge formation 
in ACE dimerisation is explored further in Chapter 5. 
The role of dimerisation in ACE processing is unclear.  The inhibition of dimerisation by 
mAbs 9B9 and 3G8 implicates this process in shedding since both these mAbs have been 
shown to affect cleavage secretion of ACE expressed in CHO cells (Balyasnikova et al, 
2005a; Kost et al, 2003).  Furthermore, mutations in the overlapping regions of the epitopes 
of these mAbs have a significant effect on shedding from CHO cells.  Mutation of Q22 
significantly increases dimerisation, compounding the link between dimerisation and 
shedding.  ACE inhibitor induced dimerisation mediated via the C domain initiated the ACE 
signalling cascade (Kohlstedt et al, 2006).  It seems that these two mechanisms involve 
distinct regions on both domains and it will be useful to determine the relationship between 
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CHAPTER 5:  The role of free thiols in dimerisation and shedding 
 
5.1 INTRODUCTION 
The cellular control of ACE expression and cleavage secretion is not clearly understood.  It 
has been shown that ACE inhibitor binding can initiate an intracellular signalling cascade via 
the c-Jun/Fos pathway that leads to increased ACE expression (Kohlstedt et al, 2002; 
Kohlstedt et al, 2004) (refer to Chapter 1, Section 1.3.5).  The relationship between this 
signalling process and the cleavage secretion of ACE are unclear as are the mechanisms 
which control ACE shedding.  Recent insights into the dimerisation of ACE may shed light on 
these processes.  Dimerisation is an important event for the function of membrane proteins.  
Hetero- and homo-dimerisation of receptor tyrosine kinases (RTK’s) such as vascular 
endothelial growth factor (VEGF-R) (Claffey et al, 1995), the epidermal growth factor 
receptor (EGF-R) (Ferguson et al, 2003) occurs upon substrate binding and initiates 
intracellular signalling cascades.  The cleavage secretion of the A  peptide from amyloid 
precursor protein (APP), a type I membrane protein, appears to be dependent on homodimer 
formation (Scheuermann et al, 2001).   
ACE can form a homodimer and this process initiates ACE inhibitor induced signalling 
(Kohlstedt et al, 2006).  Furthermore, an overlapping region of the epitopes of 
N domain-specific mAbs 9B9 and 3G8 has been implicated in dimerisation and shedding 
(Kost et al, 2003).  Of interest in these two studies are the proposed interactions involved in 
dimerisation.  Kost et al (2003) showed that dimerisation of human sACE and the N domain 
alone in reverse micelles could be inhibited in the presence of galactose and propose that a 
carbohydrate recognition domain in the N domain mediates dimerisation (Kost et al, 2003).  
Alternatively, sACE active mutants overexpressed in porcine aortic endothelial cells showed 
that a catalytically active C domain was required for dimerisation and initiation of signalling 
(Kohlstedt et al, 2006).  Despite the apparently contradictory findings of these two studies, it 
is possible that more than one mechanism is involved. 
Dimerisation can be mediated via non-covalent interactions involving the reactive side groups 
of the peptide backbone, mainly through the hydrophobic effect (Jones et al, 1995), and 
through the glycan residues of glycoproteins, as with follicle-stimulating hormone (Ulloa-
Aguirre et al, 1999) and human bradykinin B2 receptor (Michineau et al, 2006).  Strong 
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homodimer formation of endothelin converting enzyme 1 (ECE-1), a type II membrane 
protein, with similar functional properties to ACE (Shimada et al, 1996).  There is evidence 
for the involvement of both non-covalent and disulphide-mediated dimer formation in a 
number of proteins, where there appears to be dependence of the formation of one type of 
interaction on the formation of the second.  For example, the MAM domain of the membrane 
protein meprin forms disulphide-mediated dimers that stabilise the molecule and allow for the 
formation of non-covalent interactions (Marchand et al, 1996) via glycans (Ishmael et al, 
2006).  A similar mechanism is involved in the homodimerisation of a number of G-protein 
coupled receptors (GPCRs) such as the human B2-R (Michineau et al, 2006) and glycoprotein 
VI (GPVI) (Arthur et al, 2007). 
Thus, it is possible that the formation of ACE homodimers on the cell surface occurs via both 
non-covalent and covalent interactions, the latter involving inter-chain disulphide interactions. 
 
Figure 5.1.  Bonded and non-bonded cysteine residues in ACE.  Overlay of Ndom (light orange) and tACE 
(blue-grey) crystal structures with cysteine residues shown in magenta (N domain) and blue (C domain).  The 
three intra-chain disulphide bridges are indicated, in pink (N domain) and blue (C domain).  The linker region at 
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The N and C domains of sACE each contain seven cysteine residues that form three intra-
chain disulphide bridges with a high degree of structural homology between each domain 
(Figure 5.1).  According to the crystal structures of each domain, two of these disulphide 
bridges are buried within the structure, whereas the third (N domain: C126-C138, C domain: 
C728-734) lies within a flexible loop on the surface.  The final cysteine (N domain: C474, 
C domain: C1072) is present in the reduced form (Sturrock et al, 1996) and lies on the surface 
of the structure, proximal to the C terminal region of each domain.  This group may be 
involved in the formation of inter-chain disulphide bonds responsible for dimer formation.  
Furthermore, these interactions may be important in cellular processes such as signalling and 
shedding.  
 
Thus, the aim of this study was to determine the role of the free thiols in each domain of 
sACE. 
This included the following objectives: 
1. To investigate the role of free thiols by site-directed mutagenesis and Western blotting. 
2. To determine the role of each domain in disulphide-mediated dimerisation. 
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5.2 RESULTS 
5.2.1 Detecting mechanisms of ACE dimer formation 
Based on the observations that ACE dimerisation may be the result of non-covalent 
interactions in the N domain (Kost et al, 2003) and/or covalent interactions in the C domain 
(Kohlstedt et al, 2006), native PAGE and western blotting analysis was performed on total 
cell lysate from CHO cells expressing sACE (Figure 5.2) (Methods in Chapter 2, Sections 
2.2.7.2 & 2.2.8).  The resolution of sACE was determined under native conditions in the 
presence of the reducing agent -ME, which would disrupt any covalent disulphide-mediated 
interactions.  In addition, samples were resolved in the presence of SDS to detect non-
covalent interactions that would be susceptible to addition of this solvent.  Under native 
conditions sACE in CHO cell lysate resolves at >260kDa, corresponding to a dimeric form.  
Addition of -ME results in the appearance of a second band, resolving at approximately 
190kDa, the expected size of an ACE monomer, with the majority of ACE detected as the 
higher MW form.  In the presence of SDS, ACE resolves predominately as the 190kDa form 
with a second higher MW form and a faint higher MW band is still visible.  From these 
results, it appears that sACE resolves predominantly as a higher MW form that is susceptible 
to SDS and are thus most likely forms aggregates mediated by non-covalent interactions.  A 
smaller population is susceptible to β-ME suggesting the involvement of disulphide bridges. 
 
Figure 5.2.  Dimerisation of sACE.  Total cell lysate from CHO cells expressing full-length sACE was 
separated by 7% native PAGE under non-reducing, reducing (+ME) and denaturing (+SDS) conditions.  sACE 
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Figure 5.3.  Covalent dimerisation of ACE isoforms. A. Western blotting analysis using the N domain-specific 
mAb 4G6 and B. with the C domain-specific antibody 1D8 in the absence (left) and presence (right) of -ME.  
Purified protein (P) and concentrated medium (M) harvested from CHO-ACE cells were used as sources of 
ACE.  sACE: somatic ACE, Ndom: soluble N domain construct, 2C: CCdom-ACE chimera, tACE: soluble 
tACE-Δ36NJ. 
 
5.2.2 The role of each domain in disulphide-mediated dimerisation 
Analysis of ACE single domain constructs was performed to determine the role of each 
domain in disulphide-mediated dimerisation.  Purified sACE, tACE-36NJ and Ndom as well 
as the two domain CCdom-ACE chimera were used as sources of ACE (for a description of 
these constructs refer to Chapter 2, Section 2.1.1).  Medium harvested from CHO cells 
expressing soluble sACE and Ndom was included.  Samples were separated by SDS-PAGE 
under non-reducing and reducing conditions and western blotting analysis was performed 
(Figure 5.3) (Methods in Chapter 2, Section 2.2.8).  Under reducing conditions, sACE 
resolved as a 190kDa band in both purified and medium samples, detected with both mAbs.  
A higher MW form was observed under non-reducing conditions for both purified sACE and 
medium samples (approx. 350kDa), corresponding to a dimeric form.  The loss of this higher 
MW form in the presence of reducing agent indicates that it is formed by a disulphide-
mediated interaction.  The CCdom-ACE chimera resolved at a similar size as sACE with a 
similarly sized higher MW form.  An additional band resolving at approximately 75kDa, 
similar to the mobility of tACE, is most likely a product of limited proteolysis in the linker 
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tACE runs as two bands, one at 75kDa and the other at approximately 250kDa.  The latter 
disappears in the presence of reducing agent.  The formation of a dimeric, or from the size, an 
oligomeric, disulphide-mediated dimer would explain the presence of this higher MW form.  
Ndom resolved as a 90kDa band, larger than tACE, since this domain is more extensively 
glycosylated than the C domain.  No higher MW forms were observed under non-reducing 
conditions.  From these results, it appears that sACE is able to form a disulphide-mediated 
dimer via residues in the C domain. 
 
5.2.3 Homo-dimerisation of purified sACE 
To confirm that the higher MW bands observed by non-reducing western blotting correspond 
to ACE homodimers and not heterodimeric forms, purified sACE was separated by 2D-PAGE 
(Methods in Chapter 2, Section 2.2.7.1).  Protein was separated in the first dimension by SDS-
PAGE under non-reducing conditions.  A band corresponding to the ACE monomer was 
observed at approximately 190kDa.  Two higher MW bands could be observed, consistent 
with previous immunoblotting of crosslinked sACE cell lysate (Figure 5.4).  Electrophoresis 
was then performed in the second dimension in the presence of -ME.  The two higher MW 
bands co-migrated with the monomer, indicating that these are indeed ACE, most likely 
homodimers in two conformations.  Alternatively, a higher MW form could be a heterodimer 
formed between ACE and another protein.  However, in the second dimension, both higher 
MW bands resolved at the same size as the monomeric form.  
 
Figure 5.4.  Two-dimensional electrophoresis of purified sACE. A. sACE was separated by non-reducing 7% 
SDS-PAGE and then B. separated by reducing SDS-PAGE in the second dimension in the presence of -ME. 
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Figure 5.5.  Subcloning of C474S into pcDNA.  A 1.5kb N domain fragment containing C474S (top, middle) 
was excised from pBS-Ndom (top, left) by SmaI/AgeI digestion.  This fragment was introduced into pBS-sACE, 
generating pBS-sACE-C474S (top, right).  XbaI/HindIII digestion removed sACE cDNA (4.06kb) containing 
C474S (bottom, right), which was introduced into pcDNA3.1(-) producing pcDNA-sACE-C474S (bottom, left). 
5.2.4 Mutagenesis and expression of free thiol mutants 
5.2.4.1 Removal of free thiols by site-directed mutagenesis and introduction of mutants 
into a mammalian expression vector 
The free thiols in the N domain (C474) and the C domain (C1072) were mutated to serine 
residues by site-directed mutagenesis using pBS-Ndom and pBS-sACE, respectively, as 
templates (Methods in Chapter 2, Sec ion 2.1.2).  Mutagenesis was confirmed by nucleotide 
sequencing of the entire Ndom and sACE genes using primers complementary to pBS and 
internal primers complementary to the ACE gene.  No spurious mutations were detected in the 
C474S and C1072S constructs.  Three full-length sACE constructs were produced by 
subcloning the two mutants into the mammalian expression vector, pcDNA3.1(-) (Methods in 
Chapter 2, Section 2.1.3.)  They contain a single free thiol in the C domain (C474S), a single 
free thiol in the N domain (C1072S) and lack both free thiols (CC/SS).   
Figure 5.6.  Subcloning of C1072S into pcDNA.  The 4.06kb sACE cDNA insert containing C1072S (middle) 
was excised from pBS-sACE (left) by XbaI/HindIII digestion and introduced into pcDNA3.1(-), generating 
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Figure 5.7.  Construction of CC/SS in pcDNA.  The 1.5kb N domain fragment containing C474S (middle) was 
excised from pBS-sACE-C474S (left) by SmaI/AgeI digestion and introduced into pcDNA-sACE-C1072S, 
generating pcDNA-sACE-CC/SS (right).   
 
Due to the lack of compatible sites between pBS-Ndom and pcDNA-sACE, an intermediary 
step was used to clone C474S from Ndom into sACE (Figure 5.5).  An N-terminal portion of 
Ndom containing C474S was excised from pBS-Ndom-C474S with SmaI and AgeI and 
inserted into pBS-sACE.  The entire sACE cDNA was then cloned from pBS into 
pcDNA3.1(-) via a XbaI/HindIII digestion.  pBs-sACE contains two SmaI sites, one in the 
multiple cloning site and a second in the sACE gene, thus the 5’ region of the sACE cDNA 
could potentially be removed during subcloning.  An EcoRI digest of pcDNA-sACE-C474S 
confirmed that this region was intact since the EcoRI site that is flanked by the two SmaI sites 
was still present (Figure 5.8).  pcDNA-sACE-C1072S was constructed by excising C1072S 
from pBS-sACE using XbaI/HindIII sites (Figure 5.6).  The CC/SS mutant was generated by 
cloning an XbaI/AgeI N domain fragment from pBS-sACE-C474S into pcDNA-sACE-
C1072S (Figure 5.7).  The size and orientation of the genes and the presence of the mutations 
in pcDNA was confirmed by restriction enzyme digestion (Figure 5.8).  
 
Figure 5.8.  Restriction enzyme digestion of pcDNA constructs .  pcDNA-sACE-C474S (A), pcDNA-sACE-
C1072S (B) and pcDNA-sACE-CC/SS (C) were digested with restriction enzymes to confirm the presence and 
correct size of the ACE cDNA (EcoRI) and the presence of C474S (EcoRV) or C1072S (Bpu10I) and separated 














CHAPTER5: The role of free thiols in dimerisation and shedding  94 
  
5.2.4.2 Expression of mutants in CHO cells 
Wt sACE, sACE-C474S, sACE-C1072S and sACE-CC/SS were stably transfected into CHO 
cells (Methods in Chapter 2, Section 2.2.1).  To overcome the problems encountered with 
determining ACE shedding and mAb binding due to low expression of sACE mutants 
(Chapter 4), a FACS-based cell sorting method was introduced to generate high expressing 
cell lines.  FACS cell sorting was performed on the four cell lines, yielding an average of 
100 mU/ml ACE activity in cell lysate.  This represented a 4–fold increase in expression 
compared to transfections carried out without FACS sorting.  The level of ACE expression 
was fairly consistent between cell lines, although the amount of ACE detected in the medium 
differed (Table 5.1).   
 
Table 5.1 ACE activity of wt and mutant sACE transfected into CHO cells .  Activity in cell lysate and 





wt sACE   92.19 ± 0.62   5.25 ± 0.03 
sACE-C474S 184.15 ± 19.63   8.36 ± 0.23 
sACE-C1072S   99.01 ± 9.40  17.30 ± 0.06 
sACE-CC/SS 200.84 ± 3.84 14.99 ± 0.23 
 
5.2.5 Effect of free thiol mutants on dimerisation of sACE 
5.2.5.1 Dimerisation in total cell lysate 
Western blot analysis of total cell lysate from cells expressing wt sACE, sACE-C474S, 
sACE-C1072S and sACE-CC/SS was performed to determine the effect of the mutations on 
covalent dimerisation (Methods in Chapter 2, Section 2.2.8).  Samples were separated by 
SDS-PAGE under non-reducing and reducing conditions to detect disulphide-mediated dimer 
formation.  Wt and mutant sACE resolved as a single 190kDa band under both non-reducing 
and reducing conditions in repeated experiments and no dimer band could be detected.  In 
some experiments, a faint higher MW form could be detected for wt sACE in the absence of 
reducing agent, but this was not observed for the mutants.   
To further investigate the dimerisation of sACE in cells, mutant cell lines were incubated with 
the membrane-impermeable amide crosslinker, BS3.  This would potentially covalently link 
ACE dimers that consist of more transient protein-protein interactions, catching them in the 
act (Figure 5.9A).  In the presence of crosslinker, sACE resolved as two bands, of 
approximately 190kDa and 350kDa with the higher MW form present as 5-10% of the lower.  
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of the percentage dimer formed shows a significant increase in the formation of crosslinked 
dimer for the two single mutants sACE-C474S and sACE-C1072S, but not for sACE-CC/SS.  
 
Figure 5.9.  Dimerisation of sACE mutants .  A. Total cell lysate from CHO cells incubated in the presence of 
BS
3
, a representative Western blot (left) and densitometry (right), mean±SD of three experiments.  B. Harvested 
and concentrated medium visualised by SDS-PAGE and Western blotting in the absence and presence of -ME.  
sACE was detected using the N domain-specific mAb 1D8.  D: sACE dimer, M: sACE monomer.   
 
5.2.5.2 Dimerisation in culture medium 
Since disulphide-mediated dimers were detected in concentrated medium samples from sACE 
and Ndom (Section 5.2.2), western blot analysis was performed on concentrated medium 
harvested from cells expressing wt sACE and all three mutants (Figure 5.9B).  Under non-
reducing conditions, wt sACE and sACE-C474S resolved as two forms of approximately 
190kDa and 400kDa corresponding to the ACE monomers and dimers.  The higher MW form 
was not detected with sACE-C1072S and sACE-CC/SS. 
In the presence of the reducing agent -ME, these bands lowered in intensity (by approx. 
2-fold) but did not disappear completely.  It is unclear whether these aggregates were shed in 
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would be resistant to reduction.  The dimerisation of the sACE-C474S mutant that only had a 
free thiol in the C domain suggests that disulphide-mediated dimerisation occurs via the free 
thiol in the C domain. 
 
5.2.6 Effect of mutants on ACE shedding 
5.2.6.1 Basal shedding  
Previous findings indicated that regions of ACE might be involved in both dimerisation and 
shedding and that there might be an association between these two events (Chapter 4) 
(Kost et al, 2003).  Thus, the effect that removing the free thiols had on ACE shedding was 
determined (Methods in Chapter 2, Section 2.2.4).  The amount of ACE shed was calculated 
from the ACE activity in cell lysate and medium.  Basal shedding of wt sACE for this high 
expressing cell line was 3% of total ACE, which was consistent with previous results 
(Woodman et al, 2000; Woodman et al, 2005) (Figure 5.10).  he removal of the free thiol in 
the N domain (sACE-C474S) had no effect on shedding whereas the lack of a thiol at the 
C domain (sACE-C1072S) resulted in a 3-fold increase in shedding.  Interestingly, the loss of 
both thiols showed increased shedding from wt (sACE-CC/SS), but not as markedly as when 
a thiol is present in the N domain.  Further investigations of the role of the free thiols in 
shedding were conducted using the CC/SS mutant as this would allow for the determination 
of the effect of the complete loss of free thiols.  
 
 
Figure 5.10.  Constitutive shedding of sACE mutants.  Cells were incubated overnight in minimal medium 
and shedding was determined as described in chapter 2. Data represented is the mean±SD of 3 experiments 
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5.2.6.2 Induction and inhibition of shedding 
Shedding of sACE-CC/SS in the presence of the phorbol ester PDBu, the serine protease 
inhibitor DCI and the hydroxamate-based metalloprotease inhibitor TAPI-1 was determined 
(Figure 5.11) (Methods in Chapter 2, Section 2.2.4.1).  sACE and sACE-CC/SS shedding was 
stimulated in the presence of PDBu by 1.5- and 2-fold respectively.  A dramatic 5.5-fold 
increase in shedding was observed for sACE-CC/SS and wt sACE in the presence of DCI.  
This is consistent with previous work and likely due to a stimulation in the burst of shedding 
from the cell surface (Schwager et al, 1999).  sACE-CC/SS shedding was significantly 
increased compared to wt in the presence of DCI.  The shedding of both wt and sACE-CC/SS 
was inhibited significantly by TAPI-1.  The similar response of sACE-CC/SS to PDBu and 
TAPI-1 indicate that removal of the free thiols has no significant effect on proteolytic 
processing of ACE.  However, the increase in DCI induced shedding observed suggests that 
there may be a pool of cell surface sACE-CC/SS that is more susceptible to cleavage than wt 
sACE.  
Figure 5.11.  Induction and inhibition of shedding.  CHO cells expressing wt (white bars) and sACE-CC/SS 
(grey bars) were incubated for four hours in minimal medium containing 1M PDBu, 200M DCI and 10M 
TAPI.  The percentage ACE shed was determined as described in chapter 2.  Data is represented as the ratio of 
total percentage shed/untreated (untx) and is the mean±SD of two experiments performed in duplicate.   
 
5.2.6.3 mAb induced shedding 
Since mAbs 9B9 and 3G8 were shown to inhibit dimerisation and alter shedding and their 
epitopes have been implicated in dimerisation (Kost et al, 2003), their effect on shedding of 
sACE-CC/SS was investigated (Figure 5.12) (Methods in Chapter 2, Section 2.2.4.2).  Cells 
were incubated in the presence of IgG and the N domain-specific mAbs 9B9, 3G8, 3A5 and 
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shedding whereas mAbs 9B9 and 3A5 induced shedding by approximately 1.5- and 2-fold 
respectively, consistent with previous findings (Balyasnikova et al, 2002; Kost et al, 2003). 
mAb 3G8 had no effect on shedding of wt and sACE-CC/SS.  Shedding of sACE-CC/SS 
followed the same trend as wt, being induced by mAbs 9B9 and 3A5 by approximately 1.5- 
and 2-fold respectively.  This indicates that removal of the free thiols does not affect mAb 
induced shedding. 
 
Figure 5.12.  mAb induced shedding.  CHO cells expressing wt (white bars) and sACE-CC/SS (grey bars) 
were incubated for four hours in minimal medium containing 10g/ml mAbs to ACE.  The percentage ACE shed 
was determined as described in chapter 2.  Data is represented as the ratio of total percentage shed/IgG control 
and is the mean±SD of three experiments performed in duplicate.   
 
5.2.7 Conformational changes induced by the free thiol mutants 
The panel of 8 N domain-specific and 8 C domain-specific mAb to ACE were used to develop 
a conformational footprint of each mutant (Chapter 1, Section 1.4).  Plate precipitation assays 
of wt and mutant sACE were conducted with total cell lysate (Section 5.2.71.) and 
concentrated medium (Section 5.2.7.2) collected from each cell line (Methods in Chapter 2, 
Section 2.2.5).  To assess the effect of these mutations on mAb binding of sACE on the cell 
surface, an ELISA assay was performed on CHO cells expressing wt sACE and sACE-CC/SS 
(Section 5.2.7.3) (Chapter 2, Section 2.2.6).   
The unbound cysteine in the N domain (C474) lies proximal to the mAb 5F1 epitope (which 
is within a distinct region).  C1072 in the C domain lies within the mAb 1B3 epitope and in 
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Figure 5.13. Plate precipitation assay of cell associated sACE.  Total cell lysate from CHO cells expressing 
wt and mutant sACE was precipitated by a panel of domain-specific mAbs as described in chapter 2.  Data is the 
mean±SD of two experiments performed in duplicate, shown as the percentage ACE precipitated as a ratio of wt, 
after normalising to IgG control.   Changes in binding are indicated (grey bars).  
 
5.2.7.1 Plate precipitation assay of total cell lysate 
Similar trends were observed between the three mutants with respect to binding of mAbs to 
cell associated sACE (Figure 5.13).  There is a slight decrease in binding of mAb 5F1 with 
sACE-C474S and sACE-CC/SS, which suggests that C474 is not a critical residue in the 
epitope but may play a role in mAb 5F1:ACE interaction.  An increase in affinity for 
N domain-specific mAbs 9B9, 3A5 and i1A8 in the N-terminal antigenic region to all three 
mutants suggests an arrangement of the N domain resulting in exposure of this region.  
C domain-specific mAbs 1B3, 1B8 and 3F10, in the C-terminal antigenic region show an 
increased affinity for all three mutants, sACE-C1072S and sACE-CC/SS in particular.  Since 
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rearrangement of the domains resulting in exposure of the juxtamembrane stalk.  Increased 
affinity of C domain-specific mAbs 1E10 and 2H9, which lie in the N-terminal antigenic 
region that is shielded by the N domain (Naperova et al, 2008a), for sACE-C0172S and 
sACE-CC/SS indicate some degree of arrangement of both domains exposing these epitopes.  
Interestingly, an increased affinity of mAb i2H5 in the C-terminal antigenic region of the 
N domain for sACE-C1072S suggests the same effect. 
 
 
Figure 5.14.  Plate precipitation assay of soluble sACE.  Medium harvested from CHO cells expressing wt 
and mutant sACE was concentrated and precipitated by a panel of domain-specific mAbs as described in chapter 
2.  Data is the mean±SD of two experiments performed in duplicate, shown as the percentage ACE precipitated 
as a ratio of wt, after normalising to IgG control.   Changes in binding are indicated (grey bars).  
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5.2.7.2 Plate precipitation assay of medium 
With soluble sACE, the trends are similar for all three mutants (Figure 5.14).  There is a 
distinct loss of affinity of mAb 5F1.  For sACE-C474S and sACE-CC/SS this could be due to 
removal of the N domain thiol, however the loss of affinity for sACE-C1072S suggests that 
some other mechanism may be causing occlusion of this epitope.  Interestingly, there is a loss 
of affinity of N domain-specific mAbs i1A8 and 3G8 for sACE-C474S and an increase in 
affinity for sACE-C1072S, suggesting an alteration in this region as a result of the mutations.  
Here the noticeable increase in affinity of mAb 1B3 for sACE-C1072S and sACE-CC/SS, and 
sACE-C474S to some extent, is explained by the loss of the transmembrane domain upon 
cleavage secretion, which exposes this epitope (Balyasnikova et al, 2005b).  The increase in 
affinity of the N domain-specific mAb 1G12 and the C domain-specific mAbs 2H9 and 3F11 
for sACE-C1072S and sACE-CC/SS suggests that there has been some degree of inter-
domain movement, exposing these epitopes. 
5.2.7.3 Cell ELISA 
A cell-based ELISA assay was performed to obtain a conformational fingerprint of ACE 
expressed on live cells (Figure 5.15).  There was no significant change in binding of the 
N domain-specific mAbs to sACE-CC/SS whereas significant decreases in affinity for the 
C domain-specific mAbs 1E10, 4E3, 2H9 and 3F11 were observed (36.65 ± 10.80%, 58.44 ± 
4.87%, 41.90 ± 4.27% and 47.06 ± 15.53% compared to wt, respectively).  These mAbs lie 
within the same N-terminal antigenic region, which is occluded by the N domain 
(Naperova et al, 2008a). 
Figure 5.15.  Binding of mAbs to membrane-bound sACE.  A cell-based ELISA assay was performed on 
CHO cells expressing wt and mutant sACE as described in chapter 2.  The panel of 16 domain-specific mAbs 
were used and data is the mean±SD of three (N domain mAbs) or two (C domain mAbs) experiments performed 
in duplicate and is shown as the ratio of binding to CC/SS of wt, normalised against IgG control.   




N domain C domain 






























CHAPTER5: The role of free thiols in dimerisation and shedding  102 
  
5.3 DISCUSSION 
Protein-protein interactions and particularly dimerisation are important regulatory processes.  
The formation of homo- or hetero-dimers occurs upon ligand binding to receptors to relay 
messages across the cell membrane, to activate and regulate enzymes.  Dimerisation improves 
protein stability and alters access to active sites.   
Recently, two studies reported that sACE has the ability to form dimers (Kost et al, 2003, 
Kohlstedt 2006) and that this may play an important role in processing and signalling.  
Kost et al (2003) showed that interactions via the N domain, most likely mediated by 
carbohydrates, enable dimer formation of sACE and the N domain in reverse micelles.  
Whereas Kohlstedt et al (2006) indicated that in porcine aortic endothelial cells 
overexpressing sACE dimerisation was mediated by interactions in the C domain. 
Homodimerisation was inhibited in reverse micelles by the addition of the N domain-specific 
mAbs 9B9 and 3G8, which affect shedding of sACE from CHO cells, implicating regions 
within these epitopes in dimerisation and shedding, as discussed in Chapter 4.  The induction 
of dimerisation by ACE inhibitors was shown to initiate intracellular signalling 
(Kohlstedt 2006).   
In this study, the role of disulphide interactions in dimerisation of sACE transfected into CHO 
cells was investigated.  The relationship between dimerisation and shedding using mutants 
lacking the free thiol in each domain or both domains was explored. 
ACE dimers were detected with purified protein and in culture fluid when sufficient protein 
was present, but were not consistently detected in total cell lysate (Figure 5.9).  This may have 
been due to the means of sample preparation or possibly the condition of the cells when lysed 
causing insufficient formation of disulphide- linked dimers. 
The results from this study suggest that sACE dimers comprise both non-covalent and 
covalent interactions.  Most noticeably, the predominance of a high MW form under native, 
non-reducing conditions indicates that sACE has the propensity to form aggregates 
(Figure 5.2).  A large percentage of this aggregate resolved at a 190kDa band in the presence 
of SDS, indicating that the higher MW form is largely held together by non-covalent 
interactions.  A small percentage persisted as the higher MW form, which was susceptible to 
reduction.  Furthermore, roughly 10% of total purified sACE was visualised as a disulphide-
linked dimer under reducing conditions (Figure 5.3).  This covalently linked dimer persisted 
in culture medium from CHO cells expressing wt sACE, which suggests that the protein is 
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indicated after addition of a crosslinker to cells where visible dimer was formed 
(Figure 5.9A).  The bands observed seemed not to be accounted for solely by disulphide-
mediated interactions since these higher MW forms were present, and increased, with removal 
of the free thiols. 
The formation of disulphide-mediated sACE dimers appears to involve the C domain 
sulphydryl, C1072.  This is suggested by several observations: firstly, the appearance of 
covalent dimers in sACE and tACE but not the N domain isoform in non-reducing gels of 
purified protein and culture medium from CHO cells expressing these isoforms (Figure 5.3).  
Secondly, the lack of dimer formation in culture medium of mutants lacking the free thiol at 
1072 (sACE-C1072S) or both sites (sACE-CC/SS) while an intact C1072 (sACE-C474S) was 
able to mediate dimerisation (Figure 5.9).  Thirdly, the conformational fingerprint of sACE 
upon removal of the C domain sulphydryl is more noticeably altered compared to the 
N domain thiol (Figures 5.13 & 5.14).  In particular, three antigenic regions become exposed, 
evidenced by increased affinity for mAbs within these regions.  These are the the N-terminal 
region of the N domain, containing mAbs 9B9, 3G8 and i1A8; the regions of the N and 
C domains shown to overlap, containing N domain-specific mAbs i2H5, 6A12, 1G12 and 
C domain-specific mAbs 1E10, 4E3, 2H9 and 3F11 and lastly, the C-terminal region of the 
C domain, containing mAbs 1B3, 1B8 and 3F10.  
By removing the C domain thiol, and thus the ability of ACE to form a covalent dimer, the 
two domains may adopt an “extended” conformation (Figure 5.16), allowing access of these 
mAbs. 
It is unclear why there would be preference of formation of disulphide-mediated dimers via 
the C domain, since there is a high degree of structural homology between the N and 
C domains.  This may be due to conformational constraints where the C domain free thiol is 
more accessible and the N domain thiol is occluded by either the linker region or the 
C domain.  Since the C domain is tethered to the membrane by the juxtamembrane stalk this 
may restrain it and increase the likelihood of protein-protein interaction.  The presence of 
carbohydrates may also obstruct disulphide-mediated dimerisation, which would require that 
molecules be in close proximity.  The N domain is more extensively glycosylated than the 
C domain and the glycosylation sequon N480, unique in the N domain, proximal to C474 is 
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Figure 5.16.  Cartoon of sACE disulphide-mediated dimer.  Disulphide-mediated sACE dimers are depicted 
in the “compact” conformation, formed via the C domain free thiol (left).  With removal of this sulphydryl sACE 
could adopt an “extended” conformation (right), allowing better access of mAbs and the secretase.  CK2 
phosphorylation may be induced by disulphide-mediated dimerisation, affecting conformation and shedding. 
 
Kost et al (2003) demonstrated a link between dimerisation of sACE and cleavage secretion 
where mAbs 9B9 and 3G8 that affect shedding of sACE from CHO cells were shown to 
inhibit dimerisation of sACE in reverse micelles.  As discussed in Chapter 4, the overlapping 
region of the epitopes for these mAbs does indeed appear to play a role in dimerisation and 
shedding.  The presence of mAbs 9B9 and 3G8 were shown to have no effect on ACE 
inhibitor induced dimerisation in porcine aortic endothelial cells overexpressing sACE 
(Kohlstedt et al, 2006) and the authors point out that this mechanism may be distinct from 
dimerisation involving the CRD described by Kost et al (Danilov et al, 2006; Fleming & 
Kohlstedt, 2006). 
Interestingly, the loss of the C domain thiol (C1072) that appears to be involved in disulphide-
mediated dimerisation results in a highly significant increase in shedding whereas the 
presence of this group alone in the C474S mutant has no effect (Figure 5.10).  This suggests 
that shedding is impaired by covalently linked dimerisation via the C domain in CHO cells, 
but not necessarily inhibited since disulphide-mediated dimers were observed in culture 
medium.  This may be due to steric hinderance of the secretase by the dimer and might be an 
important regulatory mechanism in cleavage-secretion.  This is corroborated by the increased 
affinity of mAbs 1B3, 1B8 and 3F10 for cell-associated sACE-C1072S, suggesting that the 
juxtamembrane stalk is exposed (Figure 5.13).  Increased affinity for mAb 1B3 has been 
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Kohlstedt et al (2006) showed that dimerisation via the C domain induced an intracellular 
signalling cascade, mediated by phosphorylation on S1270 by CK2 (Chapter 1, Section 1.3.5).  
Interestingly, a mutant, S1270A, lacking the ability to be phosphorylated was retained in the 
membrane and significantly reduced shedding (Kohlstedt et al, 2002).  The significant 
increase in shedding observed upon removal of the C domain thiol may be related to this 
mechanism (Figures 5.10 & 5.16). 
Removal of both thiols affected the DCI-stimulated release of sACE from CHO cells but not 
PDBu stimulated shedding (Figure 5.11).  It has been proposed that the sharp increase in 
shedding induced by DCI is due to the release of a pool of ACE on the cell surface 
(Schwager et al, 1999).  Thus, the loss of both thiols, and potentially the ability of ACE to 
form disulphide-mediated dimers, appears to affect the pool of membrane bound protein, 
suggesting that dimerisation occurs on the cell surface.  The presence of mAbs 9B9 and 3G8 
had no significant effect on shedding when both thiols were removed (sACE-CC/SS), 
suggesting that the mechanism, which causes an increase in shedding with the loss of the 
C domain thiol, is not the same as that induced in the presence of mAbs (Figure 5.12).   
The ability to consistently observe disulphide-mediated dimers in total cell lysate limited the 
conclusions that could be drawn directly regarding disulphide-linked dimerisation and 
shedding.  It is interesting to note that removal of the thiol from each domain individually 
increased the formation of dimers in the presence of crosslinker, with the loss of the C domain 
thiol having the greatest effect.  This may be an indication of the interplay between different 
mechanisms of dimerisation, where loss of the ability to form disulphide-mediated dimers has 
enabled the formation of non-covalent interactions.  Albeit if the hypothesis that disulphide-
mediated dimerisation occurs via the C domain holds, this does not explain why removal of 
the N domain thiol (sACE-C474S) increased dimer formation and why the removal of both 
(sACE-CC/SS) had no effect at all.  The possibility that the high MW form observed after 
crosslinking is an ACE heterodimer can also not be ruled out, although there is some evidence 
to suggest that it is in fact a homodimer.  First, Kohlstedt et al (2006) showed that sACE 
forms a homodimer using a split-ubiquitin assay.  Second, bands at consistently the same 
position were observed with sACE samples from total cell lysate and medium, as well as 
purified ACE.  Third, 2-D PAGE of purified sACE showed that the higher MW forms 
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Figure 5.17.  Cartoon of sACE dimers.  Disulphide-mediated sACE dimers are depicted in the “compact” 
conformation, formed via the C domain free thiol (left) and non-covalent dimers in the “extended” conformation, 
formed via carbohydrate interaction.  CK2 phosphorylation may be induced by disulphide -mediated 
dimerisation, affecting conformation and shedding 
 
In conclusion, the generation of mutants lacking free thiols in one or both domains has 
indicated that ACE dimerisation involves two possible mechanisms, via non-covalent 
interactions in the N domain, possibly through the proposed carbohydrate recognition domain 
(Kost et al, 2000; Kost et al, 2003), and via disulphide-mediated interactions through the free 
thiol in the C domain (Figure 5.17).  The latter appears to play a role in cleavage secretion of 
ACE and is most likely the mechanism involved in ACE inhibitor initiated signalling 
(Figure  5.16) (Kohlstedt et al, 2006). 
However, further investigation into the relationship between dimerisation, shedding and 
intracellular signalling is required.  The role of non-covalent interactions, particularly via 
glycans, in dimerisation needs to be further explored.  The minimal glycosylation 
requirements for expression of the N domain (Anthony et al, 2010) and tACE (Gordon et al, 
2003) have been determined and the panel of mutations generated from these studies would 
be a useful springboard for further investigations.  The design and expression of tagged sACE 
constructs could be a viable system for determining homodimerisation, as used successfully to 
investigate homodimerisation of the human B2-R (Michineau et al, 2006) and its 
heterodimerisation with ACE (Chen et al, 2006). The relationship between non-covalent and 
covalent interactions in dimerisation could also be investigated in this way.  Finally, the role 
of covalent dimerisation in ACE inhibitor initiated signalling could be investigated using the 
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CHAPTER 6:  A novel ACE substitution: the role of the N domain in 
shedding of sACE 
6.1 INTRODUCTION 
In addition to expression on the surface of endothelial cells in a number of tissues, ACE is 
found in biological fluids including plasma and seminal fluid as the result of cleavage-
secretion of membrane-bound ACE (Ching et al, 1983; Hooper et al, 1997; Wei et al, 1991b).  
Cleavage has been shown to occur in the juxtamembrane stalk region between R1203 and 
S1204 (Ramchandran et al, 1994; Ehlers et al, 1996; Woodman et al, 2000). 
Levels of plasma ACE remain fairly stable in healthy individuals, but are elevated with 
certain clinical symptoms including Gaucher’s disease and granulomatous diseases such as 
sarcoidosis (Lieberman, 1975; Lieberman & Beutler, 1976; Silverstein et al, 1976).  Two 
novel ACE substitutions that are associated with increased plasma ACE have been recently 
described.  Firstly, the P1199L mutation in studies of unrelated individuals in Germany 
(Linnebank et al, 2003), Holland (Kramers et al, 2001, Eyries et al, 2001) and the USA 
(Semmler et al, 2006) was shown to be responsible for elevated plasma ACE.  Expression of 
recombinant P1199L sACE in COS-7, CHO and HMEC-1 cells (Eyries et al, 2001) showed 
that this mutation caused increased cleavage-secretion of ACE, most likely through a local 
conformational change in the juxtamembrane region allowing better access of the secretase.  
The second study described the W1197Stop transition in a family of African-Americans that 
introduced a premature stop codon into the stalk region resulting in the expression of 
exclusively soluble sACE in cells carrying the mutation (Nesterovich et al, 2009).  In both 
these cases, no adverse clinical symptoms were associated with the increased levels of plasma 
ACE.   
The role of soluble plasma ACE remains unclear; however, it has been shown that membrane-
bound sACE is critical for AngII production in the vascular endothelium since soluble ACE is 
not sufficient to restore blood pressure in null ACE mice (Kessler et al, 2007).   
A novel ACE substitution has recently come to light that seems to be associated with adverse 
clinical symptoms (Prof. S. Danilov, personal communication).  It is present in a family of 
individuals where the affected members suffer from intermittent nausea, vomiting, fatigue and 
depression.  This was discovered through the youngest member affected, a 17-year male.  
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discovered that the patient had dramatically elevated levels of plasma ACE (367U/L vs 
normal range of 12-68U/L).   
A number of known causes for elevated plasma ACE, including Gaucher’s disease, 
histoplasmosis and sarcoidosis (Leiberman et al, 1975; Leiberman & Beutler, 1976; 
Silverstein et al, 1976) were investigated and ruled out.  The CARD15/NOD2 gene was 
sequenced and a P723L substitution was discovered.  Substitutions of this gene have been 
associated with Blau syndrome (Miceli-Richard et al, 2001), Crohn’s diease and early onset 
sarcoidosis (Kambe et al, 2005).  However the only family members to have this mutation 
were the index patient and the mother, who did not present with any of the clinical symptoms.  
Thus, this was ruled out as a potential cause.  Therefore the most likely explanation for the 
elevated plasma ACE was a novel ACE substitution.  Sequencing of the entire ACE gene of 
the index patient found a single base pair substitution at position 1480 converting the codon 
TAT to GAT, which converts a Tyr to Asp at position 465 in the ACE protein.  The patient 
was heterozygous for the substitution and this transition was found in only affected members 
of the family, who also had elevated plasma ACE (Prof. S. Danilov, personal 
communication). 
Within the secondary structure of sACE, Y465 lies in the C terminal portion of the N domain 
on helix -21 in proximity to C474, within 10Å of the linker region, close to the epitope of 
mAb 5F1 (refer to Chapter 1, Section 1.4).  The aromatic side chain of Y465 forms a 
predominant protuberance from the cell surface, which could be involved in intra-chain 
interactions or protein-protein interactions.  The transition to the acidic Asp results in the loss 
of this protuberance from the surface structure (Figure 6.1).  The altered surface structure 
induced by the Y465D mutation may result in conformation changes that alter ACE 
expression or processing that result in elevated plasma ACE. 
Figure 6.1.  Change in surface structure with Y465D substitution.  Surface representation of the crystal 
structure of the N domain indicating Y465 (left, pink ) and D465 (right, magenta), the linker region (orange) and 
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A likely cause of the symptoms experienced by affected family members is elevated levels of 
substance P, a peptide involved in pain and chronic inflammation associated with nausea, 
vomiting, depression and fatigue (Harrison et al, 2001).  This could be the result of increased 
production of substance P through aberrant signalling or of insufficient breakdown.  The 
major enzymes involved in degradation of substance P are neprilysin (NEP) and sACE 
(Skidgel et al, 1984; Ehlers & Riordan, 1991a).  Considering the novel ACE substitution in 
affected individuals, there may be a correlation between the role of ACE in substance P 
catalysis and the symptoms observed.  Interestingly, plasma samples from the same 
individuals were shown to have elevated substance P levels (Prof. S. Danilov, personal 
communication).   
 
Thus the aim of this study was to investigate the mechanism responsible for increased soluble 
ACE in affected individuals using a model system in CHO cells.  
This involved the following objectives: 
1. To generate the Tyr 465 to Asp in sACE by site-directed mutagenesis, express the 
Y465D mutant in CHO cells and determine its effect on the rate of ectodomain 
shedding. 
2. Assess what effect this mutation has on the conformation of ACE by mAb binding. 
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6.2 RESULTS 
6.2.1 Expression of sACE-Y465D in CHO cells 
sACE-Y465D cDNA, a generous gift from Prof S. Danilov (refer to Chapter 2, Section 2.1.2), 
was stably transfected into CHO cells.  Soluble wt sACE (pcDNA-sACE-sol) expressed in 
CHO cells was used as a source of ACE for protein purification (for details refer to Chapter 2, 
Section 2.1.1) 
High-expressing sACE-Y465D CHO stable cell lines were generated by FACS-based cell 
sorting (refer to Chapter 2, Section 2.2.1 for methods).  The level of expression was 
determined by ACE activity assays of culture medium and total cell lysate (refer to Chapter 2, 
Section 2.2.2 for methods).  The sACE-Y465D cell line had comparable levels of cell 
associated ACE activity compared to wt sACE (Figure 6.2A).  However, activity in culture 
medium from CHO cells expressing sACE-Y465D was significantly increased compared to 
wt, indicating that this mutant has an effect on ACE shedding (Figure 6.2B).  Thus, the 
Y465D mutation did not appear to have affected sACE expression in CHO cells, but appeared 
to influence proteolytic processing from the cell surface. 
Figure 6.2.  ACE activity in CHO cell lysate and culture medium.  The ACE activity in total cell lysate (A) 
and culture medium (B) from CHO cell expressing wild-type sACE and sACE-Y465D was determined using 
ZFHL as a substrate.  Data is shown as the total mU in each sample and is the mean±SD of four experiments 
(wt) or three experiments (sACE-Y465D) performed in triplicate. 
 
6.2.2 Protein expression and processing of membrane-bound and soluble sACE-Y465D  
Western blot analysis was performed on total cell lysate and culture medium from CHO cells 
expressing wt sACE and sACE-Y465D to further examine the effect of the mutation on sACE 
expression and processing (for methods refer to Chapter 2, Section 2.2.8).  The cell associated 
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>300kDa was observed for both wt and the mutant consistent with a disulphide-mediated 
ACE dimer, since this form is not observed in the presence of reducing agent (refer to 
Chapter 5).  Densitometric analysis of cell lysate indicated a 5-fold increase in the ratio of 
dimer to monomer with sACE-Y465D (Figure 6.3B).  However, these data were not 
reproducible and the increase in dimer could not be confirmed.  The amount of soluble sACE 
in harvested medium assessed by an activity assay was insufficient to perform western 
blotting analysis.  Thus, culture medium from CHO cells expressing wt sACE was 
concentrated to obtain sufficient protein for western blotting.  sACE-Y465D resolved as band 
similar in size to the wt and cell associated sACE, of approximately 190kDa.  In both cell 
associated and soluble forms, the mutant resolves slightly higher than the wt, which could be 
the result of alterations in post-translational processing such as glycosylation or 
phosphorylation that might alter its migration through the gel.  These results suggest that the 
mutation has no aberrant effect on sACE expression and processing to the cell membrane.  In 
addition, the elevated plasma ACE levels observed in individuals expressing the Y465D 
substitution are more likely to be the result of changes in the cleavage-secretion of sACE-
Y465D than the result of increased protein expression. 
 
Figure 6.3.  Protein expression of sACE-Y465D in CHO cells.  A. Western blot analysis was performed on 
total cell lysate and concentrated medium from CHO cells transfected with wt and sACE-Y465D.  Samples were 
separated by 6% SDS-PAGE in the presence (right) or absence (left) of -ME. Immunoloblotting was performed 
and ACE was detected with the C domain-specific mAb 1D8.  B.  Densitometric analysis of cell lysate separated 
by Western blot, calculated as the percentage dimer of monomer (D/M).  Data is the mean±SD of samples 
prepared in duplicate. 
 
6.2.3 Purification of sACE-Y465D 
Purified sACE-Y465D was prepared for further biochemical analysis.  CHO cells expressing 
full-length sACE-Y465D were used as a source of soluble ACE in cell culture medium for 
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chromatography, as described (Chapter 2, Section 2.2.3).  Sufficient yields were obtained for 
further experiments (3.2mg/L) and protein resolved as a ~190kDa band with SDS-PAGE 
under reducing conditions (Figure 6.4).  Faint bands of ~80kDa and ~90kDa were observed 
with wt sACE and sACE-Y465D, consistent with the N and C domain products generated 
from limited proteolysis of sACE (Sturrock et al, 1997).  There was a negligible amount of 
proteolysis evident as faint bands migrating slightly faster than sACE.  Since these were 
present as a small percentage of the total protein, these samples were considered suitable for 
further experimentation.    
Figure 6.4.  Protein purification of sACE-Y465D.  Soluble sACE-Y465D was purified from CHO cell culture 
medium by lisinopril-sepharose affinity chromatography.  15g-20g protein was separated on a 6% SDS-PAGE 
and visualised by Coomassie Blue staining.  Purified sACE (refer to Chapter 3, Section 3.2.4.2) was included as 
a molecular weight control.  
 
6.2.4 Shedding of sACE-Y465D 
Since Y465D did not alter enzyme activity (Section 6.2.1) or protein expression 
(Section 6.2.2) in CHO cells, it seemed that the elevated levels of soluble ACE in vivo and in 
vitro could be explained by changes in the cleavage-secretion of sACE.  This could be the 
result of either aberrant shedding or conformational changes in sACE that improve 
accessibility of the sheddase. 
6.2.4.1 Basal shedding 
ACE activity in culture medium from CHO cells expressing sACE-Y465D was noticeably 
increased compared to wt sACE (Figure 6.2).  Basal shedding was calculated from activity 
assays of culture fluid and total cell lysate from CHO cells expressing wt and sACE-Y465D 
(Figure 6.5) (for methods refer to Chapter 2, Section 2.2.4).  There was an 8-fold increase in 
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Figure 6.5.  Basal shedding of sACE-Y465D in CHO cells.  Shedding of wild-type sACE (white) and sACE-
Y465D (grey) was calculated as the percentage ACE activity in culture medium of total activity in cell lysate and 
medium after incubation in minimal medium for 4 hours.  A. Percentage shed of total ACE activity and B. 
Percentage total shed of wild-type.  Data is the mean±SD of three experiments performed in triplicate.  
 
6.2.4.2 Induction and inhibition of shedding 
The effect of stimulation of shedding by the phorbol ester, PDBu, and the serine protease 
inhibitor, DCI, as well as inhibition by the hydroxymate-based metalloprotease inhibitor, 
TAPI-1, was determined (Figure 6.6) (refer to methods in Chapter 2, Section 2.2.4.1).  PDBu 
induced basal shedding of wt sACE by approximately 1.5-fold and DCI caused an increase in 
shedding (140.77% ± 8.15%, p < 0.05 and 238% ± 11.29%, p < 0.001 of untreated, 
respectively) (Figure 6.6).  Shedding was significantly inhibited in the presence of TAPI-1 
(32.77% ± 2.08% of untreated, p < 0.01).  A similar trend was observed for sACE-Y465D, 
where a 4-fold induction of shedding in the presence of PDBu and a 5-fold increase in the 
presence of DCI was observed  (PDBu: 434.00% ± 16.26%, p < 0.001; DCI: 527.42% ± 
14.57%, p < 0.001 of untreated).  There was a significant inhibition of shedding in the 
presence of TAPI-1 (27.04% ± 3.30%, p < 0.05 of untreated).  The induction of shedding by 
PDBu and DCI was significantly increased with the mutant compared to wt.  These results 
suggest that cleavage-secretion of sACE-Y465D occurs via the same mechanism as native 
sACE and that an aberrant shedding mechanism is not likely the cause of its increased 
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Figure 6.6.  Stimulation and inhibition of shedding of sACE-Y465D.  CHO cells expressing wt (white) and 
sACE-Y465D (grey) were incubated in minimal medium containing PDBu, DCI or TAPI-1 for four hours.  
Shedding was calculated as described in Figure 6.5.  Data is the mean±SD of two experiments performed in 
duplicate, expressed as % of untreated (untx).   
 
6.2.4.3 mAb induced shedding 
Induction of shedding by mAbs 9B9 and 3A5 to ACE as well as inhibition by mAb 3G8 has 
been reported previously (Balyasnikova et al, 2002).  This has been attributed to localised 
conformational changes, which either improve or reduce access of the secretase by altering 
the conformation of ACE upon mAb binding.  The effect of the Y465D mutation on mAb 
induced shedding was determined to investigate whether similar effects are observed 
(Figure 6.7) (for methods refer to Chapter 2, Section 2.2.4.2). 
 
 
Figure 6.7.  mAb induced shedding of sACE-Y465D.  CHO cells expressing wt (white) and sACE-Y465D 
(grey) were incubated in the presence of mAbs to ACE in minimal medium for four hours.  Shedding was 
calculated as described in Figure 6.5.  Data is the mean±SD of two experiments performed in duplicate. 
 
A 2.7-fold induction of shedding by mAb 9B9 and 4.1-fold induction by mAb 3A5 was 
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respectively) whereas no inhibition of shedding by mAb 3G8 was observed.  There was no 
significant change in mAb induced ACE shedding with sACE-Y465D for all the mAbs tested, 
except mAb 3A5 where the induction of shedding observed with wt returns to basal levels and 
a slight but not significant increase in shedding was observed in the presence of mAb 9B9. 
6.2.4.4 Effect of substance P on shedding 
In addition to the elevated plasma ACE levels observed in individuals with the Y465D 
substitution, increased levels of substance P were detected.  Substance P is a substrate for 
sACE (Jaspard et al, 1993) but its interaction with ACE and involvement in ACE expression 
and regulation is unknown.  To determine whether substance P plays a role in ACE cleavage-
secretion, shedding was determined after incubation of cells in the presence of substance P for 
four hours (refer to methods in Chapter 2, Section 2.2.4.3).  No sig ificant difference in 
shedding of sACE-Y465D compared to wt was observed (Figure 6.8).  In addition there was 
no observable difference in ACE activity in cell lysate in the presence of substance P.  This 
suggests that substance P does not have a direct effect on ACE expression and proteolytic 
processing of sACE Y465D.  
 
Figure 6.8.  Effect of substance P on shedding of sACE-Y465D.  CHO cells expressing wt (white) and sACE-
Y465D (grey) were incubated in the presence of 10M substance P in minimal medium for four hours.  
Shedding was calculated as described in Figure 6.5.  Data is the mean±SD of two experiments performed in 
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Figure 6.9.  MALDI TOF/TOF spectrum of sACE-Y465D after tryptic digest.  An in gel tryptic digest was 
performed on sACE-Y465D and subjected to MALDI TOF/TOF.  Masses corresponding to predicted ACE 
peptides are labelled.  The masses corresponding to peptide containing Y465D and the C-terminal cleavage 
peptide are indicated in bold, labelled with the peptide sequence, and expected masses are indicated in brackets.   
 
6.2.4.5 Cleavage site determination 
A possible explanation for the 8-fold increase in shedding observed for sACE-Y465D is that 
the mutation has altered the interaction of the secretase with ACE causing aberrant shedding, 
most likely at a novel cleavage site.  To test this hypothesis, the cleavage site of sACE-
Y465D was determined by MALDI MS/MS (Figure 6.9. & Table 6.1) (for methods refer to 
Chapter 2, Section 2.2.10).  A tryptic digest of purified soluble ACE revealed a fragment 
(m/z 1689.81, expected m/z 1689.81), which corresponds to the C-terminal cleaved peptide 
(L1190-R1203).  The peptide, containing Y465D (Y459-R467) was identified as an 
m/z 1314.58 fragment (expected m/z 1314.59), confirming the presence of the mutation in the 
protein sequence.  Thus, the Y465D transition does not alter the cleavage site of the ACE 
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Table 6.1.  MALDI MS/MS analysis of sACE-Y465D after tryptic digest.  Masses (m/z) corresponding to 
ACE peptides, the peptide containing Y465D (underlined) and the C-terminal peptide are indicated (bold) 




Peptide sequence  
identified by MS/MS 
53-71 2190.70 2191.08  
133-151 2121.03 2121.04  
188-199 1416.61 1416.61  
327-340 1753.76 1753.80  
433-446 1724.92 1724.91  
447-453 808.41 808.38  
459-467 1314.59 1314.58 YNFDWWDLR 
518-532 1807.81 1807.80  
623-629 957.43 957.41  
751-762 1623.76 1623.75  
776-785 1176.64 1176.62  
798-811 1697.77 1697.76  
812-828 2117.15 2117.15  
1055-1065 1524.69 1524.68  
1068-1077 1186.60 1186.59  
1174-1180 912.53 912.51  
1190-1203 1689.81 1689.81 LGWPQYNWTPNSAR 
 
6.2.5 Conformational changes induced by the Y465D mutation 
The possibility of conformational changes induced by the Y465 transition was investigated 
using a plate precipitation assay and cell-based ELISA.  The same panel of domain-specific 
mAbs were used as that used to investigate changes in conformation in Chapters 3, 4 and 5.  
6.2.5.1 Binding of mAbs to cell-associated and soluble sACE-Y465D  
Plate precipitation assay of total cell lysate (cell associated) and concentrated cell culture 
medium (soluble) from cells expressing wt sACE and sACE-Y465D revealed the following 
trends (Figure 6.10) (refer to Chapter 2, Section 2.2.5 for methods).  There is a marked 
decrease in precipitation of both cell-associated and soluble sACE-Y465D by mAb 5F1, 
which indicates or suggests that Y465 is important for mAb 5F1:ACE interaction or that this 
epitope is occluded with sACE-Y465D.  With cell-associated sACE-Y465D, precipitation by 
the N domain-specific mAbs; 9B9, 3G8, i1A8 and 3A5; in the N-terminal antigenic region is 
increased.  C-terminal N domain epitopes, namely mAbs 1G12 and 6A12, appear to be 
occluded with sACE-Y465D, as evidenced by the decreased affinity of these mAbs for the 
mutant.  However, N-terminal C domain epitopes appear to be exposed since there is an 
increased affinity of mAbs 1E10 and 2H9 for the mutant.  A marked increase in precipitation 
of sACE-Y465D by C domain-specific mAbs to the C-terminal region indicates that there has 
been rearrangement of the juxtamembrane stalk allowing access to the cleavage site, as was 
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Soluble sACE-Y465D does not exhibit as marked changes in affinity for the ACE mAbs 
compared to the cell-associated form, indicative of domain rearrangement upon shedding.  
Greater exposure of the cleavage site due to domain rearrangement is compounded by the 
increased affinity of mAb 1B3 for the mutant.  
 
Figure 6.10.  Precipitation of sACE-Y465D by ACE mAbs.  A plate precipitation assay was performed with 
total cell lysate (top) and culture medium (bottom) from cells expressing wt sACE and sACE-Y465D using the 
panel of domain-specific mAbs.  Data is shown as the ratio of binding of sACE-Y465D to wt, normalised to 
control (IgG) and is indicated as a noticeable increase in binding (black ), decrease in binding (light grey) and no 
change in binding (dark grey) compared to wt. 
 
6.2.5.2 Binding of mAbs to membrane-bound sACE-Y465D 
An ELISA assay was performed on CHO cells to determine the binding affinity of the panel 
of domain-specific mAbs for membrane-bound sACE-Y465D compared to wt sACE 
(Figure 6.11) (for methods refer to Chapter 2, Section 2.2.6).  As seen with the plate 
precipitation assay, there was a significantly decreased affinity of mAb 5F1 for membrane-
bound sACE-Y465D (50.51% ± 6.49% of wt, p ,< 0.001), supporting the observation that 
Y465 is important for mAb 5F1 binding or that this epitope is occluded.  The N domain-
specific mAb 3A5 showed significantly increased affinity for the mutant (141.58% ± 6.98% 
of wt, p < 0.001) whereas mAbs to other epitopes in the N-terminal region did not.  This may 
be due to decreased accessibility of these epitopes when sACE is tethered to the membrane.  
N domain C domain 
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Similarly to cell-associated sACE-Y465D, the membrane-bound form showed significantly 
increased affinity for the C domain-specific mAbs 1B3, 1E10 and 2H9, (324.33% ± 23.16%, 
295.17% ± 18.01% and 179.66% ± 6.68% of wt respectively, p < 0.001) suggesting 
movement of the N domain to expose these epitopes.   The striking increase in binding of 
mAb 1B3 to membrane-bound sACE-Y465D observed with the cell-associated and soluble 
forms, substantiates the rearrangement of the juxtamembrane region, exposing this epitope. 
 
Figure 6.11.  Binding of ACE mAbs to membrane-bound sACE-Y465D.  A cell ELISA assay was performed 
on cells expressing wt sACE and sACE-Y465D using the panel of domain-specific mAbs.  Data is shown as the 
ratio of binding of sACE-Y465D to wt, normalised to control (IgG) and is the mean±SD of two experiments 
(N domain mAbs) or three experiments (C domain mAbs) performed in duplicate.  mAbs showing significant 
changes in binding compared to wild-type are indicated (grey bars).  
 
6.2.6 Kinetic characterisation of sACE-Y465D 
The hydrolysis of the physiological ACE substrates, angiotensin I (angI) and substance P 
(subsP), by wt sACE and sACE-Y465D was determined to evaluate whether the Y465D 
substitution had any effect.  HPLC was performed to visualise the hydrolysis products, which 
may be altered by the mutation, particularly as sACE is known to digest subsP at multiple 
sites (Yokosawa et al, 1983; Skidgel et al, 1984).  The rate of hydrolysis was determined 
using fluorogenic assays since this was the routine approach for determining enzyme activity 
in our hands and would require less substrate (for methods refer to Chapter 2, Section 2.2.12). 
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Figure 6.12.  Hydrolysis of angiotensin I by wt and sACE-Y465D.  HPLC profile of undigested angI (A) and 
angI incubated with wt sACE (B) or sACE-Y465D (C) for 1 hour in 50mM HEPES, 0.3M NaCl, 10M ZnSO4.  
Samples were separated over a 14-70% ACN gradient, absorbance at 215nm is shown.  Peaks corresponding to 
angI substrate (solid arrow) and angII product (dashed arrow) are indicated. 
 
6.2.6.1 Hydrolysis of angiotensin I  
AngI digestion by wt sACE and sACE-Y465D was visualised by HPLC (refer to Appendix 
A.3 for peptide sequence and Chapter 2, Section 2.2.12.1 for methods).  Undigested angI 
eluted at approximately 16 minutes at λ = 215nm in a control run (Figure 6.12A).  After an 
hour digestion with wt sACE, a second peak was observed at 215nm that eluted at 
approximately 15 minutes (Figure 6.12B), consistent with angII product.  The same profile 
was observed after digestion with sACE-Y465D (Figure 6.12C).  
Michaelis-Menten kinetics were determined using a fluorogenic assay based on the protocol 
used for the synthetic substrate ZFHL (for methods refer to Chapter 2, Section 2.2.2).  To 
overcome the potential derivitisation of the N-terminal primary amine by the fluorophore, 
leading to increased background fluorescence, a modified form of angI with an acetylated 
N-terminal group (acetyl-angI) was used.  Thereby, a fluorogenic assay was established using 
the same conditions as ZFHL-based assay where hydrolysis of acetyl-angI was determined 
from a standard curve of the fluorescence of the product HL (refer to Appendix A.2.2) and 
detected using the fluorophore o-phthaldialdehyde (Figure 6.13 & Table 6.2) (refer to Chapter 
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Figure 6.13.  Michaelis-Menten curve of angiotensin I hydrolysis by wt and sACE-Y465D.  5nM ACE was 
incubated with increasing concentrations of angI for 15min at 37C in 50mM HEPES, 0.3M NaCl, 10M 
ZnSO4.  Hydrolysis products were detected with o-pthaldialdehyde as described (Chapter 2, Section 2.2.12.2).  
Data shown is a representative curve (mean±SD) of three experiments performed in duplicate (wt, black ) and 
two experiments performed in triplicate (sACE-Y465D, grey).  A Michaelis-Menten curve was generated using 
the in-built analysis software in GraphPad Prism.  
 
Rate constants were determined from Michaelis-Menten curves to compare the rate of 
hydrolysis of acetyl-angI by sACE-Y465D to wt sACE.  The mutation resulted in a ~1.5-fold 
decrease in affinity for angI, according to the Km, with a 1.5-fold increase in turnover (kcat).  
The overall catalytic efficiency of sACE-Y465D was unchanged compared to wt (kcat/Km).  
This indicates that the mutant does not have a remarkable effect on ACE activity with respect 
to this physiological substrate.  
 
Table 6.2.  Kinetics of hydrolysis of acetyl-angI by wt sACE and sACE-Y465D.  Rate constants were 
determined from the Michaelis-Menten curve (Figure 6.13) 
  WT Y465D  
 Km (M) 33.46 ± 2.77 57.92 ± 2.82  
 k cat (s
-1
) 3.25 ± 0.31 5.11 ± 0.54  




) 0.097 ± 0.003 0.089 ± 0.014  
 
6.2.6.2 Hydrolysis of substance P 
Digestion products of subsP by wt sACE and sACE-Y465D were separated by HPLC and 
absorbance recorded at λ = 215nm (refer to Chapter 2, Section 2.2.12.1 for methods and 
Appendix A.3 for peptide sequence).  Undigested subsP eluted at 17 minutes (Figure 6.14A) 
and after 1 hour digestion with sACE, three peaks that eluted at approximately 12, 15 and 17 
minutes, were observed (Figure 6.14B).  The appearance of multiple peaks is consistent with 
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similar profile was observed after digestion with sACE-Y465D (Figure 6.14C) and it appears 
that the mutant does not affect the ability of the enzyme to cleave substance P.  
 
Figure 6.14.  Hydrolysis of substance P by wt and sACE-Y465D.  HPLC profile of undigested subsP (A) and 
subsP incubated with wt sACE (B) or sACE-Y465D (C) for 1 hour in 50mM HEPES, 0.3M NaCl, 10M ZnSO4.  
Samples were separated over a 14-70% ACN gradient, absorbance at 215nm is shown.  Peaks corresponding to 
subsP substrate (solid arrow) and products (dashed arrows) are indicated. 
 
A fluorogenic assay was established to determine the rate of hydrolysis of substance P by 
sACE and the mutant sACE-Y465D (for methods refer to Chapter 2, Section 2.2.12.1).  The 
derivitising agent fluorescamine was used to detect the product.  This compound reacts with 
primary amines to form a highly fluorescent fluorophore (Udenfriend et al, 1972).  In the case 
of subsP, high baseline fluorescence, proportional to the concentration of substrate present 
was observed, which was used to adjust readings (refer to Appendix A.2.3).  Rate constants of 
subsP hydrolysis by sACE-Y465D were determined from Michaelis-Menten curves 
(Figure 6.15 and Table 6.3).  
 
 
Table 6.3.  Kinetics of hydrolysis of substance P by wt sACE and sACE-Y465D.  Rate constants were 
determined from the Michaelis-Menten curve (Figure 6.15) 
  WT Y465D  
 Km (M) 89.36 ± 14.27 87.78 ± 46.42  
 k cat (s
-1
) 5.48 ± 0.27 8.44 ± 0.82  
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Figure 6.15.  Michaelis-Menten curve of substance P hydrolysis by wt and sACE-Y465D.  5nM ACE was 
incubated with increasing concentrations of subsP for 15min at 37C in 50mM HEPES, 0.3M NaCl, 10M 
ZnSO4.  Hydrolysis products were detected with fluorescamine as described (Chapter 2, Section 2.2.12.2).  Data 
shown is a representative curve (mean±SD) of two experiments performed in duplicate and triplicate (wt sACE, 
black ; sACE-Y465D, grey).  A Michaelis-Menten curve was generated using the in-built analysis software in 
GraphPad Prism. 
 
The mutation did not appear to affect the affinity of ACE for subsP as the Km values were 
similar.  There was 1.5-fold increase in the turnover of subsP by the mutant and the overall 
catalytic efficiency increased 1.8-fold.  However, there was a degree of experimental error, 
evident from the rate constants, most likely introduced due to difficulty in handling the 
fluorescamine solution.  Therefore, these results suggest that the mutation does not affect the 
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6.3 DISCUSSION 
A novel sACE mutation has recently emerged in a family where certain members presented 
with chronic nausea, fatigue and vomiting (Prof. S. Danilov, personal communication).  
Elevated plasma ACE levels were observed in affected individuals within the family and 
sequencing of the ACE gene in the primary patient revealed a single base pair mutation at 
nucleotide position 1480, causing a Tyr to Asp transition at residue 465 (Figure 6.1). 
The increase in plasma ACE observed in affected individuals could be explained in the 
following ways.  First, it might be due to altered expression of sACE in cells, leading to a 
higher amount of ACE released into the plasma, as observed with the recently described 
W1197Stop substitution.  This mutation introduces a premature stop codon in the stalk region, 
resulting in the expression of an active soluble form of sACE (Nesterovich et al, 2009).  
Second, an increased rate of shedding caused by changes in the affinity/access of the ACE 
secretase or changes in the shedding mechanism itself could result in increased plasma ACE, 
as observed with the P1199L substitution (Kramers et al, 2001; Eyries et al, 2001). 
To investigate the cause of the increased levels of soluble ACE, the biochemical effects of the 
Y465D substitution on ACE expression and processing were characterised.  The substitution 
was introduced into sACE cDNA by site-directed mutagenesis and the mutant expressed in 
CHO cells.  The effect of this mutation on ACE expression, shedding, conformation and 
substrate hydrolysis was investigated.  
The Y465D mutation had no observable effects on protein expression in CHO cells.  
Equivalent levels of enzyme were detected in cell lysate using an ACE activity assay 
(Figure 6.2) and western blotting (Figure 6.3).  However, levels of ACE were significantly 
increased in culture medium from CHO cells (Figure 6.2).  This was consistent with the 
observed increase in plasma ACE in affected individuals and suggested that transfection of 
sACE-Y465D into cultured cells was an effective model system to characterise the 
biochemical effects of this substitution.  Since protein expression did not appear to be affected 
by the mutation, the increased plasma ACE levels observed with affected individuals could be 
explained by an increased rate of shedding of ACE from the cell surface. 
Indeed, the Y465D mutation led to a dramatic increase in basal shedding of sACE from CHO 
cells (8-fold) (Figure 6.5).  The profile of sACE-Y465D shedding in the presence of PDBu, 
DCI and TAPI-1 showed the same trend as wt (Figure 6.6) indicating that the same 
mechanism and moreover, the same sheddases might be involved.  The cleavage site within 
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(Figure 6.9, Table 6.1), as previously observed for wt sACE (Woodman et al, 2000).  This 
suggests that the increased basal shedding observed is not due to changes in the mechanism of 
shedding and that the same sheddase is involved.  This also supports the hypothesis that 
altered access of the secretase to the cleavage site might have led to increased shedding. 
A significantly greater induction of sACE-Y465D shedding compared to wt sACE was 
observed in the presence of PDBu and DCI.  This may be the result of altered signalling 
pathways and thus increased expression of the secretase.  The DCI-induced response could be 
the result of an increase in the pool of membrane-bound ACE.  However, without observable 
changes in ACE expression, this seems unlikely.  sACE shedding is less efficient compared to 
tACE, which has been proposed to be the result of occlusion by the N domain of a recognition 
motif in the C domain (Beldent et al, 1995; Woodman et al, 2005).  Regardless of the 
concentration of membrane-associated sACE, the rate-limiting step for cleavage would then 
be the access of the secretase to the scissile bond.  Therefore, it seems that increased PDBu or 
DCI-induced shedding may be due to a greater efficiency of shedding rather than increased 
levels of the sheddase or ACE. 
Increased binding of mAb 3A5 to cell-associated and membrane-bound sACE-Y465D was 
observed (Figures 6.10 & 6.11).  Moreover, shedding of the mutant was not induced by 
mAb 3A5, or mAb 9B9 to some extent (Figure 6.7).  These mAbs bind to the antigenic region 
of the N domain that appears to be involved in regulation of ACE shedding, most likely due to 
steric hinderance of a recognition motif on the C domain or juxtamembrane region 
(Balyasnikova et al, 2002).  These results suggest that sACE-Y465 has adopted the 
conformation typically imposed by binding of mAbs 3A5 and 9B9 and thus has adjusted the 
basal levels of shedding by allowing better access of the secretase.  This is supported by the 
increased affinity of C domain-specific mAbs 1E10 and 2H9 for both cell-associated and 
membrane-bound sACE-Y465D (Figures 6.10 & 6.11).  It appears that sACE has assumed a 
conformation similar to the “extended” model proposed by Corradi et al (2006) and observed 
in the EM structure (Chen et al, 2010) (refer to Chapter 1, Section 1.2.5 & Figure 1.5), 
reducing the occlusion of the N domain by the C domain.  Interestingly, mAb 3A5 induces a 
4.5-fold increase in shedding (Figure 6.7), whereas shedding of sACE-Y465D is 8-fold more 
efficient than wt.  This suggests that besides the unmasking of the C domain, another effect 
may be involved.  The striking increase in affinity for the C domain-specific mAb 1B3 
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(Danilov et al, 2005), suggests that greater accessibility of the cleavage site may also be a 
factor. 
These results indicate a novel mechanism in the regulation of ACE shedding where a 
mutation in the N domain results in rearrangement of the domains, exposing the cleavage site 
and a potential cleavage recognition domain.  It is possible that Y465 is involved in this 
mechanism through interactions with residues in the linker region.  In the N domain crystal 
structure Y465 is 10-12Å from the peptide backbone of the linker region.  Considering the 
flexibility of the linker region, it is possible that some interaction of the amino acid side 
chains with proximal residues in the N domain could occur.  Interaction of Y465 and residues 
in the linker region could facilitate positioning of sACE in a conformation closer to the 
“compact” model proposed by Corradi et al (2006) (refer to Chapter 1, Section 1.2.5 & 
Figure 1.5), with the N and C domains in close proximity.  The introduction of an acidic Asp 
group at position 465 could potentially disrupt this interaction, allowing for movement of the 
N domain, leading to the “extended” conformation of sACE.  There was a consistent loss of 
affinity for the N domain-specific mAb 5F1 with cell-associated and soluble sACE-Y465D in 
the precipitation assay as well as membrane-bound sACE-Y465D (Figures 6.10 & 6.11).  It is 
possible that Y465 is necessary for mAb 5F1 binding, or that the mutation has resulted in 
conformational changes that have altered access of this region.  Interestingly, Y465D lies 
within the dimer interface observed in the most recently solved crystal structure of the 
N domain (Anthony et al, 2010), which suggests that Y465D may be involved in protein-
protein interactions, such as dimerisation, that regulate shedding.  
This is the first endogenous ACE mutation described where increased plasma ACE levels are 
associated with deleterious effects.  The increased rate of shedding observed with sACE-
Y465D does not directly explain the clinical symptoms observed with affected individuals.  
Elevated levels of soluble ACE and substance P were observed in plasma of the index patient 
as well as affected family members suggesting that these may play a role.  This is surprising 
considering that substance P is a substrate for ACE and it would be expected that the 
increased levels of ACE would result in increased hydrolysis of substance P.  A recent study 
of migraineurs showed a similar phenomenon (Fusayasu et al, 2007), but the authors fail to 
explain this observation.   
There is no evidence to suggest that elevated plasma ACE is detrimental, despite this being a 
good marker for sarcoidosis (Lieberman et al, 1975; Rømer, 1984; Danilov et al, 2010), or 
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sensitivity of ACE to endogenous substrates or inhibitors that has led to alterations in 
expression or processing.  Alternatively, the mutation could have altered the kinetic 
parameters of ACE with regards to some substrates thereby disrupting important 
physiological pathways.  The most likely candidate is substance P, a substrate for sACE as 
well as being associated with similar clinical symptoms.  The first possibility seems unlikely 
since there was no change in the level of expression of sACE-Y465D in both the absence and 
presence of substance P.  Furthermore, this substrate had no effect on basal shedding of 
sACE-Y465D (Figure 6.8).  This leaves aberrant degradation of substance P by sACE-Y465D 
as a possible explanation.  However, it appeared that the kinetic parameters of angI hydrolysis 
were not affected by Y465D, indicating that this mutation has had little effect on ACE activity 
(Figures 6.12 & 6.13, Table 6.2).  Similarly, the rate of substance P hydrolysis was unchanged 
and similar peak profiles compared to wt were obtained by HPLC (Figures 6.14 & 6.15, 
Table 6.3).  Thus, altered hydrolysis of substance P by ACE is not likely the cause of elevated 
levels or the symptoms described. 
It appears that the mechanism involved may be due to an indirect effect of ACE on 
substance P, potentially mediated by other substrates or enzymes. 
For the benefit of this family, it is imperative that the underlying mechanism is elucidated.  
This would entail investigating other candidate genes for substitution that may assist in this 
phenotype, which include the NEP gene, genes related to substance P production.  Whole 
genome sequencing of the index patient and 2 affected family members is currently being 
conducted. 
In conclusion, a novel ACE substitution has been described which does not affect ACE 
expression but results in aberrant shedding from the surface of CHO and HEK cells.  This is 
attributed to the conformational rearrangement of the N domain, most probably exposing a 
recognition motif on the C domain as well as the stalk region, which allows better binding and 
access of the ACE secretase.  This substitution has been described in family were it seems to 
result in chronic clinical symptoms that may be the result of elevated substance P.  This is the 
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CHAPTER 7:  Conclusions and Future Directions  
 
Increased understanding of the structure-function of biological molecules has led to the 
development of interactomes, or protein-protein interaction networks, which, in terms of 
proteomics, describe the cross-talk between components of different pathways.  Predictions of 
protein-protein interactions have made use of complexes of solved protein structures and their 
interaction surfaces.  Furthermore, mapping of the interaction regions or “hotspots” on 
proteins gives insight into particular biological reactions and allows for modelling of 
unknown protein structures. 
With the identification of novel physiological substrates of ACE, it has become increasingly 
evident that this enzyme acts outside of its classic role as a regulator of the cardiovascular 
system.  Its action on the Aβ peptide implicates it in Alzheimer’s disease (Oba et al, 2005) 
and on AcSDKP with stem cell haematopoiesis (Azizi et al, 2006).  The cross-talk of ACE 
between these pathways is most likely regulated by specific interactions, which need to be 
better appreciated.  Moreover, the development of domain-specific inhibitors necessitates 
clearer definition of the sACE interactome and the role of each domain in these interactions.  
One approach is to harness the structural knowledge of ACE and investigate the surface 
topology of each domain towards pinpointing regions involved in protein-protein interactions 
and biological processes. 
Thus, the overall aims of this work were to identify regions of sACE involved in protein-
protein interactions and to determine their role in processes such as dimerisation, shedding 
and inter-domain movement.  Particular regions and residues were identified using site-
directed mutagenesis and a panel of domain-specific anti-ACE mAbs, where several aspects 
were investigated.  These included the effect of an engineered disulphide bridge on inter-
domain movement (Chapter 3); determining the role of each domain in dimerisation and 
shedding through fine epitope mapping of three N domain-specific mAbs (Chapter 4).  
Furthermore, the role of the free cysteine in each domain was investigated (Chapter 5) and 
finally, the biochemical effects of a novel mutation, Y465D, on shedding were determined 
(Chapter 6).   
The interaction of the two domains has been demonstrated in several ways.  First, it has been 
suggested by the negative cooperativity of the domains with respect to substrate hydrolysis 
(Andujar-Sanchez et al, 2004).  Second, the occlusion of domain-specific mAb epitopes by 
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regions of the N domain implicated in shedding indicate interplay between the two domains 
(Balyasnikova et al, 2002).  Third, the inefficient rate of shedding of sACE compared to 
tACE implicates the N domain in shedding regulation (Woodman et al, 2005).  These findings 
indicate that domain interaction is an important regulatory mechanism in post-translation 
processing of ACE, such as in ectodomain shedding and dimerisation.   
Much of what is known regarding ACE ectodomain shedding is the result of work with the 
tACE isoform, used to determine the basis of secretase recognition and binding.  It is 
generally agreed that a recognition domain in the C domain or juxtamembrane stalk is 
responsible for interaction while the role of the N domain in sACE shedding is unclear.  Steric 
hinderance of a C-domain recognition motif by the N domain is purported to be the reason for 
inefficient shedding of sACE compared to tACE (Woodman et al, 2005).  Indeed, the 
N domain mutations produced in this study had a significant effect on shedding, namely those 
in the overlapping portion of the epitopes of mAbs 9B9 and 3G8 (Q18H, L19E and Q22A) 
and the Y465D mutation proximal to the linker region.  With Y465D in particular, a dramatic 
increase in shedding was concomitant with an altered conformational footprint, determined 
using the panel of domain-specific anti-ACE mAbs, that exposed epitopes associated with 
shedding (mAb 3A5) and domain interaction (mAbs 1E10 and 2H9) (Balyasnikova et al, 
2002; Naperova et al, 2008a).  Moreover, the increased shedding induced by mutations such 
as Y465D and CC/SS were associated with increased affinity of mAbs to the C-terminal 
antigenic region of the C domain (containing the epitopes of mAbs 1B3, 1B8 and 3F10).  
These results support the hypothesis that the conformation of the N and C domains in sACE 
are largely responsible for its poor efficiency with respect to ectodomain shedding when 
compared to the single domain tACE.  A similar mechanism was attributed the increased 
shedding observed upon binding of N domain-specfic mAbs 3A5 and 9B9 (Balyasnikova et 
al, 2002).  Under physiological conditions, specific protein-protein interactions, such as 
dimerisation or binding of a co-factor, could trigger this conformational change that might be 
an important regulatory mechanism for sACE shedding. 
The role of dimerisation in the regulation of shedding has been alluded to in previous studies, 
where mAbs 9B9 and 3G8 that inhibit dimerisation in reverse micelles, altered shedding of 
sACE from CHO cells (Kost et al, 2003).  However, a direct link between these two events 
has not been established.  This work sought to define the role of residues in an overlapping 
region of the epitopes of the N domain-specfic mAbs 9B9 and 3G8 and the free thiols in each 
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mechanisms.  These studies indicated that ACE dimerisation occurs via two mechanisms, 
though covalent interaction of the C domain free thiol and non-covalent interactions in the 
N domain.  Disulphide-linked dimerisation via the C domain may be associated with the ACE 
inhibitor induced dimer activation of CK2 phosphorylation and intracellular signalling 
(Kohlstedt et al, 2006).  Moreover, this mechanism has been associated with negative 
regulation of shedding (Kohlstedt et al, 2002) and could be the link between the two 
processes, particularly since removal of the C domain thiol had a significant effect on sACE 
shedding.  It is unclear what role dimerisation of the N domain plays, although residues in the 
N terminal antigenic region, particularly Q22, affected both dimerisation and shedding.  A 
future direction would be to determine the role of the N domain glycans in dimerisation, 
which would be assisted by the set of minimally glycosylated N domain mutants that have 
been generated (Anthony et al, 2010).  However, further investigations into dimerisation 
would benefit from a means to differentiate between non-covalent and covalent interactions 
and from a robust approach to detecting native dimers on the cell surface.  Non-covalent 
dimers of human B2K-R were successfully characterised by co-immunoprecipitation of V5- 
and myc-tagged receptors (Michineau et al, 2006).  This is a reliable and standard technique 
for detecting protein-protein interactions in their native state, if the proper controls are in 
place to rule out non-specific interactions.  Difficulties arise when the protein complex is in 
low abundance or proteins interact indirectly, via a co-factor for example (Phizicky & Fields, 
1995).  An alternative approach would be to use fluorescence resonance energy transfer 
(FRET) or bioluminescence resonance energy transfer (BRET) fusion proteins, as was used to 
detect human ACE/B2K-R heterodimers (Chen et al, 2006).  These techniques are highly 
advantageous in that they can monitor protein-protein interactions in live cells and detect 
interactions within 100Å (Rebois et al, 2008).  However, this requires the correct combination 
and position of donor and acceptor tags to maximise energy transfer, careful implementation 
of a number of controls to eliminate artefacts (Pfleger et al, 2006) and potentially complicated 
and expensive instrumentation.  In addition, there may likely be a decrease in signal due to the 
formation of ACE-donor and ACE-acceptor homodimers.  
The linker region confers flexibility of movement between the domains and, according to the 
sACE model proposed by Corradi et al (2006), allows the enzyme to adopt conformations 
ranging between two extreme “compact” and “extended” poses.  The recent cryo-EM 
structure of sACE attests to the “extended” pose as a native conformation, albeit in solution 
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confirms that certain regions are involved in domain interaction, particularly those that affect 
shedding.  These include the epitopes of the N domain-specific mAbs 1G12, 6A12 and 3A5 
and the C domain-specific mAbs 1E10, 4E3 and 2H9.  From the changes in binding it seems 
that with increased shedding efficiency and the exposure of certain epitopes, sACE adopts a 
pose closer to the “extended” conformation that would allow access of mAbs 3A5, 9B9, 3G8, 
6A12 and 1G12 on the N domain and rearrangement of the juxtamembrane region, exposing 
the epitopes of mAbs 1B3, 1B8 and 3F10.  This is in agreement with the Corradi et al (2006) 
models.  However, this requires further confirmation from a high resolution structure of sACE 
has been resolved, which is hampered by the difficulty in obtaining viable crystals.  
Engineering a disulphide into the linker region was a viable approach towards limiting inter-
domain movement, although this study has shown that the positioning of the bridge is vital.  
The most likely mutation to succeed would be one that introduces a link between the two 
domains downstream of the linker region.  However, without knowing where the two domains 
interact it is difficult to engineer disulphide bridges.  The conformational footprint of the 
mutants has given clues as to which epitopes are affected and these may be a stepping stone 
towards determining inter-domain interaction.  Intramolecular FRET may be useful here, 
where fluorescent tags could be attached to candidate regions in order to determine whether 
the two domains interact.  A means to identify key residues might be to define the epitopes 
even further.  The most viable approach would be to co-crystalise the single domain isoform 
and an anti-ACE mAb fragment, as has been performed with other proteins (Leonard et al, 
2008; Newman et al, 2009; Teplyakov et al, 2009).  Considering the advance in x-ray 
crystallography and the development of viable candidates for crystallisation, this may be a 
viable approach.  Alternatives to obtaining structural data such as cryo-EM and small-angle x-
ray scattering (SAXS) could be pursued, both of which have the advantage of not requiring 
crystals for analysis.  However, the resolution with both these techniques is low compared to 
x-ray crystallography (50-250Å for SAXS, 5-10Å for cryo-EM at best). 
In summary, this is the first set of studies exploring the functions of the free thiols; to identify 
residues in the N domain that play a role in shedding and dimerisation and to attempt to 
engineer disulphides in the linker region towards stabilising ACE.  These studies have given 
insight into the role of inter-domain interaction(s) of ACE and post-translational processing -
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APPENDIX 
 
A.1. MUTAGENESIS AND SUBCLONING 
A.1.1. Primers for site-directed mutagenesis 
Table A.1.  Primers for site-directed mutagenesis (SDM) of Ndom or sACE.  The forward primer is 
indicated, both the forward and the reverse complementary primer was used in each reaction.   Restriction 
enzyme (RE) sites altered are underlined and nucleotides changed are indicated in bold. 
  RE Site Tm 
H600C 5’-GGGCTGGCCGGAGTACCAGTGGTGCCCGCCGTTGCCTGAC-3’ + BsaXI  89.3°C 
P3A 5’-CTGGCGTTGGACGCAGGACTGCAGCCCGGC-3’ - SmaI 79.1°C 
G4E 5’-CCCTGGCGTTGGATCCCGAACTGCAGCCCGGC-3’ + BamHI 80.5°C 
Q6A 5’-CTGGCGTTGGACCCTGGGCTGGCACCCGGCAACTTTTC-3’ - PstI 80.2°C 
Q18H 5’-GCTGACGAGGCCGGAGCTCATCTCTTCGCGCAGAGC-3’ + SacI 81.8°C 
L19E 5’-CGAGGCCGGGGCCCAGGAGTTCGCGCAGAGC-3’ + ApaI 78.6°C 
Q22A 5’-CGCAGCTCTTCGCGGCGAGTTATAACTCCAGCGCC-3’ + PsiI 76.6°C 
N25Q 5’-GCAGAGCTACCAATCCAGCGCTGAACAGGTGCTG-3’ + Eco47III 76.9°C 
Q30V 5’-CAACTCCAGCGCCGAAGTGGTCCTGTTCCAGAGCGTGG-3’ - AlwNI 81.7°C 
I79V 5’-GGAGCTGTATGAACCGGTCTGGCAGAACTTCAC-3’ + AgeI 80.4°C 
R340A 5’-CTTGGGACTTCTACAACGCTAAGGACTTCAGGATCAAGCAGTG-3’ + Bpu10I 78.8°C 
D374A 5’-CAGTACTACCTGCAATACAAGGCTCTGCCCGTCTCCC-3’ - PstI 81.1°C 
C474S 5’-GTATCAGGGGATATCTCCTCCTGTTACC-3’ + EcoRV 70.8°C 
C1072S 5’-GAAGTACCAAGGCCTCAGCCCACCAGTGCCC-3’ + Bpu10I 76.5°C 
 
A.1.2. Internal sequencing primers 
A set of internal primers to ACE were used for nucleotide sequencing.  They comprise both 
forward and reverse complementary primers designed to enable sequencing of the entire 
N domain and sACE genes in pBS. 
 
Figure A.1.  Schematic representation of sACE gene.  Forward primers are indicated above gene and reverse 
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A.1.3. Bacterial Cell Lines And Culturing 
E.coli JM109 cells (endA1 glnV44 thi-1 relA1 gyrA96 recA1 mcrB+ Δ(lac-proAB) e14- [F' 
traD36 proAB+ lacIq lacZΔM15] hsdR17(rK
-mK
+)) were used for plasmid DNA expression.  
Bacterial cells were cultured in Luria Broth (LB) growth medium (10g tryptone, 5g yeast 
extract, 10g NaCl in 1L dH2O) and plated on LB agar plates (Luria broth with 1.5% w/v agar) 
containing 100g/ml ampicillin for selection of cells containing recombinant DNA.   
Competent cells were prepared using the CaCl2 method (Sambrook & Russell, 2001).  
Overnight bacterial mini-cultures grown in LB in the absence of antibiotic were inoculated 
into a larger volume (1/100 dilution) and grown until OD600 ~ 0.5.  Cells were pelleted at 
5000rpm at 4C and resuspended in cold 100mM MgCl2.  After a 30 minute incubation on 
ice, cells were re-pelleted at 5000rpm at 4C and then resuspended in cold 100mM CaCl2 with 
15% glycerol.  Competent cells were aliquoted and stored at -80C until use. 
For transformation into competent E.coli JM109 cells, 50-100ng plasmid DNA was mixed 
with cells and incubated on ice for 30 minutes.  DNA uptake occurred by heat-shock at 42C 
for 45 seconds followed by 2 minutes on ice.  Cells were then diluted 1/10 in LB without 
antibiotic and grown at 37C for 1 hour.  Cells were pelleted by centrifugation, resuspended in 
100l LB, plated onto LA plates containing antibiotic and grown overnight at 37C.     
A.1.4. DNA isolation 
Small-scale DNA isolation was performed to screen colonies for positive clones after 
mutagenesis using a STET buffer based protocol.  A single colony from plated culture of cells 
transformed with plasmid DNA was inoculated into Luria broth and grown at 37C overnight.  
Cells were pelleted by centrifugation and resuspended in STET buffer [200mM sucrose, 
50mM Tris-HCl (pH 8), 50mM EDTA (pH 8), 5%w/v Triton X-100] containing 1mg/ml 
lysozyme.  Cells were lysed by boiling and protein precipitated by centrifugation.  The protein 
pellet was removed and DNA precipitated with 25% isopropanol by centrifugation and dried 
on a SpeedyVac (Savant, USA).  DNA was re-suspended in dH2O with 100g/ml RNaseA. 
A.1.5. Restriction enzyme digestion 
A 20l digestion cocktail containing 100-300ng DNA, 1X restriction enzyme buffer, 
0.5U restriction enzyme  (Fermentas, USA) in dH2O was incubated at 37C for 1 hour.  
Double restriction enzyme mixes calculated using the online DoubleDigestTM Tool 
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stopped with 1/6 volume 6X loading dye (0.025g Bromophenol Blue, 0.025g Xylene Cyanol, 
30% glycerol) and separated by agarose gel electrophoresis. 
A.1.6. DNA ligation 
Vector and insert DNA were mixed (3:1 ratio) with 1X ligation buffer and 1U T4 DNA ligase 
(Fermentas, USA) in dH2O and placed at 4C for 48 hours.  Aliquots of the reaction were 
transformed into competent E.coli JM109 cells and plated onto LB agar plates containing 
100g/ml ampicillin. 
A.1.7. cDNA synthesis 
Synthesis of cDNA from total RNA was performed using the Advantage® RT-for-PCR kit 
(Clonetech Laboratories, USA) according to the manufacturer’s instructions.  Briefly, 1ug 
total RNA was incubated with 1.5M oligo(dT)18 primer at 70C for 2 minutes, then 
quenched on ice.  A cocktail containing 1X reaction buffer, 500M dNTPs, 0.5l 
recombinant RNase inhibitor and 10U recombinant Moloney-Murine Leukemia Virus 
(MMLV) reverse transcriptase was added and the mixture incubated at 42C for 1 hour 
followed by a denaturation step at 95C for 5 minutes.    
A.1.8. PCR protocols 
A.1.8.1. Site-directed mutagenesis with Pfu DNA polymerase 
A 50l cocktail in nf dH2O: 
1 x Pfu Polymerase Buffer* 
400M dNTP mix 
200nM Forward primer 
200nM Reverse primer 
5% DMSO  
2-6mM MgCl2 
25-50ng Template DNA 
2U Pfu DNA Polymerase  
Reaction parameters: 
94C, 5 minutes  
16 cycles of: 
94C, 30 seconds  
Tm of primer, 30 seconds  
75C, 10 minutes  
Followed by: 
75C, 15 minutes  
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A.1.8.2. Site-directed mutagenesis with HiFiTM DNA polymerase 
A 50l reaction cocktail of: 
1x HiFi Fidelity buffer (2mM Mg+) 
300M dNTP mix 
300nM Forward primer  
300nM Reverse primer  
0-4mM MgCl2 
20ng Template DNA  
1U HiFiTM DNA polymerase  
Reaction parameters: 
94C, 2 minutes  
20 cycles of: 
98C, 20 seconds  
Tm of primer, 15 seconds  
68C, 30s/kb template DNA 
Followed by: 
68C, 5 minutes
in nuclease-free dH2O 
A.1.8.3. RT-PCR 
cDNA synthesis from total RNA extracted from CHO cells was performed using the 
following protocol: 
A 50l reaction cocktail of: 
1x HiFi Fidelity buffer (2mM Mg+)  
300M dNTP mix 
300nM Forward primer* 
300nM Reverse primer  
10l cDNA  
1U HiFiTM DNA polymerase  
in nuclease-free dH2O 
Reaction parameters: 
94C, 2 minutes  
20 cycles of: 
94C, 20 seconds  
72C, 30 seconds  
68C, 15 seconds 
Followed by: 
68C, 2 minutes 
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A.2. PROTEIN EXPRESSION AND CHARACTERISATION 
A.2.1. Bradford Protein Concentration Determination 
Protein concentration of full-length sACE was determined using the IgG curve and for single 
domain ACE (Ndom and tACE), the albumin curve was used.  The curves were determine by 
linear regression analysis using GraphPad Prism 4.0 software. 
Figure A.2.  Standard curve of absorbance over increasing protein concentration. 
 
Protein concentration was determined using the following equation: 
 
         
                
     
 
 
A.2.2. HL Standard Curve 
A 5mM HL (Sigma, USA) stock solution in dH2O was prepared and diluted into a 0.5mM 
working stock solution in 1X potassium phosphate buffer.  30l aliquots of HL in increasing 
concentrations, prepared by diluting in 1X potassium phosphate buffer, were placed in a 
96-well plate in triplicate and assayed for fluorescence as described (Chapter 2, Section 
2.2.2), beginning with the addition of 0.4M NaOH.  The curve was determine by linear 
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Figure A.3.  Standard curve of fluorescence over increasing HL concentrations .   
 
ACE activity was calculated as follows: 
 
       
                                   
                                       
           
 
A.2.3. Baseline fluorescence of substance P 
Dilutions of subsP in 50mM HEPES buffer (containing 300mM NaCl, 10M ZnSO4) were 
aliquoted into 96-well plates in triplicate.  Derivitisation was performed by the addition of 
2mg/ml fluorescamine and assayed as described in Chapter 2, Section 2.2.12.2. 
 
Figure A.4.  Baseline fluorescence of substance P after derivatisation with fluorescamine.  Data is mean±SD 
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A.2.4. Complete hydrolysis of substance P 
Increasing concentrations of subsP were incubated with 10nM ACE at 37°C overnight to 
allow for complete hydrolysis.  A fluorogenic assay to determine fluorescence of product was 
determined in triplicate as described (Chapter 2, Section2.2.12.2), beginning with the addition 
of 1M HCl.  The curve was determine by linear regression analysis using GraphPad Prism 4.0 
software. 
 
Figure A.5.  Standard curve of complete hydrolysis of substance P. 
 
A.2.5. Synthetic peptides 
A.2.5.1 Preparation of  ZFHL 
A 20mM ZFHL stock was prepared by dissolving 110g powder (MW = 549.63 g/mol)  in 1ml 
0.28M NaOH (with heating), with dropwise addition of 9ml dH2O, aliquoted and stored 
at -20C until use.   A 1mM working stock was prepared by dilution in 4ml 5X potassium 
phosphate buffer (pH 8.3), 2ml 3M NaCl, 13ml dH2O and 20l 10mM ZnSO4, filter sterilised 
and stored at 4C. 
A.2.6. Endogenous peptides 
A.2.6.1 Preparation of endogenous substrates 
AngI, acetyl-angI and subsP were received in powder form.  A 1mM stock of subsP 
(MW = 1347.63 g/mol) and 10mM stocks of angI (MW = 1296.50 g/mol) and acetyl-angI 
(MW = 1338.53 g/mol) were prepared by dissolving the appropriate weight in dH2O. 
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A.2.6.2. Sequence of peptides 
Cleavage site indicated by arrow, with relevant references indicated. 
 
Angiotensin I:   Asp1-Arg2-Val3-Tyr4-Ile5-His6-Pro7-Phe8-His9-Leu10 
 
(Skidgel, 1984) 
Substance P:   Arg1-Pro2-Lys3-Pro4-Gln5-Gln6-Phe7-Phe8-Gly9-Leu10-Met11 
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